Screening women for intimate partner violence in healthcare settings

O'Doherty, L. , Hegarty, K. , Ramsay, J. , Davidson, L.L. , Feder, G. and Taft, A.

Published PDF deposited in Coventry University’s Repository

Original citation:

http://dx.doi.org/10.1002/14651858.CD007007.pub3

DOI: 10.1002/14651858.CD007007.pub3
ISSN: 1469-493X

Publisher: Wiley

Copyright © and Moral Rights are retained by the author(s) and/ or other copyright owners. A copy can be downloaded for personal non-commercial research or study, without prior permission or charge. This item cannot be reproduced or quoted extensively from without first obtaining permission in writing from the copyright holder(s). The content must not be changed in any way or sold commercially in any format or medium without the formal permission of the copyright holders.
Screening women for intimate partner violence in healthcare settings (Review)

O’Doherty L, Hegarty K, Ramsay J, Davidson LL, Feder G, Taft A

This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in The Cochrane Library 2015, Issue 7

http://www.thecochranelibrary.com

WILEY
# Table of Contents

- **Header** ........................................................................................................... 1
- **Abstract** .......................................................................................................... 1
- **Plain Language Summary** ................................................................................ 2
- **Summary of Findings for the Main Comparison** ............................................... 4
- **Background** ...................................................................................................... 6
- **Objectives** ........................................................................................................ 9
- **Methods** ........................................................................................................... 9
  - Figure 1 .................................................................................................................. 12
- **Results** ............................................................................................................. 15
  - Figure 2 .................................................................................................................. 19
  - Figure 3 .................................................................................................................. 20
- **Additional Summary of Findings** ..................................................................... 26
- **Discussion** ....................................................................................................... 28
- **Authors' Conclusions** ...................................................................................... 32
- **Acknowledgements** .......................................................................................... 32
- **References** ....................................................................................................... 33
- **Characteristics of Studies** .................................................................................. 42
- **Data and Analyses** ........................................................................................... 85
  - Analysis 1.1. Comparison 1 Universal screening for intimate partner violence (IPV) versus control, Outcome 1 Identification of IPV by health professionals .......................................................................................... 86
  - Analysis 1.2. Comparison 1 Universal screening for intimate partner violence (IPV) versus control, Outcome 2 Identification of IPV by type of healthcare setting .............................................................................. 87
  - Analysis 1.3. Comparison 1 Universal screening for intimate partner violence (IPV) versus control, Outcome 3 Referrals .................................................................................................................. 88
  - Analysis 2.1. Comparison 2 Face-to-face screening for intimate partner violence (IPV) versus written/computer-based screening, Outcome 1 Identification of IPV ............................................................................. 89
- **Appendices** ...................................................................................................... 89
- **What's New** ...................................................................................................... 100
- **History** ............................................................................................................ 101
- **Contributions of Authors** ................................................................................. 101
- **Declarations of Interest** .................................................................................... 101
- **Sources of Support** .......................................................................................... 102
- **Differences between Protocol and Review** ...................................................... 102
- **Index Terms** ..................................................................................................... 103
Screening women for intimate partner violence in healthcare settings

Lorna O’Doherty¹,², Kelsey Hegarty², Jean Ramsay³, Leslie L Davidson⁴, Gene Feder⁵, Angela Taft⁶

¹Centre for Research in Psychology, Behaviour and Achievement, Coventry University, Coventry, UK. ²Department of General Practice, The University of Melbourne, Melbourne, Australia. ³Centre for Primary Care and Public Health, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK. ⁴Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, USA. ⁵Centre for Academic Primary Care, School of Social and Community Medicine, University of Bristol, Bristol, UK. ⁶Mother and Child Health Research, La Trobe University, Victoria, Australia

Contact address: Lorna O’Doherty, Centre for Research in Psychology, Behaviour and Achievement, Coventry University, Priory Street, Coventry, CV1 5FB, UK. lorna.odoherty@coventry.ac.uk. lornajaneodoherty@hotmail.com.

Publication status and date: New search for studies and content updated (no change to conclusions), published in Issue 7, 2015.
Review content assessed as up-to-date: 17 February 2015.


Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

ABSTRACT

Background

Intimate partner violence (IPV) damages individuals, their children, communities, and the wider economic and social fabric of society. Some governments and professional organisations recommend screening all women for IPV rather than asking only women with symptoms (case-finding). Here, we examine the evidence for whether screening benefits women and has no deleterious effects.

Objectives

To assess the effectiveness of screening for IPV conducted within healthcare settings on identification, referral, re-exposure to violence, and health outcomes for women, and to determine if screening causes any harm.

Search methods

On 17 February 2015, we searched CENTRAL, Ovid MEDLINE, Embase, CINAHL, six other databases, and two trial registers. We also searched the reference lists of included articles and the websites of relevant organisations.

Selection criteria

Randomised or quasi-randomised controlled trials assessing the effectiveness of IPV screening where healthcare professionals either directly screened women face-to-face or were informed of the results of screening questionnaires, as compared with usual care (which could include screening that did not involve a healthcare professional).

Data collection and analysis

Two authors independently assessed the risk of bias in the trials and undertook data extraction. For binary outcomes, we calculated a standardised estimation of the odds ratio (OR). For continuous data, either a mean difference (MD) or standardised mean difference (SMD) was calculated. All are presented with a 95% confidence interval (CI).
Main results

We included 13 trials that recruited 14,959 women from diverse healthcare settings (antenatal clinics, women's health clinics, emergency departments, primary care) predominantly located in high-income countries and urban settings. The majority of studies minimised selection bias; performance bias was the greatest threat to validity. The overall quality of the body of evidence was low to moderate, mainly due to heterogeneity, risk of bias, and imprecision.

We excluded five of 13 studies from the primary analysis as they either did not report identification data, or the way in which they did was not consistent with clinical identification by healthcare providers. In the remaining eight studies (n = 10,074), screening increased clinical identification of victims/survivors (OR 2.95, 95% CI 1.79 to 4.87, moderate quality evidence).

Subgroup analyses suggested increases in identification in antenatal care (OR 4.53, 95% CI 1.82 to 11.27, two studies, n = 663, moderate quality evidence); maternal health services (OR 2.36, 95% CI 1.14 to 4.87, one study, n = 829, moderate quality evidence); and emergency departments (OR 2.72, 95% CI 1.03 to 7.19, three studies, n = 2608, moderate quality evidence); but not in hospital-based primary care (OR 1.53, 95% CI 0.79 to 2.94, one study, n = 293, moderate quality evidence).

Only two studies (n = 1298) measured referrals to domestic violence support services following clinical identification. We detected no evidence of an effect on referrals (OR 2.24, 95% CI 0.64 to 7.86, low quality evidence).

Four of 13 studies (n = 2765) investigated prevalence (excluded from main analysis as rates were not clinically recorded); detection of IPV did not differ between face-to-face screening and computer/written-based assessment (OR 1.12, 95% CI 0.53 to 2.36, moderate quality evidence).

Only two studies measured women's experience of violence (three to 18 months after screening) and found no evidence that screening decreased IPV.

Only one study reported on women's health with no differences observable at 18 months.

Although no study reported adverse effects from screening interventions, harm outcomes were only measured immediately afterwards and only one study reported outcomes at three months.

There was insufficient evidence on which to judge whether screening increases uptake of specialist services, and no studies included an economic evaluation.

Authors' conclusions

The evidence shows that screening increases the identification of women experiencing IPV in healthcare settings. Overall, however, rates were low relative to best estimates of prevalence of IPV in women seeking healthcare. Pregnant women in antenatal settings may be more likely to disclose IPV when screened; however, rigorous research is needed to confirm this. There was no evidence of an effect for other outcomes (referral, re-exposure to violence, health measures, lack of harm arising from screening). Thus, while screening increases identification, there is insufficient evidence to justify screening in healthcare settings. Furthermore, there remains a need for studies comparing universal screening to case-finding (with or without advocacy or therapeutic interventions) for women's long-term wellbeing in order to inform IPV identification policies in healthcare settings.

Plain Language Summary

Screening women for intimate partner violence in healthcare settings

Background

We carried out this review to find out if asking all women (screening) attending healthcare settings about their experience of domestic violence from a current or previous partner helps to recognise abused women so that they may be provided with a supportive response and referred on to support services. We were also interested to know if this would reduce further violence in their lives, improve their health, and not cause them any harm compared to women's usual healthcare.

Women who have experienced physical, psychological, or sexual violence from a partner or ex-partner suffer poor health, problems with pregnancy, and early death. Their children and families can also suffer. Abused women often attend healthcare settings. Some people have argued that healthcare professionals should routinely ask all women about domestic violence. They argue that 'screening' might encourage women who would not otherwise do so, to disclose abuse, or to recognise their own experience as 'abuse'. In turn,
this would enable the healthcare professional to provide immediate support or refer them to specialist help, or both. Some governments and health organisations recommend screening all women for domestic violence. Others argue that such screening should be targeted to high-risk groups, such as pregnant women attending antenatal clinics.

Study characteristics

We examined research up to 17 February 2015. We included research studies that had women over 16 years of age attending any healthcare setting. Our search generated 12,369 studies and we eventually included 13 studies that met the criteria described above. In all, 14,959 women had agreed to be in those studies. Studies were in different healthcare settings (antenatal clinics, women’s health/maternity services, emergency departments, and primary care centres). They were conducted in mainly urban settings, in high-income countries with domestic violence legislation and developed support services to which healthcare professionals could refer. Each of the included studies was funded by an external source. The majority of the funding came from government departments and research councils, with a small number of grants/support coming from trusts and universities.

Key results and quality of the evidence

Eight studies with 10,074 women looked at whether healthcare professionals asked about abuse, discussed it, and/or documented abuse in participating women’s records. There was a twofold increase in the number of women identified in this way compared to the comparison group. The quality of this evidence was moderate. We looked at smaller groups within the overall group, and found, for example, that pregnant women were four times as likely to be identified by a screening intervention as pregnant women in a comparison group. We did not see an increase in referral behaviours of healthcare professionals but only two studies measured referrals in the same way and there were some shortcomings to these studies. We could not tell if screening increased uptake of specialist services and no studies examined if it is cost-effective to screen. We also looked to see if different methods were better at picking up abuse, for example, you might expect that women would be more willing to disclose to a computer, but we did not find one method to be better than another. We found an absence overall of studies examining the recurrence of violence (only two studies looked at this, and saw no effect) and women’s health (only one study looked at this, and found no difference 18 months later). Finally, many studies included some short-term assessment of adverse outcomes, but reported none.

There is a mismatch between the increased numbers of women picked up through screening by healthcare professionals and the high numbers of women attending healthcare settings actually affected by domestic violence. We would need more evidence to show screening actually increases referring and women’s engagement with support services, and/or reduces violence and positively impacts on their health and wellbeing. On this basis, we concluded that there is insufficient evidence to recommend asking all women about abuse in healthcare settings. It may be more effective at this time to train healthcare professionals to ask women who show signs of abuse or those in high-risk groups, and provide them with a supportive response and information, and plan with them for their safety.
### Summary of Findings for the Main Comparison

**Screening for intimate partner violence (IPV) compared with usual care or screening without health professional involvement**

**Patient or population:** women attending healthcare settings for any health-related reason  
**Settings:** healthcare  
**Intervention:** face-to-face screening or written/computerised screening with result passed to the healthcare professional  
**Comparison:** non-screened women or those whose screening result was not passed on to the healthcare professional or those screened for issues other than IPV

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>Universal screening for IPV</th>
<th>Control</th>
<th>Effect</th>
<th>Number of participants (studies)</th>
<th>Quality of the evidence (GRADE)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Identification of IPV by health professionals (assessed immediately or up to 1 month)</td>
<td>259/5006 (5.2%) 86/5068 (1.7%)</td>
<td>1.7%</td>
<td>OR 2.95 (1.79 to 4.87)</td>
<td>31 more per 1000 (from 13 more to 61 more)</td>
<td>⊕⊕⊕ Moderate1</td>
</tr>
<tr>
<td>Identification of IPV by type of healthcare setting - Antenatal clinics</td>
<td>24/317 (7.6%) 6/346 (1.7%) 1.7%</td>
<td></td>
<td>OR 4.53 (1.82 to 11.27)</td>
<td>57 more per 1000 (from 14 more to 149 more)</td>
<td>⊕⊕⊕ Moderater2</td>
</tr>
<tr>
<td>Identification of IPV by type of healthcare setting - Maternal health services</td>
<td>51/594 (8.6%) 9/235 (3.8%) 3.8%</td>
<td></td>
<td>OR 2.36 (1.14 to 4.87)</td>
<td>48 more per 1000 (from 5 more to 124 more)</td>
<td>⊕⊕⊕ Moderate3</td>
</tr>
<tr>
<td>Identification of IPV by type of healthcare setting - Emergency departments</td>
<td>71/1218 (5.8%) 36/1390 (2.6%) 1.2%</td>
<td></td>
<td>OR 2.72 (1.03 to 7.19)</td>
<td>42 more per 1000 (from 1 more to 135 more)</td>
<td>⊕⊕⊕ Moderate4</td>
</tr>
</tbody>
</table>

4Screening women for intimate partner violence in healthcare settings (Review)  
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
<table>
<thead>
<tr>
<th>Identification of IPV by type of healthcare setting</th>
<th>Hospital-based primary care</th>
<th>OR 1.53 (0.79 to 2.94)</th>
<th>53 more per 1000 (from 23 fewer to 167 more)</th>
<th>Moderate³</th>
</tr>
</thead>
<tbody>
<tr>
<td>Referrals (assessed immediately)</td>
<td>7/555 (1.3%)</td>
<td>OR 2.24 (0.64 to 7.86)</td>
<td>7 more per 1000 (from 2 fewer to 35 more)</td>
<td>Low¹</td>
</tr>
</tbody>
</table>

CI: confidence interval; GRADE: Grades of Recommendation, Assessment, Development, and Evaluation; IPV: intimate partner violence; OR: odds ratio.

GRADE Working Group grades of evidence

- **High quality**: Further research is very unlikely to change our confidence in the estimate of effect.
- **Moderate quality**: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
- **Low quality**: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.

¹Downgraded due to heterogeneity.
²Downgraded due to imprecision.
³Downgraded due to risk of bias.
⁴Downgraded due to imprecision and risk of bias.
BACKGROUND

Description of the condition

Intimate partner violence (IPV)

Intimate partner violence (IPV) is a violation of a person’s human rights and is now recognised as a global public health issue. For the purpose of this review, we adopt the definition of IPV (often termed domestic violence) of the World Health Organization (WHO), that is, any behaviour within an intimate relationship that causes physical, psychological, or sexual harm to those in the relationship (Krug 2002; WHO 2013a). Intimate partner violence often involves a combination of abuse behaviours. These include threats of and actual physical violence, sexual violence, emotionally abusive behaviours, economic restrictions, and other controlling behaviours. Many survivors of IPV report that the physical violence is not the most damaging: it is the relentless psychological abuse that leaves the person with long-lasting adverse effects (Campbell 2002; WHO 2013b).

Intimate partner violence against men is a social problem with potential adverse outcomes for victims (Coker 2002). Data from the British Crime Survey suggested that 4.4% of men experienced IPV in the 2012/13 period compared to 7.1% of women (Office for National Statistics 2014). In this review, however, we do not include IPV against men because the majority of abuse with serious health and other consequences is that committed by men against their female partners (Coker 2002), with women being three times more likely than men to sustain serious injury and five times more likely to fear for their lives (CCJS 2005), which is why most screening interventions target women (Tåfå 2001). We also exclude abuse towards women that is perpetrated by other family members such as in-laws or children. We do include in this review, women who experience violence by female partners, and by ex-partners given the increased risks of violence associated with separation (Wilson 1993; Campbell 2004; WHO 2013a).

Prevalence of IPV

Abuse of women by their partners or ex-partners is a common worldwide phenomenon (Garcia-Moreno 2006). Latest figures from the WHO indicate that one in three women globally experiences physical or sexual violence, or both, by a partner, or non-partner sexual violence, in their lifetime (WHO 2013a). Based on 48 population-based surveys across low-, middle-, and high-income countries, the 2002 World Report on Violence and Health revealed rates of between 10% and 69% for lifetime physical violence by a partner (Krug 2002). Definitions used in prevalence studies ranged from physical abuse in current relationships to the inclusion of physical, emotional, sexual, or a combination of abuses in past relationships (Hegarty 2006). Estimates of the magnitude of IPV are obtained from community surveys, clinical samples, and public records. Discrepancies in prevalence rates arise from differences in definitions of IPV, sensitivity of tools, modes of data collection, reporting time frames, and risk variation in the populations sampled (WHO 2013a).

Impacts of IPV

Intimate partner violence can have short-term and long-term negative health consequences for survivors, even after the abuse has ended (Campbell 2002). World Development reports (World Bank 2006) and statements from the United Nations (Ingram 2005) emphasise that IPV is a significant cause of death and disability on a worldwide scale (Ellsberg 2008), and the WHO highlights violence against women as a priority health issue (WHO 2013a). The high incidence of psychosocial, physical, sexual, and reproductive health problems in women exposed to IPV leads to frequent presentations at health services and the need for wide-ranging health services (Bonomi 2009). In addition, IPV is associated with enormous economic and social costs, including those related to social, criminal justice, housing and health services, lost productivity, and human suffering (CDC 2003; Walby 2004; EIGE 2014).

Psychosocial health

The most prevalent mental health sequelae of IPV for female victims are depression, anxiety, post-traumatic stress disorder (PTSD), and substance use (Golding 1999; Hegarty 2004; Rees 2011; Trevillion 2012; WHO 2013a), and women often suffer from low self-esteem and hopelessness (Kirkwood 1993; Campbell 2002). Suicide and attempted suicide are also associated with IPV in both industrialised and non-industrialised countries (Golding 1999; Ellsberg 2008; WHO 2013a). Moreover, these effects impact detrimentally on women’s ability to parent and thus impact on their children (McCosker-Howard 2006). Exposure to IPV during childhood has been linked with poor emotional, social, and attainment outcomes (Kizmanna 2003), with around six in 10 IPV-exposed children exhibiting difficulties. Early exposure to interparental violence has also been associated with increased risk of IPV perpetration or victimisation during adolescence and adulthood (Heyman 2002).

Physical health

Abused women often experience many chronic health problems (WHO 2013a), including chronic pain and central nervous system symptoms (Díaz-Olavarrieta 1999; Campbell 2002), self-reported gastrointestinal symptoms, diagnosed functional gastrointestinal disorders (Coker 2000), and self-reported cardiac symptoms (Tollestrup 1999). Intimate partner violence is also one of the most common causes of injury in women (Stark 1996; Richardson 2002), including oral-maxillofacial trauma treated in dental, emergency, and surgical settings (Clark 2014; Ferreira 2014; Wong...
Over 50% of all female murders in the UK and USA are committed by partners or ex-partners (Brock 1999; Shackelford 2005; Home Office 2010). Worldwide, 38% of female homicides are perpetrated by partners (WHO 2013a). In Australia, as elsewhere, a far higher percentage of indigenous compared with non-indigenous women are murdered by their partners (Mouzos 2003).

Sexual and reproductive health

The most consistent and largest physical health difference between abused and non-abused women is the experience of gynaecological symptoms (McCauley 1995; Campbell 2002). Women and their fetuses and babies are also at risk, before, during, and after pregnancy (Martin 2001; Silverman 2006). The most serious outcome is the death of the mother or the fetus (Jejeebhoy 1998; Parsons 1999). Violence by a partner is also associated with high rates of pregnancy at a young age (Moore 2010), miscarriage and abortion (Taft 2004; Pallitto 2013), low birth weight (Murphy 2001), and premature birth and fetal injury (Mezey 1997). High rates of symptoms of antenatal and postnatal depression, anxiety, and post-traumatic stress disorder (PTSD) are also associated with exposure to IPV during adulthood and pregnancy (Howard 2013).

Description of the intervention

Interventions by healthcare practitioners to improve the health consequences for women experiencing IPV

Healthcare services play a central role in abused women's care (García-Moreno 2014), but the quality of healthcare professionals' responses has been a focus of concern since the 1970s (Stark 1996; Feder 2006). Over the last few decades there has been a concerted effort by women's and justice organisations and the voluntary sector to respond to the needs of women who have experienced IPV. In contrast, the response of health services has been slow (Feder 2009). While most health professionals believe that IPV is a healthcare issue (Richardson 2001), there are a number of barriers to identification and response on the part of practitioners (Hegarty 2001). These include a perceived lack of time and support resources, fear of offending the woman, a lack of knowledge and training about what to do for the woman, and a belief that the woman will not leave the abusive relationship (Waalen 2000). A further barrier is the lack of evidence for effective interventions (García-Moreno 2014).

Despite these barriers, there has been progress in the overall response of health systems to IPV with many health professional associations around the world publishing guidelines for clinicians on how to identify women who have been abused (Davidson 2000; Family Violence Prevention Fund 2004; Hegarty 2008). Implicit in many of these recommendations is the assumption that screening or asking routinely about abuse will increase identification of women who are experiencing violence, lead to appropriate interventions and support, and ultimately decrease exposure to violence and its detrimental health consequences, both physical and psychological (Taft 2004; WHO 2013b). Screening is predicated on the assumptions that identifying and responding supportively to, and referring on, women experiencing IPV is fulfilling health professionals' duty of care. However, advocacy or ongoing therapy requires appropriate training and time that clinicians may not have in routine care. Further, clinicians are part of a wider system of response and need to be able to identify and refer to domestic violence services that have more time, and have specialist training and connections to other community-based services such as housing. Training and knowledge of referral services should improve clinicians' motivation to identify when they are not responsible for ongoing domestic violence counselling and advocacy. This review, an update of an earlier review (Taft 2013; O'Doherty 2014a), is focused on screening with a brief response only; it does not include advocacy or psychotherapeutic interventions, which are the topics of separate reviews.

Screening

Screening aims to identify women who have experienced, or are experiencing, IPV from a partner or ex-partner in order to offer interventions leading to beneficial outcomes. However, within the field of domestic/family violence, both the immediate- and longer-term benefit of screening such women remains unproven (Taket 2004; Spangaro 2009; WHO 2013b), despite some recommendations for screening in particular countries (e.g. USA) (Nelson 2012). Many factors, such as fear or readiness to take action, influence whether or not women choose to disclose their abuse (Chang 2010), and will affect accurate measurement of screening rates. Screening for IPV, therefore, is a problematic concept when traditional screening criteria are applied (Hegarty 2006), as it is a complex social phenomenon rather than a disease. However, it still requires rigorous evidence for its effectiveness if it is to be implemented as policy.

It is important to distinguish between universal screening (the application of a standardised question to all symptom-free women according to a procedure that does not vary from place to place), selective screening (where high-risk groups, such as pregnant women or those seeking pregnancy terminations are screened), routine enquiry (when all women are asked but the method or question varies according to the healthcare professional or the woman’s situation), and case-finding (asking questions if certain indicators are present).

For this review, screening is defined as any method that aims for every woman patient in a healthcare setting to be asked about her experiences of IPV, both past and present. Screening may be conducted directly by a healthcare professional or indirectly through a self-completed questionnaire (often by computer) with the healthcare professional informed of the questionnaire results. This may include the use of screening tools (Rabin 2009), which vary in...
their validity and reliability and therefore in their effectiveness to accurately detect abuse. These tools are reviewed in CDC 2007 and Feder 2009. Alternatively, clinicians may ask one or a range of questions related to IPV only at one time point or at several. It is very unlikely that one single question will address the range of women's experiences of IPV. Whether a woman is currently experiencing IPV from a current partner or an ex-partner (e.g. harassment) or has previously experienced IPV, the goal of screening is the same - to identify her and offer support appropriate to her needs that will prevent any further abuse (e.g. advocacy, legal or police help) and reduce any consequent problems she is experiencing (e.g. offering therapeutic support) or a combination of these. There has long been debate about the value of screening per se (Taket 2004; Feder 2009), with some arguing that asking questions can raise awareness in women experiencing IPV who are contemplating their situation. Generally, most women are in favour of universal screening, although this varies with abuse status and age (Feder 2009). However, studies have found that women's preferences vary according to the method of screening used (MacMillan 2006; Feder 2009); readers are referred to several studies that have examined this question but were excluded from this review (Furbee 1998; Bair-Merritt 2006; Chen 2007; Rickert 2009). Bair-Merritt 2006 found a similar rate of disclosure in audiotaped (11%) compared with written questionnaires (9%) with both methods preferred to direct physician enquiry. Chen 2007 found that there was little difference between self completion and healthcare professional enquiry in terms of participant comfort, time taken, and effectiveness, but that women who had experienced IPV were less comfortable with physician screening. MacMillan and colleagues reported that women found self completion methods easier and more private and confidential (MacMillan 2006). However, women's preferences for how they are asked about IPV needs to be examined in the context of outcomes beyond disclosure. In other words, self interview methods may yield higher disclosure rates, but does this translate into increased awareness about IPV, better uptake of services, reduced re-exposure to IPV, and improvements in health?

Identifying IPV is only the first step in intervention. Among women receiving care in US primary care clinics, Klevens 2012b tested computer-assisted screening accompanied by a brief video in which an advocate provided support and information and encouraged women to seek help and referral information versus no screening with referral information only, versus usual care. One year later they found no difference between the three groups in physical or mental health status. Women may have experienced long-standing abuse or it may have commenced recently; they may be unaware that the behaviour constitutes abuse or be actively seeking support for change, and therefore responses to their needs may need to differ (Chang 2010; Reisenhofer 2013), and may require involvement of a healthcare professional rather than a list of resources.

Two reviews of studies addressing the UK National Screening Committee criteria found that screening by healthcare professionals leads to a modest increase in the number of abused women being identified following screening, but that screening was not acceptable to the majority of health professionals surveyed (Ramsay 2002; Feder 2009). Hegarty 2006 outlines the many clinician barriers (e.g. time, lack of ongoing or effective training and resources) and system barriers (e.g. different health priorities, lack of referral options in the community) that impede effective screening and routine enquiry, and that need to be addressed before clinicians will feel comfortable asking women about their experiences of abuse. In addition, women experience barriers to disclosure, especially during pregnancy, with the presence of abusive partners or monitoring of her attendance at healthcare services where she might disclose. Most reviews to date have concluded that there is no evidence that women experience better outcomes from screening interventions (Ramsay 2002; Wathen 2003; Taft 2013). This lack of evidence has not deterred many governments around the world implementing universal IPV screening, or selective screening in high-risk populations. Previous US and Canadian Task Forces on Preventive Health Care conducted thorough systematic reviews of the evidence and concluded that there was insufficient evidence to recommend for or against routine screening for violence against women (Wathen 2003; Nelson 2004); however, the US Preventive Services Task Force revised their decision (Nelson 2012) and now recommend screening based on scant evidence from one effectiveness study (MacMillan 2009). The WHO reviewed the evidence in 2013 and recommended screening women only when they are pregnant (WHO 2013b). In some countries, screening is advocated in the absence of sufficient resources or referral options, and where there is a lack of training and resources, clinicians may undertake screening inappropriately. Some would further argue that it is unethical to implement screening for IPV in the absence of evidence of effectiveness as it may cause harm (Jewkes 2002; Wathen 2012).

How the intervention might work

Universal screening aims for 100% of women to be asked about IPV and those experiencing IPV to disclose it. Universal screening may apply to all women in a healthcare setting, such as a hospital, while selective screening could be applied to those in high-risk groups such as those in antenatal or abortion clinics or pregnant women attending community-based family practice clinics. Screening women using face-to-face methods implies the clinician is directly asking all women who attend for a given consultation whether they are experiencing or have ever experienced abusive behaviours from their partner or ex-partner, providing women with the choice to disclose or not. Women who disclose abuse may then be offered a response such as safety assessment and planning, emotional support, referral to specialist services, or information on appropriate local/national resources. Another model might offer all women attending a given health service the option of self
completing screening (through written or computer-based methods) where a woman can choose whether or not to disclose abusive behaviour from a partner or ex-partner. Positive screen results would then be assessed by the consulting healthcare professional who could exercise their own clinical judgement in how to respond to a positive result. The option of administrative or computerised follow-up has been explored where the clinician is bypassed, and instead, for example, a print-out of resources is generated. Klevens and colleagues found no effect of this type of screening intervention on outcomes for women (Klevens 2012b).

**Why it is important to do this review**

This review was originally published two years ago (Taft 2013). However, the international debate on whether or not screening in healthcare settings is beneficial to women has continued. Given that the evidence presented in the previous review was appraised as low to moderate quality and there were few studies that examined medium- and long-term health and abuse outcomes, it is important to search for and synthesise new research and, where possible, combine studies of similar outcomes in a meta-analysis. We have incorporated another review 'Domestic violence screening and intervention programmes for adults with dental or facial injury' into this update (Coulthard 2010), please see section on Differences between protocol and review. The reasons for doing this work have not changed since the original review. There is an urgent need to assess and identify health sector screening interventions for IPV (Davidson 2000; Feder 2009), in order to: have clear evidence about what health professionals can do safely and effectively to decrease the impact of IPV on women; determine what is cost-effective; and inform health professionals and policymakers about the cost/benefit of screening interventions. In particular, this systematic review examines the most rigorous evidence around health service screening interventions for IPV to ascertain whether the potential benefits of IPV screening for women's health and wellbeing outweigh any potential for harm.

**OBJECTIVES**

To assess the effectiveness of screening for IPV conducted within healthcare settings on identification, referral, re-exposure to violence, and health outcomes for women, and to determine if screening causes any harm.

**METHODS**

**Criteria for considering studies for this review**

**Types of studies**

Any study that allocated individual women, or clusters of women, by a random or quasi-random method (such as alternate allocation, allocation by birth date, etc.) to a screening intervention compared with usual care or to a condition where healthcare professionals were not aware of women's screening results.

**Types of participants**

Women (aged 16 years and over) attending a healthcare setting. We define a 'healthcare setting' as any health setting where health services are delivered (such as those listed below), and home visits by these services.

1. General (family) practice
2. Antenatal and postnatal services
3. Hospital emergency, inpatient or outpatient services
4. Private specialists (e.g. obstetrics and gynaecology, psychiatry, ophthalmology)
5. Community health services
6. Drug and alcohol services
7. Mental health services
8. Dental services

**Types of interventions**

Any IPV screening in a healthcare setting as listed above. Screening is defined as any of a range of methods (face-to-face, survey or other method, specific to IPV or where IPV was included as part of general psychosocial screening) that aims for all women patients in a healthcare setting to be asked about current or past IPV, including the use of screening tools as well as asking one or a range of screening questions related to IPV on one or more occasions. We only included studies where, in one arm of the trial, the treating healthcare professional conducted the screening or was informed of the screening result at the time of the relevant consultation. We excluded extended interventions that went beyond screening and an immediate response to disclosure, for example, interventions that include clinical follow-up or offer further counselling or psychological treatment. We made this an exclusion factor as it is rarely feasible for health professionals to deliver intensive treatments due to lack of time and skill. Furthermore, we wanted to isolate the effect of screening in order to provide evidence on the independent contribution of this particular response to IPV. Screening was compared to usual care, implying no screening in the comparative arm. However, we did include studies where an eligible screening intervention was compared to a condition of 'screening' that involved no healthcare professionals or face-to-face interaction.

**Types of outcome measures**

We did not use outcomes measured by studies as a criterion for inclusion or exclusion.
Primary outcomes

A. Identification of IPV by health professionals (data based on clinical encounter). Identification was defined as any form of acknowledgement by a healthcare professional during a consultation that the woman had experienced exposure to IPV. Identification therefore assumes communication between healthcare professional and participant that acknowledges the abuse. Studies use different terms such as identification, discussion, and patient disclosure of IPV. We carefully assessed how stated outcomes were operationalised across trials in order to determine if they met our definition of identification. Studies could collect identification data using a variety of methods (e.g. audio-recordings of encounters, surveying women and healthcare professionals about what was discussed during the encounter, and medical record review). Identification of IPV through face-to-face interviews with researchers was dealt with separately on the basis that it did not properly represent the clinical context and may threaten the validity of the primary identification data.

B. Information-giving and referrals to support agencies by healthcare professionals (including take-up rates when available). We included in this category any recording, documentation or organisational validation that women had been given information about, or referral to, support agencies.

Secondary outcomes

C. Intimate partner violence as measured by:
   1. validated instruments (e.g. Composite Abuse Scale (CAS), Index of Spouse Abuse (ISP)); and
   2. self reported IPV, even if using a non-validated scale.

D. Women’s perceived and diagnosed physical health outcomes, using measures of:
   1. physical health (e.g. Short-Form health survey - 36 (SF-36) physical subscale, General Health Questionnaire (GHQ));
   2. physical injuries, such as fractures and bruises (self reported or documented in medical records); and
   3. chronic health disorders, such as gynaecological problems, chronic pain, and gastrointestinal disorders (self reported or clinical symptoms, or both, documented in medical records).

E. Women’s psychosocial health, using measures of:
   1. depression (e.g. Beck Depression Inventory (BDI), Center for Epidemiologic Studies Depression Scale (CES-D));
   2. post-traumatic stress (e.g. Impact of Events Scale (IES), Post-traumatic Stress Disorder Checklist (PCL));
   3. anxiety (e.g. Spielberger’s State-Trait Anxiety Inventory (STAI), Beck Anxiety Inventory (BAI));
   4. self efficacy (e.g. Generalized Perceived Self-Efficacy Scale (GSE), Sherer’s Self-Efficacy Scale (SES));
   5. self esteem (e.g. Rosenberg Self-Esteem Scale (SES), Coopersmith Self-Esteem Inventory (CSEI));
   6. quality of life (e.g. WHO Quality of Life-Bref)
   7. perceived social support (e.g. Medical Outcomes Scale (MOS), Sarason’s Social Support Questionnaire (SSQ)); and
   8. alcohol or drug abuse (e.g. Addiction Severity Index (ASI), Alcohol and Other Drug Abuse (AOD) scale).

F. Occurrence of adverse outcomes such as:
   1. increased deaths, all-cause or IPV-related (documented in medical records or routinely collected data);
   2. increase of IPV as measured by any of the above;
   3. increase of physical or psychosocial morbidity as listed above; and
   4. false negatives and false positives of screening tests.

G. Services and resource use:
   1. family/domestic violence services;
   2. police/legal services;
   3. counselling or therapeutic services;
   4. health service use; and
   5. other services.

H. Cost/benefit outcomes, using measures of:
   1. health service use;
   2. days out-of-role; and
   3. medication use.

Timing of outcome assessment

We documented the duration of follow-up in all included studies. For the purposes of this review, we defined short-term follow-up as less than six months since baseline or delivery of the screening intervention, medium-term follow-up as between six and 12 months, and long-term follow-up as more than 12 months.

Selecting outcomes for 'Summary of findings' table

We included the results of outcomes that could be pooled together in a meta-analysis in the 'Summary of findings' tables (Summary of findings for the main comparison and Summary of findings 2). These were the primary outcomes of clinical identification of IPV, and referral. We also included an outcome that was not indicated a priori, an alternative identification outcome, which we refer to as non-clinical identification (these data were not drawn from documentation of abuse; medical records etc. within the clinical context) (see Differences between protocol and review).

Search methods for identification of studies

We searched the international literature for peer-reviewed and non-peer-reviewed studies and published and unpublished studies. We did not apply any date or language restrictions to our search strategies. We chose not to use a randomised controlled trial (RCT) filter as we wanted the search to be as inclusive as possible; an initial check of the differences between using and not using a RCT filter uncovered a trial not captured when the RCT filter was applied. Our previous search strategies were not limited to...
any healthcare setting, and so did not require any revisions as they already captured records relevant to oral and maxillofacial injury clinics. The previous version of this review included studies up to July 2012. The searches for this update cover the period from 2012 to 17 February 2015.

Electronic searches
We searched the following databases on 17 February 2015.
1. Cochrane Central Register of Controlled Trials (CENTRAL 2015, Issue 1), which includes the Specialised Register of the Cochrane Developmental, Psychosocial and Learning Problems Group (CDPLPG).
2. Ovid MEDLINE(R) 1946 to February Week 2 2015.
3. Ovid MEDLINE(R) In-process and other non-indexed citations 13 February 2015.
5. CINAHL PLUS (EBSCOhost) 1937 to current.
6. PsycINFO (Ovid) 1806 to February Week 2.
7. Sociological Abstracts (ProQuest) 1952 to current.
8. Conference Proceedings Citation Index - Social Science and Humanities (CPCI-SS&H; Web of Science) 1990 to 17 February 2015.
10. Cochrane Database of Systematic Reviews (CDSR) 2015, Issue 2, part of the Cochrane Library.
11. WHO International Clinical Trials Registry Platform (ICTRP) (who.int/ictrp/en/).
The search strategies used for this update are in Appendix 1. Search strategies used for earlier versions of the review are in Appendix 2. The searches were originally run by Joanne Abbott, former Trials Search Co-ordinator (TSC) of CDPLPG. Subsequent searches were conducted by Margaret Anderson, current TSC of CDPLPG. We also searched the website of the World Health Organization (WHO) (who.int/topics/violence/en/) and the Violence Against Women (VAW) Online Resources (vaw.umn.edu/).

Searching other resources

Handsearching
Due to insufficient resources, we were unable to undertake planned handsearching of the Journal of Family Violence, Journal of Interpersonal Violence, Violence and Victims, Women’s Health, American Journal of Preventive Medicine, American Journal of Public Health, Annals of Emergency Medicine, Archives of Internal Medicine, Australian & New Zealand Journal of Public Health, and Journal of the American Medical Association. We are confident that any major screening trials involving healthcare professionals would have been identified through our other search strategies, including our electronic searches and searches of trials registers, citation tracking, networks of the review authors, and communication with authors of included studies.

Citation tracking
We examined the reference lists of acquired papers and tracked citations forwards and backwards.

Personal communication with the first authors of all included articles
We emailed the authors of all primary studies included in the review about any omissions (and, in particular omissions of non-peer-reviewed studies). We contacted the WHO Violence and Injury Programme to inquire about any screening studies that might fit our inclusion criteria of which we were unaware, especially in low- and middle-income countries (García-Moreno 2015 [pers comm]).

Data collection and analysis

Selection of studies
We ran searches four times for this review (September 2009, September 2011, July 2012, and February 2015; see Figure 1). In the original review, two review author pairs (LOD and AT, LOD and KH) independently reviewed abstracts. For this update, TL and EC independently reviewed studies by title and abstract. LOD and AT reviewed studies independently from the point at which full-text articles had been retrieved (n = 42 in this update).
Where possible, we resolved disagreement about abstract inclusion between any review authors by reading the full study followed by discussion. When agreement could not be reached, a third review author outside that author pairing (GF, LD, JR or KH) assessed whether or not the study fulfilled the inclusion criteria. Originally, the complex nature of the 'screening' definition required that the entire team met in order to discuss at length and finalise the revised definition of a screening intervention now governing criteria for this review. Two review authors (LOD and AT) independently assessed each study included to this stage against the inclusion criteria with KH also assessing the 42 full-text articles in the 2015 update. As with the earlier stage of the study review process, we resolved any disagreement by discussing studies in-depth with other review authors (GF, LD or JR). Where additional information was required to adequately understand the nature of the screening intervention and design, we contacted the first author of the study in question. This led to all outstanding issues being resolved. The reasons behind decisions to exclude otherwise plausible studies are offered in the 'Characteristics of excluded studies' table.

**Data extraction and management**

Two review authors (LOD and AT prior to 2015, or LOD and TL in 2015) independently extracted the data from the included studies and entered data into electronic data collection forms. We requested any missing information or clarification from the first or corresponding authors of papers, and of the nine authors that we contacted, eight replied (Rhodes 2002; Carroll 2005; MacMillan 2009; Koziol-McLain 2010; Humphreys 2011; Klevens 2012a;
We resolved any disagreements between the two review authors as regards data extraction through discussion; no adjudication by a third review author was necessary. We noted all instances where additional statistical data were provided by study investigators and we distinguished these data as such in the text (Effects of interventions). Once agreed, we entered all relevant data into Review Manager (RevMan) software, Version 5.3 (RevMan 2014).

We recorded the following information in the ‘Characteristics of included studies’ table.

1. Method: randomisation or quasi-randomisation method, intention-to-treat analysis, power calculation, and study dates.
2. Participants: setting, country, inclusion and exclusion criteria, numbers recruited, numbers dropped out, numbers analysed, age, marital status, ethnicity, socioeconomic status, and educational background.
3. Interventions: brief description of intervention, including screening tool and method, and method of usual care.
4. Outcomes: timing of follow-up events, outcomes assessed, and scales used.
5. Notes: further information to aid understanding of the study such as source of funding.

Assessment of risk of bias in included studies

Two review authors (LOD and AT prior to 2015, or LOD, AT, and TL in 2015) independently assessed the risk of bias of all included studies using the criteria outlined below and cross-checked in accordance with the updated methodological criteria in Section 8 of the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011). We rated each domain, for each included study, as either 'high', 'low' or 'unclear' risk of bias.

Sequence generation

Description: the method used to generate the allocation sequence was described in sufficient detail so as to enable an assessment to be made as to whether it should have produced comparable groups. Review authors’ judgement: was there selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence?

Allocation concealment

Description: the method used to conceal allocation sequences was described in sufficient detail to assess whether intervention schedules could have been foreseen in advance of, or during, recruitment.

Review authors’ judgement: was there selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment?

Incomplete outcome data

Description: the study reported data on attrition and the numbers involved (compared with total randomised) as well as the reasons for attrition or these were obtained from investigators.

Review authors’ judgement: was there attrition bias due to the amount, nature, or handling of incomplete outcome data?

Selective outcome reporting

Description: attempts were made to assess the possibility of selective outcome reporting by authors. Where available, we checked protocols and trial databases for prior outcome specification. Where a protocol was not available, we searched the databases of registered trials to check pre-specified outcome measures. Where neither were available, we were unable to assess this and therefore nominated this as ‘uncertain’.

Review authors’ judgement: were reports of the study free of suggestion of selective outcome reporting?

Baseline measurement of outcome measures

Review authors’ judgement: were baseline data (if available) evenly distributed?
Reliability of outcome measures
Review authors’ judgement: were outcome measures validated and referenced?

Protection against contamination
Review authors’ judgement: was there adequate protection against the study being contaminated?

Measures of treatment effect

Continuous outcomes
We analysed continuous data if (i) means and standard deviations (SDs) were available in the report or obtainable from the authors of studies, and (ii) the data were said to be normally distributed. If the second standard was not met then we did not enter such data into RevMan (RevMan 2014) (as it assumes a normal distribution). (More detail on the treatment of continuous data is available in Appendix 3).

Binary outcomes
For binary outcomes (e.g. woman identified/not identified, referred/not referred), we calculated a standard estimation of the odds ratio (OR) and 95% confidence intervals (CI) using a random-effects model (Higgins 2011). Where data required to calculate the OR were neither reported nor available from the authors of studies, we did not try to calculate these but have provided the findings as published by the authors.

Unit of analysis issues
We anticipated both individual- and cluster-randomised controlled trials would be identified. With regard to cluster trials, we examined studies to assess whether they had accounted for the effects of clustering using the CONSORT (Consolidated Standards of Reporting Trials) recommendations (Campbell 2012). We have archived methods for re-analysing cluster trials in future updates of this review (Appendix 3). We did not use indirect comparisons as all included studies compared the intervention to a suitable comparison condition (usual care or no involvement of healthcare professionals).

Dealing with missing data
We assessed missing data and dropout rates for each of the included studies. If studies were required to impute missing data in published articles, and tables of outcomes with and without imputation were provided, we used the imputed figures. The ‘Characteristics of included studies’ tables specify the number of women who were included in the final analysis in each group as a proportion of all women randomised in the study. Where available, we provided the reasons given for missing data in the narrative summary along with an assessment of the extent to which the results may have been influenced by missing data. We planned to use sensitivity analysis to deal with missing data. No study conformed to all intention-to-treat analysis criteria. We included those in which all completed cases were analysed in the groups to which they were randomised (available case analysis, Higgins 2011, Section 16.2), irrespective of whether or not they received the screening intervention. More detail on the treatment of missing data is available in Appendix 3.

Assessment of heterogeneity
We assessed the consistency of results visually and by examining the $I^2$ statistic - a quantity that describes approximately the proportion of variation in point estimates that is due to heterogeneity rather than sampling error (Higgins 2002). Where significant statistical heterogeneity was detected ($I^2 > 50\%$), we explored differences in clinical characteristics (participants, interventions, outcomes) and methodological characteristics (risk of bias, study design) with modified analyses. We then summarised any differences in the narrative synthesis.

Assessment of reporting biases
There were not enough studies to assess reporting biases. Methods for assessing reporting bias, archived for future updates of this review, are available in Appendix 3.

Data synthesis
We only performed a meta-analysis where there were sufficient data and it was appropriate to do so. The decision to pool data in this way was determined by the compatibility of populations, denominators, and screening methods (clinical heterogeneity), duration of follow-up (methodological heterogeneity), and outcomes. As fixed-effect models ignore heterogeneity, we have used the random-effects models to take account of the identified heterogeneity of the screening interventions. The Mantel-Haenszel method, a default program in RevMan (RevMan 2014), can take account of few events or small study sizes and can be used with random-effects models. Where it was inappropriate to combine the data in a meta-analysis, we provided a narrative description of the effect sizes as specified in the original study and 95% CIs or SDs for individual outcomes in individual studies. We did not access individual patient data (IPD) as we did not encounter unpublished studies or studies whose data could not be included in our analyses. The main issue with studies included in this review was risk of bias and the IPD approach cannot, generally, help avoid bias associated with study design or conduct (Higgins 2011).
'Summary of findings' table

We used the online Guideline Development Tool (GDT; GRADEpro GDT) to develop 'Summary of findings' tables (Summary of findings for the main comparison and Summary of findings 2). These tables summarise the amount of evidence, typical absolute risks for screened and non-screened women, estimates of relative effect, and the quality of the body of evidence. We used the Grades of Recommendation, Assessment, Development, and Evaluation (GRADE) approach to classify the review findings: high quality (further research is unlikely to change our confidence in the estimate of effect); moderate quality (further research is likely to have an important impact on our confidence in the estimate of effect, and might change it); and low or very low quality (further research is likely to have an important impact on our confidence in the estimate of effect and is likely to change it). The quality of a body of evidence involves considering risk of bias within studies (methodological quality), directness of evidence, heterogeneity, precision of effect estimates, and the risk of publication bias.

Subgroup analysis and investigation of heterogeneity

We performed subgroup analyses for type of healthcare setting, and analysed data from a subset of studies that measured prevalence (or non-clinically based identification) rather than clinical identification. Not enough studies were identified to perform all subgroup analyses planned in the protocol for this review (Tift 2008). Please also see Appendix 3 for subgroup analyses archived for future updates of this review.

Sensitivity analysis

We based our primary analyses on available data from all included studies relevant to the comparison of interest. To assess the robustness of conclusions to quality of data and approaches to analysis, we conducted the following sensitivity analyses:
1. study quality;
2. differential dropout.
We have archived additional analyses for future updates of this review. Please see Appendix 3.

RESULTS

Description of studies

Results of the search

Our searches of the listed electronic databases (see Figure 1) generated 12,369 records (including nine records identified from the reference lists of included studies and from contact with authors) of which 3533 were duplicates; we therefore screened 8836 abstracts. Authors agreed that 8597 abstracts were irrelevant and that 239 required joint review. Following discussions, we excluded a further 137. We subsequently retrieved full-text papers for 102 records. We determined that 42 were ineligible. A further 43 articles, which appeared as though they could meet inclusion criteria, ultimately did not and we excluded them (reasons for their exclusion are detailed in the 'Characteristics of excluded studies' tables). Thirteen studies (that were published in 17 papers) met the inclusion criteria.

Included studies

Study designs

Thirteen randomised controlled trials (Carroll 2005; MacMillan 2006; Rhodes 2006; Ahmad 2009; MacMillan 2009; Kataoka 2010; Koziol-McLain 2010; Humphreys 2011; Kleven 2012a; Fraga 2014; Fincher 2015), of which, two were quasi-randomised controlled trials (Rhodes 2002; Trautman 2007), met the criteria for inclusion in this review. All 13 studies were reported in peer-reviewed journals.

Location

Four studies were conducted in Canada (Carroll 2005; MacMillan 2006; Ahmad 2009; MacMillan 2009), six in the USA (Rhodes 2002; Rhodes 2006; Trautman 2007; Humphreys 2011; Kleven 2012a; Fincher 2015), one in Japan (Kataoka 2010), one in Portugal (Fraga 2014), and one in New Zealand (Koziol-McLain 2010).

Several were cluster-randomised trials, which accounted for clustering in their analyses, and were conducted in diverse healthcare settings (Carroll 2005; MacMillan 2006; MacMillan 2009). Rhodes 2006 stratified by clinic location (inner urban or suburban) and randomised within location.

Healthcare settings

In three studies, women were recruited from antenatal clinics (Carroll 2005; Kataoka 2010; Humphreys 2011), while Fraga 2014 enrolled women who were one year postpartum at a hospital obstetrics department and MacMillan 2009 included an obstetrics and gynaecology clinic. Four were located in emergency departments (EDs) only (Rhodes 2002; Rhodes 2006; Trautman 2007; Koziol-McLain 2010). Ahmad 2009 was conducted in a hospital-affiliated family practice, and both MacMillan 2006 and MacMillan 2009 combined primary and tertiary care sites (family practices, EDs, and women’s health services). Kleven 2012a was conducted in assorted women’s health clinics in a hospital. Fincher 2015 screened women participating in a Special Supplemental Nutrition Program at a Women, Infants, and Children's
(WIC) service. We identified no eligible trials in dental or ophthalmology settings or in maxillofacial injury or fracture clinics.

Characteristics of participants

Both clinicians and their patients participated in all included studies.

Healthcare professionals

In two studies, the first type of participant to be recruited was the clinician (Carroll 2005; Ahmad 2009). They were trained prior to the recruitment of patient participants.

Ahmad 2009 recruited 11/14 eligible family physicians from urban academic hospital-affiliated family practice clinics. Seven were white female clinicians who had an average age of 46 years and averaged 16 years in practice. Carroll 2005 recruited 48 family physicians, obstetricians, and midwives from four practices diverse in location and populations, which provided antenatal and postpartum care. These different clinicians were paired by age, sex, clinician type, and health service location where possible and then randomised in pairs. Thirty-six of 48 (75%) were family physicians; the mean age was 42 years and 50% were female. They averaged 13.5 years in practice.

Participants

The 14,959 women recruited to the 13 studies were very diverse in sociodemographic characteristics, and while some studies described the entire screened population, others only described those whose abuse status was identified through screening. The majority of women were Canadian, with over 9000 recruited to MacMillan 2006 and MacMillan 2009.

Pregnant women screened in antenatal settings were aged 30 years or less (Carroll 2005; Kataoka 2010; Humphreys 2011). In Carroll 2005, among the 253 women, 84% were Canadian born; the majority were married with an even income spread and no or minor concerns about their pregnancy. Similarly, although located in an urban Japanese clinic, the 323 women in Kataoka 2010 were overwhelmingly married (over 90%); around 60% were having their first child; and around 80% had post secondary school qualifications, with 42% having college graduate or postgraduate qualifications.

In contrast, Humphreys 2011 described only those 50/410 pregnant women assessed as ‘at risk’ for IPV at five San Francisco bay antenatal clinics; their profile is consistent with disadvantage. These 50 women were ethnically diverse: 17 were Hispanic, 11 were black or African-American, 15 were white, and seven were from other backgrounds. Twenty-three had never married and 29/50 had only high school education or less. The mean age was 28 years and 38 women had been previously pregnant. Women’s mean gestational age was 20 weeks and 14 had smoked tobacco in the past 30 days. Forty-three had been abused in the year before pregnancy and 19 since pregnancy. Twelve had been abused one to three times; four had been abused four to six times; and one more than six times (two had missing data for frequency). Fraga 2014 involved women in a maternity setting who were one year postpartum and had consented to be contacted a year earlier around the time their baby was born. Although they do not provide sociodemographic information for the 915 women in this rapid report, the sample from which women were drawn involved 2660 white women, 9.7% of whom had experienced physical abuse during pregnancy. Women who were abused were more likely to experience preterm birth compared to non-abused women (21% versus 6.8% respectively), and they were less educated and more likely to be under 20 years of age, not cohabiting, have lower incomes, and have received less antenatal care (Rodrigues 2008).

Klevens 2012a recruited 126 predominantly disadvantaged black women (78.6%) from diverse women’s health clinics (obstetric, gynaecological, and family planning) of a Chicago public hospital. The women had a mean age of 35.8 years; either a high school education or less (42.4%) or vocational/college (41.9%); and were uninsured (57.1%) or had Medicaid (37.3%).

Women in emergency settings only were recruited from urban hospitals with ethnically diverse populations (Rhodes 2002; Rhodes 2006; Trautman 2007; Koziol-McLain 2010). These women tended to be older. In the New Zealand study (Koziol-McLain 2010), 37.6% of 399 women were Maori and their median age was 40 years. The women’s incomes were evenly spread but tended to be in a low-income bracket; just under half (45.6%) had completed a post-school qualification other than a university degree (8.3%). About 67.4% currently had partners; and 64.9% were from the main urban area. In a Baltimore Level 1 trauma hospital, the 411 women in Trautman 2007 were overwhelmingly non-white (83.9%); 41% were aged 35 to 54 years; the majority (50.9%) had children at home; and 34.8% were on Medicaid insurance. While 42.3% had high school graduates, 30.5% had not graduated from high school and 42.4% had an income in the lowest quintile. Around one-half had physical and mental health summary scores one or two standard deviations (SDs) below norms. The 323 women recruited in Rhodes 2002 had similar characteristics to the urban women in Rhodes 2006. The 1281 women in Rhodes 2006 were very diverse according to whether they were recruited in an urban or suburban ED setting. In the urban ED, 86% of 883 women were African-American (90% in 2002); had a mean age of 32 years (37 years in 2002); 35% had a high-school diploma or less and 38% qualifications after high school, but 53% had an income in the lowest quartile; 46% relied on Medicaid (39% in 2002); and 51% were single (59% in 2002). By contrast, in the suburban ED clinic, the median age of the 398 women was 36 years; 80% were white; 71% had post-high-school qualifications; the income spread was more even; 65% had private insurance; and 43% were married with only 31% single.

Ahmad 2009 was the only study to be based solely in a family practice clinic affiliated with an urban academic hospital in Toronto,
Screening women for intimate partner violence in healthcare settings (Review)

Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Canada. The mean age of the 293 women was 44 years; 34.5% of women were born outside Canada; over half were married with 29% having children under 15 years of age living at home. Two-thirds were employed full- or part-time with an even spread of income, although just under one-third were in the lowest quintile. MacMillan 2006 recruited 2461 women from mixed settings: two family practices, two EDs, and two women's health clinics. The women's mean age was 37.1 years; 87% were born in Canada; 55% were married; 46.6% had children at home; 52.2% were educated for more than 14 years; 46.9% were working full- or part-time; and 17.6% had incomes in the lowest quintile.

In the MacMillan 2009 study, 6743 women were also recruited from mixed settings: 12 primary care clinics, 11 EDs, and three obstetric/gynaecology clinics. Characteristics were only described for the 411 women retained and 296 women lost to follow-up (LTFU) since recruitment, but there was a clear trend to greater abuse and disadvantage among those LTFU compared with those retained. Compared to those LTFU, women retained were more educated, less likely to be single, and had lower scores on the Women Abuse Screen Tool (WAST) and Composite Abuse Scale (CAS).

Fincher 2015 recruited 402 African-American women, with a mean age of 27 years, who were attending a Women, Infants, Children's (WIC) clinic in Atlanta, Georgia USA. This is an area of high disadvantage with 19% of families living below the federal poverty line and one in four of these families has a child under five years of age. Nearly half of families receive food stamps; the majority are African-American households. The majority of respondents were single (40%) or in an unmarried relationship (45%). Fourteen per cent of respondents completed some high school education, and 30% had received a high school degree.

### Screening intervention

#### Screening tools

The screening tools applied in these studies as part of the intervention were very heterogeneous. The majority employed an IPV-specific validated screening instrument, with some studies using more than one tool. Included interventions always consisted of face-to-face or healthcare professional-involved screening. Ideally this was compared to usual care (with no enquiry about IPV). However, there were instances of a screening instrument being applied in the control arm through, for example, computerised or written enquiry, which was tolerated providing those results were not processed by any clinical staff. The tools used in one or more arms of trials were: Woman Abuse Screening Tool (WAST) (MacMillan 2006; MacMillan 2009); Abuse Assessment Screen (AAS) (Rhodes 2006; Ahmad 2009; Koziol-McLain 2010; Humphreys 2011; Fraga 2014); Partner Violence Screen (PVS) (MacMillan 2006; Trautman 2007; Ahmad 2009; Koziol-McLain 2010; Klevens 2012a); Violence Against Women Screen (VAWS) (Kataoka 2010); and Revised Conflict Tactics Scale (CTS) - Short Form (Fincher 2015). Rhodes 2002 adapted questions from the AAS and PVS and others. In several cases, omnibus screening aimed to assess a range of psychosocial problems (e.g. to assess a range of health issues in pregnancy or to diminish stigma around the true purpose of the study), of which IPV was only one (e.g. Ahmad 2009; Humphreys 2011). In Carroll 2005, the Antenatal Psychosocial Health Assessment (ALPHA) tool assessed a range of psychosocial issues such as child abuse and depression; the IPV questions contained in the ALPHA are derived from the WAST (Carroll 2005). The validity of these tools is also heterogeneous and thoroughly reviewed in Feder 2009 (p 29). Often, data collected through the screening intervention fed into the primary identification outcome data.

### Screening methods and strategies

Studies used different modes of applying the screening tools indicated above in intervention and comparison groups. Five interventions involved a computer-assisted self completion screening process with positive results being conveyed to providers (Rhodes 2002; Rhodes 2006; Trautman 2007; Ahmad 2009; Humphreys 2011). MacMillan 2009 used written methods in their intervention arm before conveying results to healthcare professionals. Carroll 2005, MacMillan 2006, Kataoka 2010, Koziol-McLain 2010, and Fraga 2014 included face-to-face screening where the healthcare professionals themselves screened the women. Kataoka 2010 selected a written enquiry method as the comparison compared with face-to-face screening, but since it was face-to-face, this method guaranteed the result was processed by a healthcare professional; in this study we treated face-to-face screening as the intervention. Klevens 2012a compared healthcare professional screening with audio computer-assisted self interviews (A-CASI) screening. Fraga 2014 had three groups, but we combined the two arms that involved social worker screening (face-to-face and telephone) and compared it to a group that received a questionnaire by post. In Fincher 2015, women attending a community health programme (WIC services) received face-to-face screening by trained healthcare professional researchers who provided information and resources on issues, including healthy relationships. As this was the only included study that had researchers, as opposed to healthcare professionals, deliver the face-to-face screening, we excluded it from our primary analysis as, ultimately, the data were not part of the clinical context.

### Comparisons

Six studies compared IPV screening with usual care (Rhodes 2002; Carroll 2005; Rhodes 2006; Ahmad 2009; MacMillan 2009; Koziol-McLain 2010). Humphreys 2011 compared IPV screening and clinician follow-up with researcher-based IPV screening...
where results were not provided to the clinician. Written self-completion was used in one arm of MacMillan 2006 (which we used as a comparator arm) and they used computerised self-completion in another (which we also treated as comparison). Trautman 2007 compared screening that included questions about IPV with screening for other issues that did not include IPV, and both sets of results were pooled across all studies. Kataoka 2010 compared face-to-face screening interview by a healthcare professional with a self-administered questionnaire and Klevens 2012a compared A-CASI screening with the same screen administered by the clinician. Fraga 2014 compared screening by social workers to a group that received a questionnaire by post.

We treated groups where women self-completed IPV questions but with no follow-up or involvement of clinicians, and screening for health issues without reference to IPV, as ‘usual care’ conditions.

Outcomes and outcome measures

Identification (including discussion or detection)

All but one study, Koziol-McLain 2010, in some way measured the identification of IPV using various screening modes and tools. However, this was not always a form of clinical identification, with some studies documenting what was more akin to prevalence data according to different modes of screening (MacMillan 2006; Kataoka 2010; Fincher 2015), rather than information for use in the clinical domain. There were instances where clinical identification data were recorded but did not lend themselves to meta-analysis because they were not measured consistently across arms of the trial (Klevens 2012a). Thus, we combined these four studies in a meta-analysis of non-clinically based identification based on face-to-face screening versus other screening techniques.

Eight studies measured identification such that it could be defined as clinical identification of IPV from screening and we used this in our primary analyses (Rhodes 2002; Carroll 2005; Rhodes 2006; Trautman 2007; Ahmad 2009; MacMillan 2009; Humphreys 2011; Fraga 2014). These data were gathered through providers’ and women’s self-report about what had occurred during the consultation, chart review/clinical documentation, and audio-recordings of clinical encounters.

Information-giving, referral, and uptake of services

While most studies included some assessment of the provision of information, referral, and women’s service use, measurement of these outcomes varied enormously. First, the provision of information or resources was already linked to the majority of interventions and received by women who took up the intervention. For example, a computer print-out of resources or information pamphlets commonly occurred as part of the intervention. Thus, it was not appropriate for us to treat it as an outcome of screening interventions. Another example can be found in Rhodes 2006, where provision of services was defined as safety assessment, counselling by the healthcare providers, and provision of information on resources; to measure these would be more in keeping with an assessment of fidelity since these are features of the intervention, rather than outcomes of a screening intervention.

Studies also varied greatly in how they defined referral. For example, Klevens 2012a made reference to three types of ‘referral’ - healthcare professional, A-CASI plus provider support, and A-CASI alone, but this was more about how women in the different arms self-referred based on the list of resources provided to them in each trial arm. We were interested to know if screening interventions increased women’s formal referral to other internal and external support services, with this information being derived from medical records or self report by participants or even data from services to indicate the number of women referred to them. However, only two studies treated referral in this way and were included in a meta-analysis (Trautman 2007; Ahmad 2009). Trautman 2007 examined differences in the numbers referred to social work by the treating staff at the ED and Ahmad 2009 used audio-recordings of consultations to determine if women were referred. Ahmad also checked if any arrangements were made for follow-up appointments but this was not included in the referral data.

Uptake of services suffered similar difficulties, encompassing different variables for different studies where some looked at specific uptake based on the resources that were flagged (Trautman 2007; Klevens 2012a), and others look at a more general uptake of community services (Koziol-McLain 2010). Consequently, we were unable to include data on uptake of services in a meta-analysis.

Intimate partner violence

MacMillan 2009 and Koziol-McLain 2010 included level of exposure to IPV (using the CAS, Hegarty 2005) as a primary outcome.

Women’s health and quality of life

MacMillan 2009 included quality of life as a primary outcome (assessed with the WHO Quality of Life-Bref), but included in their secondary outcomes: general health (Short Form health survey - 12 (SF-12)), depressive symptoms (Center for Epidemiologic Studies - Depression Scale (CES-D)), post-traumatic stress disorder (Startle, Physiological arousal, Anger, and Numbness (SPAN)), alcohol use or dependency (Tolerance, Worried, Eye-opener, Amnesia, K/Cut Down (TWEAK), and Drug Abuse Screening Test (DAST)).

Adverse and other outcomes


Excluded studies

We excluded 43 studies for the following reasons.

1. Fifteen studies because screening was accompanied by an intervention that exceeded our criteria for a 'brief intervention' (Duggan 2004; Green 2005; Curry 2006; Jewkes 2008; Gillum 2009; Gripe 2010; Kiely 2010; Tiwari 2010; Florsheim 2011; Taft 2011; Subramanian 2012; Hegarty 2013; Kiely 2013; Saftlas 2014; Wagman 2015).

2. Seven studies because they were not randomised or quasi-randomised controlled trials (Furbee 1998; Larkin 1999; Knight 2000; Bonds 2006; Halpern 2009; Hewitt 2011; Kapur 2011).

3. Five studies because the results were not passed on to the healthcare professional according to our criteria (Bair-Merritt 2006; Houry 2011; Klevens 2012b; Beatty 2014; Hoelle 2014).

4. Three studies because they tested educational interventions and did not supply data on women (Coonrod 2000; Brienza 2005; Fernández Alonso 2006).

5. Three studies because they targeted children and clinicians (Dubowitz 2011; Feigelman 2011; Dubowitz 2012).

6. Three studies because there was no usual care comparison (Chen 2007; Ernst 2007; Rickert 2009).

7. Three studies because they were case-finding not screening trials (Thompson 2000; Campbell 2001; Feder 2011).

8. Two studies because screening results were passed on to the healthcare professional in both usual care and intervention groups (Hollander 2001; Taft 2012).

9. One study because it was not conducted in a healthcare setting (Robinson-Whelen 2010).

10. One study because the population were parents and data could not be disaggregated (Garg 2007).

Risk of bias in included studies

Our risk of bias judgements are summarised below and in Figure 2 and Figure 3. Further detail can also be found in the 'Risk of bias' tables beneath the Characteristics of included studies tables.

Figure 2. 'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies
Figure 3. 'Risk of bias' summary: review authors’ judgements about each risk of bias item for each included study

<table>
<thead>
<tr>
<th>Study</th>
<th>Random sequence generation (selection bias)</th>
<th>Allocation concealment (selection bias)</th>
<th>Blinding of participants and personnel (performance bias)</th>
<th>Blinding of outcome assessment (detection bias)</th>
<th>Incomplete outcome data (attrition bias)</th>
<th>Selective reporting (reporting bias)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ahmad 2009</td>
<td><img src="rating_1" alt="Rating" /></td>
<td><img src="rating_1" alt="Rating" /></td>
<td><img src="rating_1" alt="Rating" /></td>
<td><img src="rating_1" alt="Rating" /></td>
<td><img src="rating_1" alt="Rating" /></td>
<td><img src="rating_1" alt="Rating" /></td>
</tr>
<tr>
<td>Carroll 2005</td>
<td><img src="rating_1" alt="Rating" /></td>
<td><img src="rating_1" alt="Rating" /></td>
<td><img src="rating_1" alt="Rating" /></td>
<td><img src="rating_1" alt="Rating" /></td>
<td><img src="rating_1" alt="Rating" /></td>
<td><img src="rating_1" alt="Rating" /></td>
</tr>
<tr>
<td>Fincher 2015</td>
<td><img src="rating_1" alt="Rating" /></td>
<td><img src="rating_1" alt="Rating" /></td>
<td><img src="rating_1" alt="Rating" /></td>
<td><img src="rating_1" alt="Rating" /></td>
<td><img src="rating_1" alt="Rating" /></td>
<td><img src="rating_1" alt="Rating" /></td>
</tr>
<tr>
<td>Fraga 2014</td>
<td><img src="rating_1" alt="Rating" /></td>
<td><img src="rating_1" alt="Rating" /></td>
<td><img src="rating_1" alt="Rating" /></td>
<td><img src="rating_1" alt="Rating" /></td>
<td><img src="rating_1" alt="Rating" /></td>
<td><img src="rating_1" alt="Rating" /></td>
</tr>
<tr>
<td>Humphreys 2011</td>
<td><img src="rating_1" alt="Rating" /></td>
<td><img src="rating_1" alt="Rating" /></td>
<td><img src="rating_1" alt="Rating" /></td>
<td><img src="rating_1" alt="Rating" /></td>
<td><img src="rating_1" alt="Rating" /></td>
<td><img src="rating_1" alt="Rating" /></td>
</tr>
<tr>
<td>Kataoka 2010</td>
<td><img src="rating_1" alt="Rating" /></td>
<td><img src="rating_1" alt="Rating" /></td>
<td><img src="rating_1" alt="Rating" /></td>
<td><img src="rating_1" alt="Rating" /></td>
<td><img src="rating_1" alt="Rating" /></td>
<td><img src="rating_1" alt="Rating" /></td>
</tr>
<tr>
<td>Kleven 2012a</td>
<td><img src="rating_1" alt="Rating" /></td>
<td><img src="rating_1" alt="Rating" /></td>
<td><img src="rating_1" alt="Rating" /></td>
<td><img src="rating_1" alt="Rating" /></td>
<td><img src="rating_1" alt="Rating" /></td>
<td><img src="rating_1" alt="Rating" /></td>
</tr>
<tr>
<td>Koziol-McLain 2010</td>
<td><img src="rating_1" alt="Rating" /></td>
<td><img src="rating_1" alt="Rating" /></td>
<td><img src="rating_1" alt="Rating" /></td>
<td><img src="rating_1" alt="Rating" /></td>
<td><img src="rating_1" alt="Rating" /></td>
<td><img src="rating_1" alt="Rating" /></td>
</tr>
<tr>
<td>MacMillan 2006</td>
<td><img src="rating_1" alt="Rating" /></td>
<td><img src="rating_1" alt="Rating" /></td>
<td><img src="rating_1" alt="Rating" /></td>
<td><img src="rating_1" alt="Rating" /></td>
<td><img src="rating_1" alt="Rating" /></td>
<td><img src="rating_1" alt="Rating" /></td>
</tr>
<tr>
<td>MacMillan 2003</td>
<td><img src="rating_1" alt="Rating" /></td>
<td><img src="rating_1" alt="Rating" /></td>
<td><img src="rating_1" alt="Rating" /></td>
<td><img src="rating_1" alt="Rating" /></td>
<td><img src="rating_1" alt="Rating" /></td>
<td><img src="rating_1" alt="Rating" /></td>
</tr>
<tr>
<td>Rhodes 2002</td>
<td><img src="rating_1" alt="Rating" /></td>
<td><img src="rating_1" alt="Rating" /></td>
<td><img src="rating_1" alt="Rating" /></td>
<td><img src="rating_1" alt="Rating" /></td>
<td><img src="rating_1" alt="Rating" /></td>
<td><img src="rating_1" alt="Rating" /></td>
</tr>
<tr>
<td>Rhodes 2006</td>
<td><img src="rating_1" alt="Rating" /></td>
<td><img src="rating_1" alt="Rating" /></td>
<td><img src="rating_1" alt="Rating" /></td>
<td><img src="rating_1" alt="Rating" /></td>
<td><img src="rating_1" alt="Rating" /></td>
<td><img src="rating_1" alt="Rating" /></td>
</tr>
<tr>
<td>Trautman 2007</td>
<td><img src="rating_1" alt="Rating" /></td>
<td><img src="rating_1" alt="Rating" /></td>
<td><img src="rating_1" alt="Rating" /></td>
<td><img src="rating_1" alt="Rating" /></td>
<td><img src="rating_1" alt="Rating" /></td>
<td><img src="rating_1" alt="Rating" /></td>
</tr>
</tbody>
</table>
Allocation

Random sequence generation
Nine studies described reliable low-risk random sampling strategies (Carroll 2005; MacMillan 2006; Rhodes 2006; Ahmad 2009; MacMillan 2009; Kataoka 2010; Koziol-McLain 2010; Humphreys 2011; Klevens 2012a), but two used methods with a high likelihood of systematic bias: Trautman 2007 used consecutive enrolment periods and Rhodes 2002 used alternate allocation. Fincher 2015 and Fraga 2014 provided no description of the sequence generation in their report so we contacted them for information but were unable to gain a comprehensive account of the procedures.

Allocation concealment
Rhodes 2006, Ahmad 2009, Koziol-McLain 2010, Humphreys 2011, Kataoka 2010, and Klevens 2012a described reliable procedures to conceal the allocation of participant status. In Carroll 2005, Fraga 2014, and Rhodes 2002, there was inadequate information to judge whether or not bias could have been introduced. In MacMillan 2006 and MacMillan 2009, monthly calendars showing shift allocation for site co-ordinators was the chosen method. Recruiters with knowledge of this allocation could have introduced bias with selective recruitment. A process with similar potential for bias was used in Trautman 2007. Fincher 2015 was also considered at high risk of bias because there was no description of how the assignment was managed/concealed, and recruiters were also the interviewers for the face-to-face group so it is possible that they knew the allocation at the time of recruiting women.

Blinding

Blinding of participants and personnel (performance bias)
It is very difficult to blind healthcare professionals in a screening trial, especially when IPV screening results are attached to the patients’ files. All studies suffered from high risk of performance bias with the exception of Kataoka 2010 and Fraga 2014, where we judged that it was unclear whether bias could have affected outcomes. Protocols to minimise performance bias (Koziol-McLain 2010) and blinding clinicians to the overall purpose of the study (Ahmad 2009) were stated strategies to minimise this type of bias, but similar to the remaining studies, knowledge that they were in a trial, and patients’ screening results attached to their files increased the possibility of performance bias. The problem of performance bias differentially affecting outcomes in the women participants was likely greater where an intervention was compared to standard or usual care (Ahmad 2009; Koziol-McLain 2010), as opposed to using an alternative screening approach.

Blinding of outcome assessment (detection bias)
We judged detection bias to be low in four trials where steps had been taken to actively blind: interviewers (MacMillan 2009; Koziol-McLain 2010), chart reviewers (Rhodes 2002), and those coding audio-recordings (Ahmad 2009). In Kataoka 2010, the likelihood of detection bias was reduced as there was no clear intervention or comparison group (it was questionnaire versus face-to-face screening) or study hypothesis, and we only used data from the first screening (there had been three in total). The risk of detection bias was unclear in Rhodes 2006, Fincher 2015, Fraga 2014, and Trautman 2007. Healthcare professionals aware of participant IPV status gave estimates of their levels of concern in Carroll 2005 and may have overestimated their levels of concern. In Humphreys 2011 and Klevens 2012a, research staff collecting outcome data may have been able to detect which study arm a woman was in (as there was no indication that they were blinded) and this may have biased outcome detection.

Incomplete outcome data
Three studies were at high risk for attrition differentially affecting groups (Carroll 2005; Ahmad 2009; Fraga 2014). In Ahmad 2009, LTFU was low, but sensitivity analyses suggest missing data potentially affected the results; this was further confirmed by imputation in an intention-to-treat analysis. Unbalanced provider attrition (nine in the intervention group versus three in the control group) in Carroll 2005 risks bias, even though participant data loss was low and evenly spread (7.5%). In Fraga 2014, the postal questionnaire group suffered from high attrition (70/305; 23%). Trautman 2007 attained 100% retention as data were collected immediately. Kataoka 2010 had no more than 10% LTFU across both intervention and control groups but this was across all three screenings, and there was no attrition when data were collected for the first screening (the data used in the review). MacMillan 2006 had approximately 5% attrition depending on the screening tool used. We judged these studies, along with Klevens 2012a, to be at low risk of bias from LTFU. The study conducted by MacMillan 2009 resulted in 42% attrition overall, with participants missing not at random (more severely abused women likely to be lost) suggesting the observed effect may be biased. Multiple imputation in MacMillan 2009 for missing data did reduce the effect size and given that the study accounted for missing data, we judged it to be low risk. Humphreys 2011, while making conservative assumptions about missing data, did not give the reasons for attrition making it dif-
difficult to judge whether assumptions were appropriate. Koziol-McLain 2010 reported 13.8% LTFU missing at random but did not provide reasons for LTFU, making it difficult to judge. Rhodes 2002 gave an inadequate account of the reasons for the 20% missing chart reviews and the 32% patient attrition, and 21% providers refusing recording probably biased the effects found in Rhodes 2006. In Fincher 2015, 12% of women dropped out of the computer group compared to 4% in the face-to-face group but we were unable to obtain any information on these women and it is unclear at what stage that occurred. At two weeks, 31.8% of women completed a follow-up suggesting high attrition but we do not know if there was differential dropout and, in any case, we were unable to incorporate the two-week data as they were not reported.

Selective reporting

Publication of protocols and trial registration reduce the risk of selective reporting. MacMillan 2006, Ahmad 2009, Kataoka 2010, Koziol-McLain 2010, Humphreys 2011, and MacMillan 2009 were registered, but the lack of study protocols across studies made the analysis and primary outcomes difficult to access. Registered trials were considered low risk if there was no indication of selective reporting in the report (e.g. we checked that all outcomes were reported at all time points). These included Ahmad 2009, Kataoka 2010, MacMillan 2006, and MacMillan 2009. There was indication of selective reporting in Koziol-McLain 2010 based on an inconsistency between the outcomes as registered and reported. In three additional studies, certain outcomes were omitted (Carroll 2005; Humphreys 2011; Fincher 2015), and the risk was unclear in five studies (Rhodes 2002; Rhodes 2006; Trautman 2007; Klevens 2012a; Fraga 2014).

Other potential sources of bias

We judged the potential for contamination in comparison groups of women to be high across a large proportion of studies (Rhodes 2002; Rhodes 2006; Trautman 2007; Ahmad 2009; MacMillan 2009; Humphreys 2011; Klevens 2012a), and low in Koziol-McLain 2010. A high proportion (21.5% compared to 15.7%) of low-income women in the computer-based group may have biased screening results in MacMillan 2006, and Kataoka 2010 acknowledges her measurement had psychometric property limitations with low specificity. The extent of bias from other sources was unclear in Carroll 2005, Fincher 2015, and in Fraga 2014, where there were imbalances at baseline and we found no reference to account for these in analyses. Also, there had been prior research involvement of the cohort of women in a study about IPV during pregnancy 12 months earlier (Rodrigues 2008), but this was not addressed.

Effects of interventions

See: Summary of findings for the main comparison; Summary of findings 2

Screening versus control (no screening/usual care; clinician not notified of screening results)

Primary outcomes

A. Identification of intimate partner violence (IPV) by health professionals

Eight of 13 included studies measured identification of female patients experiencing IPV in ways that could be combined (Rhodes 2002; Carroll 2005; Rhodes 2006; Trautman 2007; Ahmad 2009; MacMillan 2009; Humphreys 2011; Fraga 2014). In most studies, the proportion of women identified was small, and ranged from 3% to 17%. With the exception of Fraga 2014 (where 9% (n = 86) of women were lost to follow-up between recruitment/ randomisation and delivery of the intervention a year later), we used the number of women randomised as the denominator to establish identification rates, rather than the number of women who received the intervention or the number with abuse at baseline. We also made conservative assumptions about identification in four cases. In Ahmad 2009, we have taken cases as detected, rather than the broader ‘discussion opportunity’ as the measure of identification. In Trautman 2007, we were not able to distinguish identification by healthcare professionals from those detected by research staff in the study report, and therefore have only included the numbers of cases documented in patient records, as these were entered by healthcare professionals only. While MacMillan 2009 did not specify identification as an outcome, we were able to estimate figures using the reported proportions of women who discussed IPV with their clinicians, based on self report following clinical encounters (88/199 screened women (44%) compared to 17/212 (8%) of non-screened women). To allow the data to be comparable to other studies in the meta-analysis, we expressed the cases of women that discussed abuse as a proportion of all women randomised to the screened or non-screened groups. However, it is important to point out that these denominators included women with negative and mixed results on the Women’s Abuse Screening Tool and we do not know how many of these women had discussions about abuse with clinicians. In Rhodes 2002, we have only included those detected by chart review. We confirmed our calculations of the women included in the study with the author. On average, screening interventions more than doubled the identification of women experiencing abuse compared with control groups (odds ratio (OR) 2.95, 95% confidence interval (CI) 1.79 to 4.87, eight studies, n (number of women) = 10,074, P = 66%
Analysis 1.1). We downgraded the quality of the evidence to moderate due to heterogeneity. This moderate level of (methodological) heterogeneity owed to the MacMillan 2009 study being very large relative to other studies in the analysis. Removing it in sensitivity analysis, the OR was 2.35 (95% CI 1.53 to 3.59, seven studies, $n = 4393$, $I^2 = 38$%; analysis not shown).

Rates of missing data were low for the identification outcome among studies included in the meta-analysis, with nearly all randomised women being included in the analysis (see Characteristics of included studies). There was one exception where just 66% of women in the intervention group and 70% of women in the control group were successfully audiotaped (Rhodes 2006). Thus, there may have been participation bias with women who found the recording uncomfortable declining it. Removing this study in a sensitivity analysis slightly increased the odds of identifying abused women through screening (OR 2.74, 95% CI 1.65 to 4.53, six studies, $n = 3112$, $I^2 = 33$%; analysis not shown).

Subgroup analyses: type of healthcare setting

We excluded one of the eight studies that reported clinical identification data from the analysis by setting - MacMillan 2009 included multiple healthcare settings and we did not have access to the disaggregated data.

Antenatal clinics

Two studies tested screening in antenatal settings (Carroll 2005; Humphreys 2011). The OR for screening to identify victims of abuse compared to no screening was 4.53 (95% CI 1.82 to 11.27, two studies, $n = 663$, $I^2 = 0$%; Analysis 1.2). In this setting, we estimated that there could be over 300% likelihood of increased identification by healthcare professionals in screened pregnant populations. However, the studies were small and therefore more subject to sampling variation. We downgraded the quality of the evidence to moderate on account of imprecision.

Maternal health services

In one study, based in an obstetrics department with women who were one year postpartum (Fraga 2014), the OR for screening to identify victims of abuse compared to no screening was 2.36 (95% CI 1.14 to 4.87, $n = 829$; Analysis 1.2). We downgraded the quality of this evidence to moderate on the basis of risk of bias (see ‘Characteristics of included studies’).

Emergency departments (EDs)

Three studies evaluated identification from screening in emergency department (ED) settings (Rhodes 2002; Rhodes 2006; Trautman 2007). In this setting, the OR was 2.72 (95% CI 1.03 to 7.19, three studies, $n = 2608$, $I^2 = 65$%; Analysis 1.2). We downgraded the quality of the evidence to moderate due to statistical heterogeneity ($I^2 > 50$%). With regards to the source of this heterogeneity, there was clinical diversity in Rhodes 2002 as the intervention had also targeted men and a notably high proportion (> 90%) of participants were African-American. Further, it was a relatively small study, highlighting its methodological diversity. In a sensitivity analysis, we removed Rhodes 2002, which reduced the odds that screening identifies women in this setting, but improved the precision of effect estimates and reduced heterogeneity (OR 1.72, 95% CI 1.11 to 2.66, two studies, $n = 2286$, $I^2 = 0$%; analysis not shown).

Hospital-based primary care

One moderate quality study evaluated identification from screening in primary care (Ahmad 2009). In this setting, screening did not increase identification (OR 1.53, 95% CI 0.79 to 2.94, $n = 293$; Analysis 1.2).

Subgroup differences

Results were fairly consistent across location subgroups, suggesting that screening was similarly effective in all of the healthcare settings studied (Chi$^2 = 3.74$, df = 3 (P value = 0.29), $I^2 = 19.7$%; Analysis 1.2).

Individual studies not included in the meta-analysis

We excluded five studies from the primary meta-analysis of identification of exposure to IPV. Koziol-McLain 2010 did not assess it. Kataoka 2010 reported prevalence (as opposed to data on the clinical encounter) for written (29%, 48/163) versus face-to-face (19%, 32/165) enquiry. We excluded Fincher 2015 from the meta-analysis for similar reasons. However, in contrast with Kataoka 2010, they found that face-to-face screening in women one year postpartum increased disclosure of prior-year IPV (44%, 84/191 versus 28%, 50/177) and lifetime exposure (54%, 103/191 versus 44%, 76/177) compared to computer-assisted screening. MacMillan 2006 also used this design, although their study contained many more possible interactions as they used different tools, settings, and methods. They reported 12-month prevalence rates that ranged from 4% to 18% across primary care, emergency departments, and women’s clinics. The highest proportions were identified in emergency settings ($n = 768$), ranging from 10.9% of women when the Partner Violence Screen (PVS) was used in face-to-face interviews up to 17.7% for the computerised version of the PVS. In primary care ($n = 814$), proportions ranged from 5.4% on the paper-based Women’s Abuse Screen Tool (WAST) to 11.6% on the face-to-face PVS. Women’s health clinics ($n = 879$) reported
the lowest prevalence, from 4.1% (face-to-face PVS) to 10.0% (face-to-face WAST). In Klevens 2012a, disclosure to healthcare professionals (8.7%, 4/46) was compared to CASI (21.3%, 17/80). Although three women (of 80) in the CASI group later discussed abuse with the healthcare professional, we excluded it as identification was not consistently measured as clinical data across groups.

Given that there were four studies that investigated the identification of abused women using a non-clinically based approach (more consistent with investigating prevalence rates), we compared face-to-face enquiry with computer-based (Klevens 2012a; Fincher 2015), or written assessment of IPV (Kataoka 2010), or both (MacMillan 2006). For Kataoka 2010, we used data from the first screening only (it was followed up by two additional screening interventions). For MacMillan 2006, we used the data reported on the PVS only (the computer and paper-based groups completed both the PVS and WAST with the face-to-face consisting of one or the other) as it was more conservative estimate than the data derived from the WAST. We combined the two groups of women that had computer- or paper-based screening and compared them to the women who had the face-to-face screening on the PVS. Neither face-to-face screening nor written/computer-based techniques were favoured for identifying abused women (OR 1.12, 95% CI 0.53 to 2.36, four studies, n = 2765, I² = 83%; Analysis 2.1). We downgraded this evidence to moderate quality due to statistical heterogeneity. One study favoured face-to-face screening (Fincher 2015). The other three suggested no difference between face-to-face and written/computer techniques for identifying women (MacMillan 2006; Kataoka 2010; Klevens 2012a). The risk of bias was greatest for the Fincher 2015 study. In removing this study in a sensitivity analysis, heterogeneity remained high and one technique was not favoured above the other (OR 0.88, 95% CI 0.36 to 2.15, three studies, n = 2397, I² = 73%; analysis not shown). The heterogeneity in this analysis was likely due to clinical diversity across studies (different countries, healthcare settings, and participant characteristics) and methodological differences (large variation in sample sizes and study quality).

B. Information-giving and referrals to support agencies by healthcare professionals (including uptake rates)

We were able to include two studies in our investigation of healthcare professional referrals (Trautman 2007; Ahmad 2009). In the case of Trautman 2007, a narrow definition of referral was adopted (social work assistance only), suggesting that referral to other support services was not counted. Furthermore, we only included cases verified by medical records, which may be an underestimate of the number of women who were referred by healthcare professionals without verification in charts. Ahmad 2009 audio-recorded all consultations for women in both arms of the trial. There was no evidence of an effect of screening interventions on increasing referrals to supportive services (OR 2.24, 95% CI 0.64 to 7.86, I² = 0%, n = 1298; Analysis 1.3). We downgraded the evidence to low quality due to imprecision and risk of bias issues, particularly in the Trautman 2007 study.

Data on information-giving and uptake of services were too heterogeneous to be pooled in a meta-analysis. We treated healthcare professionals discussing safety with abused women as a form of information-giving. Only Ahmad 2009 reported on the extent to which physicians assessed patient safety following identification, and confirmed that physicians discussed safety with nine of the 25 women detected in the screened group and with only one woman in the control group. Ahmad 2009 reported that, of the 25 women detected, 20 (80%) were asked for follow-up appointments in the intervention arm, whereas only eight (67%) of the 12 women identified in the comparison arm were invited for follow-up appointments. Klevens 2012a found that, after one week, 4/36 (11%) who were screened by a healthcare professional had taken up services from the printout provided to women who screened positive compared to 2/66 (3%) of women in the computer-based screening groups. No participant had contacted the domestic violence advocacy programme in the hospital, but the study was unable to investigate the reasons. Rhodes 2006 assessed IPV-related services provided during the visit (which combined safety assessment, counselling by the healthcare professional provider or social worker, and referrals to domestic violence resources) to women in the screened group compared to usual care group, in separate groups of urban and suburban women. Of screened women, 25/421 (5.9%) received services compared to 10/443 (2.3%) of unscreened women. Trautman 2007 found that 18/411 (4.4%) of screened women received social work assistance for IPV compared to 2/194 (1%) in the comparison arm.

Secondary outcomes

C. Intimate partner violence

Two studies measured the effect of screening on reduction of IPV among screened compared to non-screened women and used the same measure (Composite Abuse Scale; CAS) (MacMillan 2009; Koziol-McLain 2010). However, the denominators and timelines were different; Koziol-McLain 2010 measured IPV reduction at three months post-baseline among all women, while MacMillan 2009 measured reduction of IPV among abused women at six, 12, and 18 months following screening. Therefore, we have presented their results separately. Both studies reported point estimates for ORs that were consistent with a decrease in IPV as a result of screening, however, results did not reach statistical significance. At 18 months, MacMillan 2009 reported an OR of 0.88 (CI 0.43 to 1.82, n = 707 (multiple imputation used to account for women lost to follow-up (LTFU))). At three months, Koziol-McLain 2010 found an adjusted OR of 0.86 (95% CI 0.39 to 1.92, n = 344). Koziol-McLain 2010 also assessed whether women reported using more safety behaviours in the screened versus control group and
found an OR of 1.41 (CI 0.71 to 2.81), suggesting no significant difference between groups.

D. Women’s perceived and diagnosed physical health outcomes

Only one study measured physical health (SF-12) after screening (MacMillan 2009). At 18 months, self-reported physical health had increased in the screened group, but it was not significant, with a mean difference (MD) of 1.57 (95% CI -0.59 to 3.73, n = 707).

E. Women’s psychosocial health

MacMillan 2009 is the only study to have measured our other secondary outcomes in the important area of psychosocial health. While the study measured most of the factors of interest (depression and mental health in general, post-traumatic stress disorder (PTSD), alcohol problems, drug problems, and quality of life) at each time point, we only report those at 18 months, which was the study’s final measurement point. We cite the imputed figures and more conservative figures. The study suffered considerable attrition (42%). While the complete case (n = 411) effect sizes are greater than those imputed (n = 707) in the published paper, the imputation method (requested from the author (MacMillan 2011 [pers comm])) assumed missing-at-random, however those LTFU had higher scores on the CAS, which suggests a potential underestimate of effect.

1. Depression - the observed figures found a MD of -2.32 (95% CI -4.61 to -0.03) among screened versus unscreened abused women, consistent with a decrease in depression as a result of screening. However, this reduced to -1.97 (95% CI -4.33 to 0.39) with imputation for LTFU and was no longer statistically significant.

2. PTSD - the data suggested no difference between screened and non-screened women for PTSD (OR 0.63, 95% CI 0.36 to 1.10).

3. Mental health in general (as assessed by the SF-12) - screening did not significantly improve the mental health of screened abused women as the mean improvement of 1.05 in SF-12 scores (95% CI -1.70 to 3.79) crossed the line of no significance in both observed and imputed analyses.

4. Quality of life (as assessed by the WHO Quality of Life-Brief) - screened women showed more rapid improvement in quality of life (3.74 points higher; 95% CI 0.47 to 7.00), however the imputed data suggested that there was no difference between screened and non-screened women (MD 2.29, 95% CI -1.71 to 6.28).

5. Alcohol problems - the data suggested no difference between screened and non-screened women as regards risk of alcohol problems (OR 1.23, 95% CI 0.62 to 2.44).

F. Occurrence of adverse outcomes

Included studies measured women’s preferences for screening method (MacMillan 2006), acceptability (Ahmad 2009; Koziol-McLain 2010), comfort levels (Kataoka 2010), positive and negative reactions (Klevens 2012a), overall satisfaction (Rhodes 2006), and harm from screening (MacMillan 2009). Negative reactions to screening at one week were reported as negligible in Klevens 2012a. At three months, Koziol-McLain 2010, situated in an emergency setting, reported that 82% of women agreed that “health care providers should routinely ask all women about difficulties in home life and relationships”. They found no adverse effects in participants, clinicians, or researchers. Rhodes 2006 found that enquiry about and disclosures of IPV were associated with higher patient satisfaction with care. Fincher 2015, in seeking to understand contextual issues that enable disclosure, reported that race-matching of women and interviewers had no impact on disclosure rates of IPV. In the Ahmad 2009 hospital-based primary care study, acceptance of computer-assisted screening was measured using the Computerized Assessment Lifestyle Scale (CLAS) (Ahmad 2008). It examines patient perceptions of screening for a number of health and lifestyle issues and the quality of the subsequent medical consultation. Although women had some concerns about privacy and interruptions to their interaction with the healthcare professional, on average, women agreed that screening was beneficial (mean CLAS score 3.8, standard deviation (SD) 0.67). Scores were not influenced by IPV status.

The most rigorous assessment of harm from IPV screening was undertaken by MacMillan 2009. Across various health settings, they used a specifically developed tool - the Consequences of Screening Tool (COST) (MacMillan 2009) - to assess the effects of being asked IPV screening questions. Among the COST questions, they analysed the eight-item Effects on Quality of Life subscale as it applies to women who received the screening intervention regardless of their abuse status. Items are scaled from two to minus two (range 16 to -16), with negative scores reflecting harm. The COST was administered to a subset of 591 women interviewed at baseline only (within 14 days of the index visit), comprising 227 women who screened positive for abuse, 206 with mixed screen results, and 558 who screened negative. The mean score of 3.52 (SD 3.24) on the eight-item Effects on Quality of Life subscale supported the view that being asked IPV screening questions was not harmful to women, in the short term at least. There was no variation by abuse group: the mean scores were 3.7 (SD 3.2) for women who scored negative on both the WAST and CAS, 3.3 (SD 3.3) for those who had mixed results, and 3.5 (SD 3.4) for those who scored positive on both measures (data obtained from the authors). No study examined harm or adverse outcomes be-
yond three months, with the majority of studies measuring these outcomes on the day that screening took place, and up to two weeks later.

G. Services and resource use
There was overlap between this set of outcomes and women’s take-up of services as presented in B above. In B, we described service use/uptake that was linked to the healthcare visit (e.g. services to which they were referred or were prompted to access from information provided), whereas here we present women’s use of general services. Koziol-McLain 2010 found no differences in resource use based on the Community Resource Checklist after three months. MacMillan 2009 presented women’s self reported use of violence-related services (“for descriptive purposes only”) using a six-month time frame at baseline, six-, 12-, and 18-months. Rates for service use by screened versus non-screened women were not significantly different: 75% versus 71% at baseline and 65% versus 64% at 18 months.

H. Cost-benefit outcomes
We found no studies that reported any data on cost-benefit or any other economic evaluation of interventions.
### ADDITIONAL SUMMARY OF FINDINGS

Face-to-face screening compared with written/computer-based screening for IPV

**Patient or population:** women attending healthcare settings for any health-related reason  
**Settings:** healthcare  
**Intervention:** face-to-face screening for IPV  
**Comparison:** written/computer-based screening

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>Face-to-face screening for IPV</th>
<th>Written/computer-based screening</th>
<th>Effect</th>
<th>Number of participants (studies)</th>
<th>Quality of the evidence (GRADE)</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Identification of IPV (non-clinically based, assessed immediately)</td>
<td>139/806 (17.2%)</td>
<td>247/1959 (12.6%)</td>
<td>OR 1.12 (0.53 to 2.36)</td>
<td>2. 13 more per 1000 (from 55 fewer to 128 more)</td>
<td>Moderate&lt;sup&gt;1&lt;/sup&gt;</td>
<td>⚫⚫⚫⚫</td>
</tr>
</tbody>
</table>

**CI:** Confidence interval; **GRADE:** Grades of Recommendation, Assessment, Development, and Evaluation; **IPV:** intimate partner violence; **OR:** odds ratio.

GRADE Working Group grades of evidence
- **High quality:** Further research is very unlikely to change our confidence in the estimate of effect.
- **Moderate quality:** Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
- **Low quality:** Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
- **Very low quality:** We are very uncertain about the estimate.

---

<sup>1</sup>Downgraded due to heterogeneity.
DISCUSSION

Summary of main results

We identified 13 controlled studies of screening for intimate partner violence (IPV) in healthcare settings. These recruited 14,959 women. Studies were conducted in diverse healthcare settings (antenatal and women’s health clinics, emergency departments (ED), primary care centres) in predominantly urban settings, in high-income countries. These were countries with domestic violence legislation and developed support services to which healthcare professionals could refer. Follow-up periods also varied, from immediately to one month post-intervention for identification outcomes, and up to 18 months post-intervention for violence and health outcomes. A range of different screening tools and techniques were applied but the review inclusion criteria stipulated inclusion of interventions that involved screening by, or notification of positive results to, healthcare professionals. Five studies involved computer-based screening with positive results conveyed to healthcare professionals. One study used paper-based screening before notifying treating physicians. Seven involved face-to-face or telephone screening by the healthcare professional. Of the 13 studies, eight measured clinical identification in both the intervention and comparison arm and four studies compared screening techniques based on identification rates that were not embedded in the clinical context. In these studies, women’s data were managed by researchers only, or the clinical encounter/records were not accessible in the two groups (or both), and therefore we dealt with these studies separately. Only one study discussed the implications of non-disclosure or false measurement on the outcomes.

Screening in healthcare settings is a complex intervention in a complex context, and an optimal evaluation requires multi-methods to illuminate the reasons for any successes or failures (Spangaro 2009; May 2011; Catallo 2013a; Catallo 2013b). Globally, the barriers to screening by healthcare professionals may reside at the individual professional level (lack of training and resources, fear of inadequate skills to address the problem, lack of time, unfavourable attitudes to the problem), at the clinic or team level (lack of systems for safety, supervision, and links with referral agencies), or at the wider political level (violence-tolerant societies, other healthcare priorities for funding, and services such as lack of funding for law enforcement or domestic violence services) (Colombini 2008; García-Moreno 2014). This understanding of an intervention was not adequately acknowledged in the included studies and is often overlooked in trial reporting. There was variability in the description provided about the wider organisational contexts and how healthcare professionals were trained and supported to undertake screening. Very few conducted or reported process evaluations. Similarly, the sustainability of healthcare professional screening behaviours in the future (Taft 2015), and after screening studies are complete, have been rarely addressed since earlier literature (McLeer 1989).

In surveys, qualitative studies and the studies reported here, women report that screening for intimate partner violence (IPV) is acceptable (Koziol-McLain 2008), although this can vary according to their abuse status (Feder 2009). While some governments and healthcare policymakers are in favour, the majority of healthcare professionals are not as supportive of screening policies, and many barriers to screening have been identified (Hegarty 2006; Feder 2009).

Does screening for intimate partner violence increase identification of victims?

Based on the studies in this review, we found moderate evidence that screening in high-income countries with developed referral services increases identification of women exposed to IPV compared to usual care. However, the numbers and proportions of women identified are modest when considered against the estimated prevalence of IPV among women in healthcare settings. We are mindful that many women will be not be ready to disclose (Chang 2010; Reisenhofer 2013), nor perhaps willing to disclose to that specific provider or in that setting (Catallo 2013a). The odds of identifying victims/survivors of IPV in antenatal settings were four times higher in screened women compared to those who received usual care. However, we downgraded the quality of this evidence to moderate on account of imprecision, reflected in wide confidence intervals around intervention effect estimates (likely due to the small sample sizes of these studies). Clinical identification was also increased in maternal health services and emergency departments but not in hospital-based primary care. Further rigorous studies are needed to test these findings in different settings. A gap in the identified studies is that only one report (Warthen 2008), associated with the MacMillan 2006 study, directly addressed the issue of how false positives and false negatives are managed and their impact on women and on screening effectiveness.

What kind of screening technique is preferred in the identification of abused women?

Previous studies have suggested that women have a preference for screening methods that do not involve healthcare professionals, which is understandable given the sensitive nature of IPV and women’s preferences for privacy to disclose (MacMillan 2006; Catallo 2013a; Catallo 2013b). A recent Australian trial found, through process and outcome evidence, that both women (and nurses) preferred a self-completion maternal health checklist that included IPV screening questions (Hooker 2015; Taft 2015). Although preference for screening technique was not a central question in this review, our evaluation of adverse outcomes across studies suggested that, on the whole, the women included in this review were strongly in favour of being asked about violence in healthcare settings, regardless of the technique used.
An alternative question concerns which techniques and methods (as distinct from which tools) produce more accurate prevalence rates. While this was not an a priori review question, a subset of the included studies did address it. Four studies compared screening techniques based on prevalence rates (or identification rates that were not embedded clinically). Findings suggested that neither health professional/face-to-face screening nor written/computer-based screening is favoured for identifying abused women. High levels of statistical heterogeneity were observed in this four-study analysis, suggesting clinical diversity across studies (different countries, healthcare settings, and participant characteristics such as education, preferences for privacy, and age) and methodological differences (large variation in sample sizes and study quality). These factors have the potential to moderate the effect of different techniques on disclosure; indeed MacMillan 2006 has highlighted the extent of the variability in prevalence rates depending on settings, instruments, and techniques.

The clinical identification rates in this review ranged from 3% to 17% with a median of just 8%. It would appear that women and/or the providers remained reluctant to raise IPV. For example, there was a mismatch between disclosures via computer/written pre-assessments and discussions about IPV in consultations afterwards across the studies using this approach. In Rhodes 2002, 58/170 (34%) women indicated exposure to abuse in the pre-consultation computer self assessment yet just 19/170 (11%) of those cases were documented in patients’ charts by the providers. In Trautman 2007, 68/411 women (17%) were detected in the computer pre-screen; just 12 (3%) women had IPV documented in their charts. We acknowledge that chart documentation may underestimate clinical identification and discussion of abuse. However, using women’s self reports, MacMillan 2009 found that, in encounters where physicians had been prompted that abuse was present, under half involved a discussion about violence between the woman and her doctor. This was consistent with Rhodes 2006, where just 48% of health provider prompts that abuse had been reported led to a discussion about IPV. There was more consistency between the disclosure rate in pre-screening and with the healthcare professional in Ahmad 2009 and Humphreys 2011. In Ahmad 2009, prevalence was reported in exit surveys as 20% (29/144) among screened women with 17% (25/144) having had a discussion during the consultation. In Humphreys 2011, 25/205 (12%) were identified as at-risk in computer pre-screening, with 18/205 (9%) indicating in an interview afterwards that they had talked about domestic violence with their doctor. Thus, future studies need to look at how interventions can be enhanced to increase the rate of discussion about IPV (e.g. greater emphasis on training health care professionals).

The relative success of computerised and other distal techniques for eliciting disclosures from women has led to studies that bypass healthcare professionals altogether and instead assess a participant’s risk by computer and then provide support and links to services, via a printout for instance. However, when looking beyond the rate of disclosure, these methods appear to have little impact. For example, Kleven 2012b found no evidence of effect of computer-only screening and a list of resources on women’s mental and physical health status at 12 months. Thus, while provider and patient preferences for screening techniques must be understood as yet another potential barrier (or facilitator) to implementation of screening interventions, it remains important to examine pragmatic screening interventions that will offer abused women the best chance of finding a pathway to increased safety and better health.

**Does screening increase referral to support services?**

Based on the studies that assessed formal referral following clinically-based identification, screening did not increase referral to support services compared to usual care. However, to date, we only found and included two studies (one from primary care and one from emergency departments) and the assessment of referral was unreliable, for example, referral rates may have been underestimated in Trautman 2007 as they only included referrals to social work. Thus, we judged the evidence on the effect of screening on referrals as low quality and further research is likely to have an important impact on our confidence in the effect estimate. In fact, in the Ahmad 2009 study, where only three women were reported as having received referrals, 20 women were asked to make follow-up appointments with same provider. In the comparison group, follow-up appointments were made with eight women. It supports the notion that referring women, particularly in certain settings like primary care, may not be the optimal response as abused women may not yet be ready to take up a referral at the time of immediate disclosure (Chang 2010; Reisenhofer 2013). Alternative provider practices, such as safety-planning and arranging for follow-up, may be more appropriate, with measurement of safety behaviours and take-up of subsequent appointments in follow-up (Wathen 2012; Taft 2015). An important distinction needs to be made between provider behaviours that occur as part of the consultation (i.e. ‘process’ variables of referring, safety-planning, providing emotional support, making follow-up appointments), and women’s later uptake of the specific referrals and follow-up appointments along with their more general service use. Poor definition of these various processes and outcomes was a key obstacle to the synthesis of evidence in the current review.

**Does screening reduce intimate partner violence?**

The only two studies that measured the impact of screening on a reduction of partner violence over time did not report an effect. The studies used different time frames for the outcome. More studies would be required to reach a conclusion on the impact of...
screening on recurrence of violence. Also, further work is necessary to evaluate the effectiveness of screening linked with a range of interventions, advocacy (Ramsay 2009), social support (Taft 2011), and healthcare professional interventions (Hegarty 2013), for impacting on IPV recurrence.

**Is screening beneficial for women’s health?**

One study assessed mental and physical health outcomes and reported no impact of screening at 18 months (MacMillan 2009). Given that there was only one study, we are unable to conclude if screening interventions lead to improvements in women’s psychosocial health. Future studies need to incorporate a broader range of health outcomes (including general health and pregnancy outcomes) as part of the evaluation of screening interventions in healthcare settings.

**Does screening harm women?**

One of the criticisms commonly raised against the implementation of screening is that we do not know whether or not it is harmful (Jewkes 2002). Most studies in this review incorporated a non-validated set of questions related to women’s experiences of participating in a screening programme, with none reporting adverse effects. MacMillan 2009 conducted the most comprehensive assessment of harm from screening and found no evidence of harm. However, it was undertaken immediately after the health visit only. Three months was the longest follow-up of possible adverse outcomes (Koziol-McLain 2010), with no evidence of harmful effects in the 86% of women interviewed from both arms of the trial. Two recent Australian primary care trials, which used the same tool as in the MacMillan 2009 trial (Valpied 2014; Taft 2015), also found no evidence of harms over a more extended period of follow-up. Comprehensive assessment of harm needs to be incorporated into future trials, with greater focus on the weeks and months following delivery of the screening intervention. It needs to be borne in mind that the studies in this review have been undertaken in high-income countries, which may offer women more legal and social protections in the event that a woman chooses to disclose. Screening interventions may pose a more substantial risk to women’s safety and wellbeing in other settings, such as those that are resource-poor and lack comprehensive training for healthcare professionals, and in environments characterised by higher levels of gender inequality.

**Overall completeness and applicability of evidence**

The studies in this review are from high-income countries and the conclusions cannot be generalised to medium- and low-income settings where the care context and culture may be very different. For example, support services for healthcare professional referrals may be absent or underdeveloped, and the problem of violence in women’s lives may be much less visible where legal rights for women and criminal sanctions against perpetrators are lacking (Garcia-Moreno 2006). In such settings, without appropriate safeguards, screening may confer significant harm on women. There is a need for studies that can investigate the differential impact of screening on women experiencing different severity or types of abuse. Also, the evidence for the effectiveness of screening in specific healthcare settings is scant and more studies are required to confirm whether there is a differential effect (e.g. the finding in antenatal care, which was compatible with an increase in identification following screening). Having incorporated a review on ‘Domestic violence screening and intervention programmes for adults with dental or facial injury’ (Coulthard 2010), we identified no studies in oral and maxillofacial injury settings, an area that warrants attention in future studies.

Given the costs to healthcare systems to provide support for sustainable and effective screening programmes, it would be helpful to have studies that compared screening to case-finding strategies (such as Feder 2011), including economic analyses and longer-term outcomes. Nevertheless, there are sufficient studies to suggest that screening is effective in raising identification rates. It must be acknowledged that the actual number of eligible women in any healthcare setting who are screened has been found to be well below 50% (Stayton 2005) (although the number of eligible women screened across the trials included in this review ranged from 41% to 94% with a median of 69%). The proportions of women asked, those choosing not to disclose, and the impact of false identification on women’s lives need further investigation before we can fully understand the effectiveness of screening.

To date, the evidence reviewed here cannot demonstrate that screening involving clinical assessment and referral alone reduces violence, improves health, and does not cause harm. However, we acknowledge that reported outcomes were in the desired direction (less violence, less depression, more referrals), suggesting that linking screening interventions with support, advocacy, or psychological therapies may achieve positive outcomes with significant public health implications. We need larger studies to investigate these outcomes. While the increased rate of identification from screening is encouraging, it is unclear whether the healthcare professionals would continue to screen if they were not part of a study and for how long. The question of sustainability of screening for IPV as in other healthcare behaviour change interventions is a vexed one and calls for greater understanding if we hope to implement such programmes effectively at a state or national level (Colombini 2008; May 2011). A study aimed at improving maternal and child health care for vulnerable mothers provides some evidence that a nurse-designed, systems approach to screening was sustained with the outcome of safety planning increasing at two years follow-up (Taft 2015).
Quality of the evidence

Overall in this review, studies performed random sequence generation effectively. Allocation concealment was more open to bias. Steps taken to conceal the sequence prior to assignment of interventions was generally poorly described, and the risk of selection bias could have been reduced by adopting CONSORT guidance. A further difficulty was identified. Ideally all provider-level (e.g. training interventions) and patient interventions are delivered after baseline assessment and randomisation has occurred. However, with a screening intervention, it is unlikely to be feasible to assign patients and providers simultaneously as the patient-level intervention needs to be delivered immediately so training needs to have already occurred. Achieving full allocation concealment is made difficult where there is a two-stage allocation process as knowledge about provider training activities among personnel responsible for recruiting patient participants could influence the enrolment process.

In regards to post-assignment, it is widely accepted that blinding of staff and participants to minimise performance bias is hard to achieve with complex interventions. This was the greatest threat to validity across studies. Screening women for a range of health issues or withholding full information about the trial aims until a debriefing afterwards, or both, could help to reduce performance bias among patient participants (e.g. Ahmad 2009). However, the challenge of non-blinding providers remains, which may lead to an overestimate of effect (e.g. due to inappropriate administration of another ‘co-intervention’ and other differential behaviours) or underestimate of effect (e.g. due to contamination bias in comparison arms). Cluster trials were uncommon in the studies, however this design may offer some solution to issues of allocation concealment and performance bias. Blinding of outcome assessment was very complex, given that for our primary outcomes - identification and referral - we mainly used clinical documentation and self report. Thus, we may have underestimated the levels of these outcomes. Selecting a reliable measure of identification of IPV is a persistent challenge in screening trials and warrants much planning. In regards to selective reporting, around half of trials had been registered, but protocols were uncommon and there was widespread indication that not all outcomes listed a priori were addressed in trial reports.

We made 91 judgements about the quality of evidence using seven domains across 13 studies. We considered less than one-third of domains at low risk of bias, whereas we judged 40% to be at high risk and the remainder to be at unclear risk. Therefore, most information is from studies at high or unclear risk of bias. We downgraded evidence quality in response to risk of bias in studies and imprecision arising mainly from small studies/sample sizes. We observed high levels of statistical heterogeneity in some analyses (though not in the main identification analysis). Although interventions were similar, clinical diversity across studies arose from factors such as studies being set in different countries and healthcare settings and variability in participant characteristics. It is likely that the large variation in sample sizes and study quality contributed to methodological heterogeneity. Where possible, we used sensitivity analyses to assess the robustness of the findings. We considered the evidence on identification to be of moderate quality suggesting further research is likely to have an important impact on our confidence in the estimate of effect (and may change it). While we detected no evidence of an effect on referrals, this evidence was of low quality; further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change it.

Undertaking trials of complex interventions in a sensitive area is challenging not least because there is a constant need to balance ethical concerns against methodological and practical issues. For example, ensuring the safety of the comparison arm demands some basic training for providers, however, this may lead to an under-estimate of a true effect. Future studies need to incorporate guidance, such as that supplied by CONSORT, in designing, implementing, and evaluating their trials. Understanding the context of a complex intervention, such as screening, requires better theoretical underpinning. It also requires detailing (in process evaluation (Moore 2015) and protocols) of the steps leading to the establishment, implementation, and evaluation of a screening programme, so that those wishing to replicate or scale-up a given intervention have adequate information.

Potential biases in the review process

We believe that our review process allowed us to identify all published randomised or quasi-randomised controlled trials of screening interventions, as defined in the review and published up to the most recent search date (February 2015). All of the authors included in the review and other experts in the field responded to our requests for knowledge of other trials, which we may have missed, but they did not identify any further trials that met our inclusion criteria. We scoured all trial databases for those that may be about to be published. At least two review authors made decisions about inclusion or exclusion of studies and we made any changes to the protocol with all authors’ involvement. Two review authors also independently assessed study quality.

Agreements and disagreements with other studies or reviews

This review reinforces the findings of our original review, Taft 2013, and is consistent with other major systematic reviews (Wathen 2003; U.S. Preventive Services Task Force 2004; Feder 2009), and guidance from the UK National Institute for Health and Care Excellence (NICE 2014) and from the WHO (Feder 2013), which state that insufficient evidence exists to justify universal screening for IPV in healthcare settings on the basis of demonstrated benefit to women. We do not agree with the Nelson
2012 update on U.S. Preventive Services Task Force 2004, which concluded, mainly from MacMillan 2009, that screening is effective; the evidence does not yet warrant this conclusion. The earlier reviews of screening for IPV found no evidence of either direct harm or benefit to women, despite evidence that it may increase identification and referral. By conducting more recent searches and combining the results of those few studies where feasible, this review has confirmed the modest effects of screening on increasing identification of IPV, though there remains limited evidence of a positive impact of screening on referral by healthcare professionals, on other key outcomes related to women’s health and wellbeing, and on any possible harm to women from the screening process.

AUTHORS’ CONCLUSIONS

Implications for practice

In this update of our review, our conclusions remain that there is insufficient evidence to justify implementation of intimate partner violence (IPV) screening for all women in healthcare settings. It would be equally or more effective to train healthcare professionals in effective case-finding for IPV as part of the routine social history, to ask women who show signs of abuse or those in high-risk groups, and provide them with a supportive response, safety-planning, and information. This review cannot reach any conclusions about the benefits of screening combined with advocacy or other interventions by healthcare professionals. Further trials are required to test these hypotheses.

Implications for research

Further research is required to extend the limited evidence identified in this review. More studies that examine the complexities of screening in diverse settings (including low- or middle-income countries), with diverse populations, and that examine the social, health, and economic benefits for the differing strategies of identifying women are needed. We need further pragmatic trials of what proportion of women are successfully screened in real-world settings and over what period can they be sustained as well as systems-levels interventions to address the manifold barriers that exist to enquiry about IPV by healthcare professionals and disclosure by victims. The question of which subgroups of women, at which stage of their journeys, may benefit from screening programmes also remains.

In addition to emphasising trial registration, publication of protocols, and parallel process evaluation studies, we make a number of recommendations for future studies. We recommend trials compare:

- screening all women in particular health settings or from high-risk groups (e.g. mental health services, antenatal clinics) versus a comparison intervention that also includes basic training for all healthcare providers in asking about and responding to IPV (it would be unethical to conduct such a trial using a usual care arm where the health practitioners have not received basic education/training) (the extent and nature of the training should be clearly stated or available online);
- screening plus intensive support intervention in any healthcare setting versus comparison (as described above);
- case-finding plus intensive support intervention versus comparison (as described above);
- screening plus intensive support intervention in any healthcare setting versus case-finding plus intensive support intervention; and
- the above applied in low- and middle-resource settings.

Outcome selection and measurement recommendations include:

- improving the clarity around definition, operationalisation, and data collection methods for clinical identification and formal referral (short-term, ‘process’ outcomes);
- explicit timelines to improve the comparability of data across studies (e.g. three months, six months, one year, two years);
- measurement of take-up of referrals and follow-up appointments (specific) and health service use (general) (short-to medium-term);
- assessment of violence and health and wellbeing outcomes (medium- to long-term);
- outcomes for children;
- economic evaluation; and
- systematic harm assessment.

Although the number of eligible women randomised across studies was acceptable and there was little dropout prior to the delivery of interventions, studies that featured follow-up beyond the day of screening were affected by the loss of more vulnerable women. Given our recommendation for assessing important outcomes such as violence, women’s health, and quality of life over the long term, studies will need to develop recruitment and follow-up protocols that maximise the retention of disadvantaged women as part of further testing of identification programmes in conjunction with other interventions for IPV.

ACKNOWLEDGEMENTS
The review was produced within the Cochrane Developmental, Psychosocial and Learning Problems Group.

The authors acknowledge, with thanks, the support of the Australasian Cochrane Centre for training and support; the Cochrane Developmental, Psychosocial and Learning Problems Group (CDPLPG) for their support and assistance with searches; and La Trobe University; the Cochrane Collaboration; UNDP/UNFPA/UNICEF/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction (HRP); Department of Reproductive Health and Research (RHR); and the World Health Organization, Switzerland for funding support.

We would like to particularly thank Liesje Toomey who assisted in the original search strategy, and Jo Abbott, Trial Search Coordinator (TSC) of CDPLPG at that time. Jo ran the initial search and the current TSC, Margaret Anderson, updated the searches in 2015. We thank Joanne Wilson (CDPLPG) and Sonja Henderson (WHO) for their ongoing support and co-ordination through the process of updating the review.

We would also like to acknowledge Evelina Chapman for her assistance on the screening of studies, and Tess Lawrie who assisted with screening studies, data extraction, 'Risk of bias' assessment, and advised on data analyses and interpretation. Their work for the 2015 update was financially supported by the UNDP/UNFPA/UNICEF/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction (HRP); Department of Reproductive Health and Research (RHR); and the World Health Organization. The named authors alone are responsible for the views expressed in this publication.

Finally, we acknowledge the work of Paul Coulthard, Sin Leong Yong, Linda Adamson, Alison Warburton, Helen V Worthington, Marco Esposito and Mohammad O Sharif, the author team responsible for ‘Domestic violence screening and intervention programmes for adults with dental or facial injury’, a related Cochrane review that has now been merged with our review.

REFERENCES

References to studies included in this review

Ahmad 2009 [published data only]

Carroll 2005 [published and unpublished data]


Fincher 2015 [published and unpublished data]

Fraga 2014 [published and unpublished data]

Kataoka 2010 [published and unpublished data]

Klevens 2012a [published data only]

Koziol-McLain 2010 [published and unpublished data]

**MacMillan 2006** *(published and unpublished data)*


**MacMillan 2009** *(published and unpublished data)*


**Rhodes 2002** *(published data only)*


**Rhodes 2006** *(published and unpublished data)*


**Trautman 2007** *(published and unpublished data)*


**References to studies excluded from this review**

**Bair-Merritt 2006** *(published data only)*


**Beatty 2014** *(published data only)*


**Bonds 2006** *(published data only)*


Brienza 2005 *(published data only)*


**Campbell 2001** *(published data only)*


Chen 2007 *(published data only)*


**Coonrod 2000** *(published data only)*


**Cripe 2010** *(published data only)*


**Curry 2006** *(published data only)*


**Dubowitz 2011** *(published data only)*


**Dubowitz 2012** *(published data only)*


**Duggan 2004** *(published data only)*


**Ernst 2007** *(published data only)*

Screening women for intimate partner violence in healthcare settings (Review)

Feder 2011 (published data only)

Feigelman 2011 (published data only)

Fernández Alonso 2006 (published data only)

Florsheim 2011 (published data only)

Furbee 1998 (published data only)

Garg 2007 (published data only)

Gillum 2009 (published data only)

Green 2005 (published data only)

Halpern 2009 (published data only)

Hegarty 2013 (published data only)

Hewitt 2011 (published data only)

Hooley 2014 (published data only)

Hollander 2001 (published data only)

Houy 2011 (published data only)

Jewkes 2008 (published data only)

Kapur 2011 (published data only)

Kiely 2010 (published data only)

Kiely 2013 (published data only)

Klevens 2012b (published data only)
Screening women for intimate partner violence in healthcare settings (Review)

Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

References to ongoing studies

NCT01207258 (published data only)

NCT01661504 (published data only)

Additional references

Ahmad 2008

Bonomi 2009

Brock 1999

Campbell 2002
Physical health consequences of physical and psychological
CCJS 2005
CDC 2003
CDC 2007
Chang 2014
Clark 2014
Coker 2000
Coker 2002
Colombini 2008
Coulthard 2010
Davidson 2000
Donner 1980
Díaz-Olavarrieta 1999
Egger 1997
EIGE 2014
Ellsberg 2008
Family Violence Prevention Fund 2004
Screening women for intimate partner violence in healthcare settings (Review)

Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Howard 2013

Ingram 2005

Jejeebhoy 1998

Jewkes 2002

Kirkwood 1993

Kitzmann 2003

Koziol-McLain 2008

Krug 2002

MacMillan 2011 [pers comm]
MacMillan H (Oifford Centre for Child Studies, McMaster University, Canada). [personal communication]. Conversation with: A Taft (La Trobe University) 2011.

MacMillan 2015 [pers comm]
MacMillan H (Oifford Centre for Child Studies, McMaster University, Canada). [personal communication]. Conversation with: L O'Doherty (Coventry University, UK) 5 May 2015.

Martin 2001

May 2011

McCauley 1995

McCusker-Howard 2006

McLeer 1989

Mezey 1997

Moore 2010

Moore 2015

Mouzos 2003

Murphy 2001

Nelson 2004
Nelson 2012

NICE 2014

Office for National Statistics 2014

Pallitto 2013

Parsons 1999

Rabin 2009

Ramsay 2002

Ramsay 2009

Rees 2011

Reisenhofer 2013

RevMan 2014

Richardson 2001

Richardson 2002

Rickert 2009

Rodrigues 2008

Shackelford 2005

Silverman 2006

Spangaro 2009

Stark 1996

Stayton 2005
References to other published versions of this review

O’Doherty 2014a

Taft 2008

Taft 2013

Walby 2004

* Indicates the major publication for the study
### Characteristics of included studies  
*ordered by study ID*

**Ahmad 2009**

| Methods | Study design: randomised controlled trial  
|         | Randomisation method: random-number sampling scheme stratified by participating physicians. Before recruitment, the randomisation assignment was computer-generated using varying block sizes of 2 and 4. Women were individually randomised  
|         | Power calculation: reported  
|         | Study dates: March to September 2005 |

| Participants | Setting: urban, hospital-affiliated, academic, family practice clinic  
|             | Country: Canada  
|             | Inclusion criteria: women, 18 years and over, in relationship in last 12 months, able to read and write English  
|             | Exclusion criteria: none stated  
|             | Number (%) of eligible recruited: 314/586 (53.6%)  
|             | Numbers recruited: 314; intervention group 156, control group 158  
|             | Number of dropouts: 34; intervention group 17, control group 17  
|             | Numbers analysed (% of recruited): 280; intervention group 139 (89%), control group 141 (89%)  
|             | Numbers analysed (sensitivity analysis): 293; intervention group 144, control group 149  
|             | Age: mean 44 years (SD 14 years)  
|             | Marital status: married/living with a partner 74%, single 21%, separated/divorced/widowed 5%  
|             | Ethnicity: outside Canada 34%  
|             | Socioeconomic status: ≤ USD 40,000 28%, USD 40,001 to 60,000 18%, USD 60,001 to 80,001 14%, USD 80,001 to 100,001 16%, > USD 100,000 24%  
|             | Education background: 18% ≤ high school, 33% ≤ college, 34% ≤ university, 15% ≤ postgraduate  
|             | Children: children at home aged < 15 years 58%  
|             | Positive IPV result exit survey 62/286; intervention group 28/140, control group 34/146 |

| Interventions | Intervention group  
|               | • Computer-assisted screening for IPV and control, which included items from the Abuse Assessment Screen and Partner Violence Screen embedded among items assessing a range of health issues. A ‘yes’ response to any IPV items was reported on a one-page risk report ‘Possible partner abuse-assess for victimisation’ that was provided to physicians. Relevant community referrals were printed at the end of the report  
|               | Control group  
|               | • Standard medical care |

| Outcomes | Primary outcomes  
|          | • Initiation of discussion about risk for IPV by either participant or provider (discussion opportunity)  
|          | • Detection of women at risk  
|          | Secondary outcomes  
|          | • Provider assessment of participant safety |
• Referrals
• Advice for follow-up
• Participant acceptance (collected in exit survey)

Discussion and detection of other health risks were also measured but not relevant to this study.

Data collected through audio-recording (short-term)

Notes
Funding: Canadian Institutes of Health Research (grants IGF 63976 and FOW 68219), Institute of Gender and Health, Ontario Women's Health Council, and Strategic Training on Health Care, Place and Technology Program

**Risk of bias**

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk</td>
<td>A random-number sampling scheme for eligible women stratified by participating physician was used. The randomisation assignment was computer-generated by an off-site biostatistician using varying block sizes of 2 and 4.</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Low risk</td>
<td>Women who had provided informed consent were randomly assigned to the intervention group or control group: “Patient assignments were sealed in opaque envelopes that were marked on the outside with a physician number and sequence number. The envelopes were opened by the recruiter after patients’ written consent.”</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias) All outcomes</td>
<td>High risk</td>
<td>All physicians initially received study information and those willing to participate provided written consent. Training was provided during clinical team meetings at the time of consent. Although “Physician participants were blinded to the study’s primary purpose throughout the trial by emphasizing all health risks included in the multirisk computer survey and by using a nonspecific study title”, they would not have been entirely blinded to the intervention. For example, the prompt in the women’s records of the intervention group would have alerted providers to who was in the intervention group and conceivably have influenced their performance. Women were blinded to the study’s primary purpose.”</td>
</tr>
</tbody>
</table>
purpose by using strategies similar to those used for physician participants and embedding questions about women’s risk for IPV allowed the authors to conceal the study focus from both physician and patient participants. However, the patients were still aware that the computer survey was part of the intervention that could have influenced their behaviour. Awareness of being a control group participant (i.e. not doing the computer survey) may have altered the control group participants’ behaviour in some way that related to the outcome.

| Blinding of outcome assessment (detection bias) | Low risk | 2 people undertook primary outcome assessment, working independently to code the audio-recordings of the clinical encounters. Although efforts were made to blind coders to the patients’ group assignments, this may have been compromised by what they heard (i.e. some information during the consultation that revealed the patient’s allocation). However, this was unlikely to have affected their observation of the primary outcomes (initiation of discussions on IPV and detection of IPV). After their visit, women completed a pencil-and-paper exit survey and received brochures on cancer screening, cardiac and mental health, and IPV, at which time the research staff disclosed the purpose of the study to women. Although women were not blinded in answering the exit surveys, the outcomes measured via the exit survey were not primary to this study or our review. |
|Incomplete outcome data (attrition bias) | High risk | Immediately following randomisation, 12/156 women in the intervention group and 9/158 women in the control group were excluded/withdrew. In the intervention group, 9 did not complete the computer assessment; 2 had their visits cancelled and 1 withdrew. In the control group, 2 women had their visit cancelled, and 6 women withdrew and 1 physician withdrew 1 woman who had mental health issues. The authors observed that women generally showed interest in the computer |
screening, and some expressed disappointment when they were not assigned to the computer-screened group, which may have explained the higher number of withdrawals in the control group. It is unclear what the actual level of attrition was, given that individual participant numbers for analyses are inconsistent across the flowchart depiction (intervention 141, control 144), and the results text (intervention 143, control 144). Numbers in Table 3 (RR analyses: intervention 139, control 141) also differed but this was due to missing data (missing covariate values for three visits and outcomes coded as “other” in 2 cases). In the final analysis, reasons for exclusions of participants appear balanced across the 2 groups occurring due to missing data, recording failures, and language barriers. Overall the attrition rate was low at 10.8% (34/314). The sensitivity analyses suggest that the missing data were enough to potentially affect the results: “Sensitivity analyses were conducted to gauge the potential effect of missing values. 2 extreme situations were considered in which each missing value was replaced with an extreme value of the variable that was most likely to diminish the observed RR toward the null value or most likely to accentuate the observed RR away from the null. These 2 extremes provide a range of likely values for each effect.” Other imputed missing data were accounted for in the appendixed reanalysed outcome data, which was undertaken by ITT.

<table>
<thead>
<tr>
<th>Selective reporting (reporting bias)</th>
<th>Low risk</th>
<th>None noted. Trial registered (NCT00385034) but study protocol not available</th>
</tr>
</thead>
<tbody>
<tr>
<td>Other bias</td>
<td>High risk</td>
<td>Protection against contamination: there was a high risk of bias in terms of what the participants in the control group received. Given that the same providers delivered both conditions to different women, this suggests the way in which they interacted with women from the control group may have been influenced by their experi-</td>
</tr>
<tr>
<td>Study: Carroll 2005</td>
<td></td>
<td></td>
</tr>
<tr>
<td>--------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Methods</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Study design: cluster-randomised controlled trial</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Randomisation method: to obtain a balanced sample, each participating provider was paired to the greatest extent possible with another provider by practice location, type of provider, sex, and age. 1 member of each pair was randomly assigned to the ALPHA group (intervention group) or control group by a biostatistician using computer-generated random numbers</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Power calculation: reported</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Study dates: from 1998 to 2002</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Participants</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Setting: 4 communities in Ontario, including urban, suburban, and rural practices with women from diverse socioeconomic and ethnic backgrounds</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Country: Canada</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inclusion criteria (providers): any HCP (e.g. physicians, obstetricians, midwives) who practised antenatal and intrapartum care, or antenatal plus transfer at 28 weeks, saw at least 10 antenatal women a year, and were not using any antenatal psychosocial screening tool other than the standard Ontario Antenatal Record</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inclusion criteria (individuals): female; 12 to 30 weeks' gestation; able to read and write English; able to provide informed consent</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Exclusion criteria: high obstetric risk as defined by Ontario Antenatal Record</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Numbers recruited (providers): 60; intervention group 30, control group 30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of dropouts (providers): 12; intervention group 9, control group 3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Numbers (% of eligible individuals recruited): 253/273 (92.7%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Numbers recruited (individuals): 253; intervention group 112, control group 141</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of dropouts (individuals): 26; intervention group 14, control group 12</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Numbers analysed (% of recruited): 227; intervention group 98 (88%), control group 129 (91%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age: intervention group mean 29.1 (range 17 to 47 years), control group mean 29.4 (range 17 to 44 years)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ethnicity: born in Canada; intervention group 85.7%, control group 84.5%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Socioeconomic status</td>
<td></td>
<td></td>
</tr>
<tr>
<td>● &lt; USD 25,000; intervention group 10.3%, control group 4.7%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>● USD 25,000 to 49,999; intervention and control group 22.7%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>● USD 50,000 to 74,999; intervention group 29.9%, control group 32.8%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>● USD 75,000 to 99,999; intervention group 19.6%, control group 24.2%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>● &gt; USD 100,000; intervention group 17.5%, control group 15.6%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Education background: high school or less intervention group 19.4%, control group 26.6%; some college or university intervention group 25.5%, control group 20.3%; degree intervention group 55.1%, control group 53.1%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pregnancy problems: no concerns intervention group 55.1%, control group 50%; minor concerns intervention group 39.8%, control group 46.9%; major concerns intervention group 5.1%, control group 3.1%</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Interventions

<table>
<thead>
<tr>
<th>Intervention group</th>
<th>Control group</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Providers administered the ALPHA tool face-to-face, which screened for 15 risk factors, including IPV</td>
<td>• Usual antenatal care</td>
</tr>
</tbody>
</table>

Outcomes

| • Providers were followed up 1 month postpartum to determine whether antenatal risks were considered 'present' for participants on the basis of providers having 'some' or 'high' concern about the risk factor. This included family violence, which had been assessed in the ALPHA tool using 5 items, one of which directly assessed concern with current or past woman abuse | • At 4 months' postpartum, the study nurse contacted all women in the trial to again complete a number of psychosocial instruments. Women with providers in the ALPHA group were asked to give feedback about the ALPHA form |

Notes

Data on psychosocial outcomes at 4 months' postpartum were not reported. Data on sample characteristics only reported for the people who completed.

Funding: Ontario Ministry of Health and Long Term Care and the Ontario Women's Health Council

Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk</td>
<td>To obtain a balanced sample, each participating provider was paired to the greatest extent possible with another provider by practice location, type of provider, sex, and age. 1 member of each pair was randomly assigned to the ALPHA group (intervention group) or control group by a biostatistician using computer-generated random numbers</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>There is a lack of information about the level of allocation knowledge of those who enrolled the provider. Presumably providers recruited women after their randomisation had occurred. If providers knew their status, this could have influenced how and which women were recruited based on their own allocation status</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias) All outcomes</td>
<td>High risk</td>
<td>Provider participants were aware of the purpose of the study and their status as intervention or control group, which may have influenced their performance. Providers were also responsible for first telling women about the study. Interested women received</td>
</tr>
</tbody>
</table>
an explanatory brochure and consent form from their provider and a telephone call from the study nurse to further explain the study and secure consent. We are not told in the report what level of awareness women had about the purpose of the trial. Knowing that the trial included a focus on IPV could have influenced how they responded to their treatment or non-treatment. However, IPV was just 1 of 15 psychosocial issues and therefore may have not been singled out. Individual women in the intervention group may have been aware that they were in a treatment group based on the introduction of the ALPHA tool into the consultation, which may have influenced their responses to the ALPHA tool. There is no mention about the blinding of other study personnel.

| Blinding of outcome assessment (detection bias) | High risk | Healthcare professional participants provided the primary outcome data in that they reported back on their level of concern with their participating patients. Both intervention and control group providers may have overestimated their level of concern as they would have been prompted by the questions asked in the data collection form. We are told a nurse undertook a follow-up of women but are not given information on level of awareness of women's allocations. The women themselves would not have been blinded in outcome reporting. |
| Incomplete outcome data (attrition bias) | High risk | 9/30 (30%) intervention group providers compared to 3/30 (10%) control group providers withdrew from the study. Intervention group: withdrawn because of illness, maternity leave or ineligibility because of language barrier (n = 5); no reason given for withdrawal (n = 4); control group: withdrawn because of illness (n = 1); no reason given for withdrawal (n = 2). 6 family physicians withdrew from the intervention group compared to 1 in the control group. There were no data reported on participants of the 12 providers that withdrew. This high level of attrition in the interven-
tion group provider could indicate deliberate withdrawal associated with the outcome (creating high risk of bias). Among providers who remained in the study, and in terms of the primary outcome, attrition of individual women was low - providers did not complete/return data collection forms on 7.5% of participants. No data were reported on the numbers of women who were assessed at the 4-month postpartum point to allow us to evaluate bias at the participant reporting level. Only 14/21 intervention group providers gave feedback on experience of using the ALPHA tool. Analysis included sensitivity analysis to accommodate loss of provider participants. Results were not robust enough to withstand the loss of providers.

<table>
<thead>
<tr>
<th>Selective reporting (reporting bias)</th>
<th>High risk</th>
</tr>
</thead>
</table>
| Importantly, there is an absence of information on the postpartum psychosocial outcomes of women. Data on characteristics of the sample are only reported on those who were included in the final analysis. The reporting of results highlighted the one significant finding (family violence, including child abuse) as the great majority of others were non-significant.

<table>
<thead>
<tr>
<th>Other bias</th>
<th>Unclear risk</th>
</tr>
</thead>
<tbody>
<tr>
<td>Protection against contamination: women in the control group may have seen intervention group providers during subsequent consultations, which may have contaminated women’s psychosocial outcome data. There is a lack of information about how the situation of the control group using the ALPHA tool was avoided. Reliability of outcome measures: while the primary outcome (akin to identification/detection) was adequately measured as 'some' or 'high' concern about a particular psychosocial issue, the time lapse between the delivery of the intervention and the data collection may have introduced bias through recall bias. Intervention group might have had more notes on which to base recall than that the control group providers.</td>
<td></td>
</tr>
</tbody>
</table>
### Methods

| Study design: randomised controlled trial |
| Randomisation method: computer-generated |
| Power calculation: reported. However, it was based on combining data from 2 clinics. We report on just 1 clinic here |
| Study dates: from 17 July 2012 to 21 September 2012 |

### Participants

| Setting: Women, Infants, Children's (WIC) clinic in the large metropolitan city of Atlanta. WIC clinics provide supplemental food, healthcare referrals and nutrition education to low-income women and their children up to five years of age |
| Country: USA |
| Inclusion criteria: females, at least 18 years of age, eligible for WIC services, English-speaking and literate. Only African-American women were included in analyses |
| Exclusion criteria: none stated |
| Number (%) of eligible recruited at 'Clinic 2': 402/648 (61.9%; this percentage was based on overall participation rate reported across the 2 clinics) |
| Numbers randomised: 402; face-to-face interview 200, CASI 202 |
| Number of dropouts: 34; face-to-face interview 9, CASI 25 |
| Numbers analysed (% recruited): 368; face-to-face interview 191 (95.5%), CASI 177 (87.6%) |
| Age: mean 27.4 years (SD 7.8) |
| Ethnic background: all African-American women in this analysis |
| Marital status: unmarried relationship 45%, single 40%, married 15% |
| Education: up to high school 44%, some college 33%, completed college 22% |
| Employment: working outside the home 45% |
| Experience of IPV: lifetime experience of any IPV 49%, prior-year experience of any IPV 36% |

### Interventions

| Intervention group |
| Face-to-face interview screening (FTFI) using the CTS2S by researchers who were trainee health professionals or health researchers had been trained in survey administration and provided with sensitivity training. All participants received brochure with resources related to WIC services, child health insurance, healthy relationships, and contact information for local domestic violence agencies and hotlines |
| Women completed the CTS2S via computer and received a printed list of resources for any health risk behaviours they disclosed (computer-assisted screening interview; CASI) |

### Outcomes

| Primary outcomes |
| Lifetime and prior-year IPV data collected through the face-to-face or computerised screening |
| Other variables measured were health behaviours, including smoking, alcohol and substance use, and contraceptive use (data not reported) |
| Timing of measurement |
| 117 women (31.8%) completed the 2-week follow-up but no data are reported here |

### Notes

| We were unable to obtain the follow-up data from the authors (Fincher 2015 [pers comm]) |
| Funding: the Georgia Department of Public Health, Maternal and Child Health Program; Emory Center for Injury Control (Grant - R49 CE001494 and PH2011120G); |
Fincher 2015  
(Continued)

and the Hubert Department of Global Health, Rollins School of Public Health, Emory University

### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Unclear risk</td>
<td>We were informed directly by authors that there was “computer generated randomization to FTFI or CASI within clinic strata. ” (Fincher 2015 [pers comm]). No further detail was supplied in the report or personal communications. There were a number of differences between the groups on sociodemographic characteristics, calling into question the success of the randomisation process</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>High risk</td>
<td>We were unable to obtain information on the steps taken to conceal the allocation or on how the personnel/interviewers moved from the recruitment/consenting stage to allocating women and delivering the face-to-face screening or CASI. 34/402 cases were omitted from the analysis due to incomplete data and it is unclear at what stage they dropped out. We were informed that those recruiting women also did interviews and recruiters would likely have had knowledge of the allocation prior to inviting individuals into the study, which could have influenced their behaviours differentially suggesting the potential for selection bias</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias)</td>
<td>High risk</td>
<td>Personnel conducting the face-to-face interview were not blinded to the purpose of the study, were aware that they were delivering the intervention condition, and had a high level of interaction with women from recruitment through to follow-up. Participants were not blinded: “Potential participants were informed that the survey asked questions about their general health and about their relationship with their partner, ” however women in both arms received this information making it less likely to influence the outcomes differentially in the groups. However, we judge that the lack of blinding for personnel could have inter-</td>
</tr>
<tr>
<td>Bias Type</td>
<td>Risk Classification</td>
<td>Risk Justification</td>
</tr>
<tr>
<td>--------------------------------------</td>
<td>---------------------</td>
<td>-----------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias)</td>
<td>Unclear risk</td>
<td>Women's disclosure data were used as the primary outcome data and it is unlikely that the 2 arms behaved differently in this regard. The follow-up at 2 weeks was conducted by the same interviewers, which could have led to detection bias, however it appears the 2-week data were not reported here. The latter could have differentially affected outcomes.</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias)</td>
<td>Unclear risk</td>
<td>34/402 cases were omitted and the rate was higher in the CASI group (12%) compared to face-to-face group (4%) as pointed out above, but is unclear at what stage that occurred. At 2 weeks, 117/368 (31.8%) of women completed a follow-up suggesting high attrition but we do not know if there was differential dropout and, in any case, we were unable to incorporate the 2-week data as they were not reported.</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>High risk</td>
<td>No protocol available. The second clinic's data are being reported elsewhere. Data on the 2-week outcomes for women were not reported. “Telephone follow-up interviews were conducted with study participants at 2 weeks to ask about their experience with and preference for screening method.”</td>
</tr>
<tr>
<td>Other bias</td>
<td>Unclear risk</td>
<td>The authors were contacted for additional information on how randomisation was conducted and on flow of participants in the study. However, we were not able to obtain clarity on a number of methodological queries. It is unclear if steps were taken to protect against contamination/cross-over</td>
</tr>
</tbody>
</table>
### Methods

Study design: 3-arm, randomised controlled trial
- Randomisation method: not described
- Power calculation: used EpiInfo software with 95% confidence interval level and 80% power, assuming prevalence of 7% in control
- Study dates: reported in Rodrigues 2008 that women were recruited over a 10-month period during 1999 and 2000. Women were contacted again 1 year postpartum, and although specific dates have not been reported in Fraga 2014, authors confirmed that between 2000 and 2001 women were re-contacted and received the screening intervention Fraga 2015 [pers comm].

### Participants

- Setting: maternity/maternal health services at a university hospital
- Country: Portugal
- Inclusion criteria: consenting women who had delivered a baby at the hospital 1 year prior
- Exclusion criteria: not reported
- Numbers recruited (12 months prior): 915 women
- Numbers randomised: intervention group one 305, intervention group two 305, control group 305
- Number dropouts (lost since recruitment): intervention group one 13, intervention group two 3, control group 70
- Numbers analysed (% of recruited): 829; intervention group one 292 (96%), intervention group two 302 (99%), control group 235 (77%)
- Age: not reported for the subset in this study
- Marital status: not reported
- Ethnicity: not reported
- Education: reported as “did not differ between randomization groups”

### Interventions

- **Intervention groups**
  - Group one: face-to-face screening using Abuse Assessment Screen by social worker
  - Group two: telephone screening using Abuse Assessment Screen by social worker
  - We combined the 2 conditions involving the social worker and compared them to postal screening
- **Control group**
  - Screening by postal questionnaire using Abuse Assessment Screen
- **Timing of measurement:** interventions were conducted at 1 year postpartum

### Outcomes

- **Primary outcome**
  - IPV for the 1 year postpartum period was assessed using the validated Abuse Assessment Screen
- Referral rates were not reported

### Notes

This was a brief report. Women who did not respond to the postal questionnaire were followed up using one of the other screening methods (face-to-face or telephone), which increased the IPV detection rate from 9/235 (3.8%) to 19/235 (8.1%) in this group. Similarly, alternative methods were used for women in the face-to-face and telephone groups if they did not respond. We only used the initial screening data from this study, which may have underestimated detection rates for the postal group (as the one with the low participation rate).

Funding: Fundacao para a Ciencia e a Tecnologia Fundação para a Ciência e a Tecnologia
### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Unclear risk</td>
<td>Randomisation was performed in the ratio 1:1:1 but method was unclear</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>Not described</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias) All outcomes</td>
<td>Unclear risk</td>
<td>Not described and not likely due to the nature of the intervention but potentially high risk for interviewers/outcome assessors as it seems that data were collected on antenatal abuse at enrolment. It is not clear whether the interviewers/outcome assessors had access to this information, which could have biased the outcome assessor to conduct more rigorous follow-up interviews of women identified at enrolment as ‘at risk’ due to abuse in the prenatal phase</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) All outcomes</td>
<td>Unclear risk</td>
<td>Not described but potentially high risk for interviewers/outcome assessors as it seems that data were collected on antenatal abuse at enrolment. It is not clear whether the interviewers/outcome assessors had access to this information, which could have biased the outcome assessor to conduct more rigorous follow-up interviews of women identified at enrolment as ‘at risk’ due to antenatal abuse</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) All outcomes</td>
<td>High risk</td>
<td>The postal questionnaire group suffered from high attrition (70/305; 23%) and 81 women (27%) received alternative screening interventions (protocol deviations), which increased the IPV detection rate in the ITT analysis. We excluded these protocol deviations from the ITT data for our meta-analyses</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Unclear risk</td>
<td>The protocol for this study was not available and therefore we were not able to determine whether selective reporting was present. Results were reported by ITT and per protocol but as percentages only</td>
</tr>
</tbody>
</table>
### Fraga 2014 (Continued)

<table>
<thead>
<tr>
<th>Other bias</th>
<th>Unclear risk</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>This was a brief report and the authors were contacted for additional information; missing data for the primary outcome were obtained, however we were not able to obtain clarity on most methodological queries. Baseline data were reported to be similar between groups, however the numerical data were not published. It was simply stated that &quot;Age, education, income, smoking, prenatal visits and abuse during pregnancy did not differ across the three randomised groups&quot;. “Abuse during pregnancy” was measured using the Abuse Assessment Screen as part of a hospital survey preceding this RCT, and this may have affected the collection and interpretation of outcome data.</td>
</tr>
</tbody>
</table>

### Humphreys 2011

<table>
<thead>
<tr>
<th>Methods</th>
</tr>
</thead>
<tbody>
<tr>
<td>Study design: randomised controlled trial</td>
</tr>
<tr>
<td>Randomisation method: women reporting risks for smoking, alcohol, drug use, and IPV were stratified by risk combination and randomly assigned by the computer (on which they completed a risk assessment) to intervention or usual care</td>
</tr>
<tr>
<td>Power calculation: none reported</td>
</tr>
<tr>
<td>Study dates: from June 2006 to June 2007</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Participants</th>
</tr>
</thead>
<tbody>
<tr>
<td>Setting: 5 antenatal clinics in San Francisco</td>
</tr>
<tr>
<td>Country: USA</td>
</tr>
<tr>
<td>Inclusion criteria: females aged 18 years and over, English speaking, &lt; 26 weeks pregnant, receiving antenatal care at one of the participating clinics, and not presenting for first antenatal visit</td>
</tr>
<tr>
<td>Exclusion criteria: none stated</td>
</tr>
<tr>
<td>Numbers recruited/assessed for IPV risk: 410</td>
</tr>
<tr>
<td>Numbers randomised: 50; intervention group 25, control group 25</td>
</tr>
<tr>
<td>Number dropouts at exit interview: intervention group 3, control group 1</td>
</tr>
<tr>
<td>Numbers analysed (% recruited) at exit interview: intervention group 22 (88%), control group 24 (96%)</td>
</tr>
<tr>
<td>Number dropouts at second interview: intervention group 5, control group 8</td>
</tr>
<tr>
<td>Numbers analysed (and % recruited) at second interview: 20 intervention group (80%), control group 17 (68%)</td>
</tr>
<tr>
<td>Numbers analysed (sensitivity analysis): 50; intervention group 25, control group 25</td>
</tr>
<tr>
<td>Age: mean 27.7 years (SD 7.1), range 18 to 43 years</td>
</tr>
<tr>
<td>Marital status: married/living with partner 38%, never married 46%, divorced/separated 16%</td>
</tr>
<tr>
<td>Ethnicity: Latino 34%, Black 22%, White 30%, Other 14%</td>
</tr>
<tr>
<td>Education: &lt; high school 22%, high school 36%, some college 28%, college degree 12%</td>
</tr>
</tbody>
</table>
### Interventions

**Intervention group**
- Computer-based assessment (to check eligibility based on Abuse Assessment Screen and randomise women) was followed by video doctor plus provider cueing prior to antenatal consultation

**Control group**
- Computer-based assessment (to check eligibility based on Abuse Assessment Screen and randomise women) was not followed by the video doctor/provider cueing sheet; women simply proceeded to their antenatal appointment

### Outcomes

**Primary outcomes**
- Patient-provider discussion of IPV
- Helpfulness of IPV discussion

Timing of measurement: short-term assessment of outcomes (immediately after the intervention and again following antenatal visit 1 month later; data collected from women)

### Notes

Analysis: no adjustment for clustering

Funding: US Department of Health and Human Services National Institute on Drug Abuse (R01 DA 15597). The preparation of this manuscript was supported, in part, by a NIDA Center grant (P50 DA 009253)

### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk</td>
<td>Women were randomly assigned by the computer (on which they completed a risk assessment) to the intervention or control group: “Women reporting risks were stratified by risk combination and randomly assigned by the computer to intervention or usual care groups”</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Low risk</td>
<td>Allocation was adequately concealed as only the computer had knowledge of the assignment and there was no opportunity to influence what groups women went into as the computer did the allocation immediately</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias) All outcomes</td>
<td>High risk</td>
<td>While some personnel may have become aware of the participant allocation (e.g. in order to place computer reports in medical records), the review authors judged that the outcome is not likely to be influenced by this lack of blinding. However, the printed report would have alerted physicians to the status of the woman in the intervention group and may have enhanced perfor-</td>
</tr>
</tbody>
</table>
### Blinding of outcome assessment (detection bias)

**All outcomes**
- **Risk:** High risk

During post-visit interviews at baseline and 1-month follow-up, participants were asked “Did you talk about domestic violence with your doctor today?” which was used to indicate that a patient-provider discussion of IPV occurred. We were not given information on the level of blinding of the research assistant and, in any case, the allocation of the woman could very easily have been revealed during the outcome evaluation potentially biasing the research assistant’s observations.

### Incomplete outcome data (attrition bias)

**All outcomes**
- **Risk:** Unclear risk

Of the 25 women in the intervention group, 3 (12%) did not provide baseline data and 5 (20%) did not provide data at 1-month follow-up. Of the 25 women in the control group, 1 (4%) did not provide baseline data and 8 (32%) did not provide data at 1-month follow-up. The sensitivity of the results to LTFU was assessed “by making the assumption that in the absence of outcome data, no discussion occurred.” Reasons for dropout were not provided and it is therefore difficult to judge if there was a differential dropout across the groups.

### Selective reporting (reporting bias)

**High risk**

There were differences between the outcomes as reported in the trial registry (NCT00540319) and those reported here.

### Other bias

**High risk**

Protection against contamination: women assigned to the control group could have received an ‘enhanced’ usual care given that providers were consulting with women from both the intervention and control groups.
### Kataoka 2010

#### Methods
- Study design: randomised controlled trial
- Randomisation method: random numbers table
- Power calculation: none reported
- Study dates: from February to November 2003

#### Participants
- Setting: antenatal clinic of an urban general hospital
- Country: Japan
- Inclusion criteria: women < 25 weeks pregnant
- Exclusion criteria: none stated
- Number (%) of eligible recruited: 328/355 (92.4%)
- Numbers randomised 328: interview 165, questionnaire 163
- Numbers analysed (% recruited) at first time point 328: interview 165 (100%), questionnaire 163 (100%)
- Number of dropouts at second time point: interview 10, questionnaire 3
- Numbers analysed (% recruited) at second time point: 315; interview 155 (93.9%), questionnaire 160 (98.2%)
- Number of dropouts at third time point: interview 7, questionnaire 11
- Numbers analysed (% recruited) at third time point: 297; interview 148 (89.7%), questionnaire 149 (91.4%)
- Age: 20 to 29 years 30.5%, 30 to 39 years 66.2%, ≥ 40 years 3%
- Marital status: married 96.3%, single 2.1%
- Education: high school 13.4%, junior college 43.6%, university degree 41.8%
- Employment: full-time 33.8%, part-time 17.7%, not working 46.9%
- Lifetime experience of physical violence by male partner: 20 (5.8%); interview 8 (4.8%); questionnaire 11 (6.8%)

#### Interventions
- **Intervention group**
  - Face-to-face screening using the 7-item Japanese VAWS with brief counselling and a community resource card on 3 occasions
- **Control group**
  - Women in the questionnaire group self completed the VAWS in an antenatal clinic interview room where the community resource cards were available on 3 occasions

#### Outcomes
- **Primary outcome**
  - Identification (from screen questionnaires)
- **Secondary outcomes**
  - Comfort level
  - Need to consult with the nurse after screening (all participants completed a questionnaire immediately after the intervention)

#### Notes
- Funding: Grant-in-Aid for COE (Centre of Excellence) Research, provided by the Ministry of Education, Culture, Sports, Science and Technology of Japan

### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bias Type</td>
<td>Risk Level</td>
<td>Notes</td>
</tr>
<tr>
<td>-----------------------------------------------</td>
<td>------------</td>
<td>-------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk</td>
<td>Researchers &quot;used a random number table in blocks of four to ensure that approximately equal numbers of women were allocated to each group&quot;</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Low risk</td>
<td>Although it was indicated that numbered, sealed envelopes were used, it was unclear whether opaque envelopes were used. However, since there was no clear intervention/comparison group, the likelihood that selection bias was introduced is low</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias)</td>
<td>Unclear risk</td>
<td>The researchers indicate “because of the nature of the screening methods, participants could not be blinded to the group assignment.” However any such bias was likely distributed equally across the 2 groups. Although the extent of the knowledge about participants' assignment, especially given the repeat visits among personnel, is unclear it is unlikely to have influenced the outcomes differentially in the groups</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias)</td>
<td>Low risk</td>
<td>There was no blinding of outcome assessment; however, the outcome measurement is not likely to be differentially influenced in the 2 groups by lack of blinding as there was not a clear intervention or comparison group. Also the &quot;same researcher performed the allocation procedure and data analysis&quot;</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias)</td>
<td>Low risk</td>
<td>Attrition rates were low and balanced in the 2 groups (intervention group 10.3%; control group 8.6%). 2 people in the interview group refused to continue compared to 0 in the questionnaire group</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Low risk</td>
<td>Primary and secondary outcomes reported as specified in protocol. The trial was registered (UMIN-CTR000000353)</td>
</tr>
<tr>
<td>Other bias</td>
<td>High risk</td>
<td>“Measurements of primary and secondary outcomes had psychometric property limitations”</td>
</tr>
</tbody>
</table>
### Methods

Study design: randomised controlled trial  
Randomisation method: the audio computer-assisted self interview computer program applied simple randomisation (simple randomisation was written into the code of the software program), which facilitated individual randomisation of women to 1 of 3 trial arms  
Power calculation: none provided  
Study dates: from 22 April 2008 to 26 September 2008

### Participants

Setting: women's health clinics (obstetrical, gynaecological, and family planning clinics) at a public hospital  
Country: USA  
Inclusion criteria: females, at least 18 years of age  
Exclusion criteria: women who did not speak English; were accompanied by their partner or a child over 3 years of age; who were visually, hearing, or mentally impaired; women who had no access to a telephone or were over 36 weeks pregnant  
Number (% of eligible recruited): 126/228 (55%)  
Numbers recruited 126: intervention group 46, control group 80  
Number of dropouts: 24; intervention group 10, control group 14  
Numbers analysed (% recruited): 102; intervention group 36 (78%), control group 66 (83%)  
Age: mean 35.8 years (SD 14.4 years)  
Ethnicity: 6.3% White, 78.6% Black, 11.9% Latino, 3.2% Asian  
Education background: ≤ high school 42.4%, ≤ college/vocational training 41.9%  
Insurance status: Medicaid/care 37.3%, private insurance 5.6%, uninsured 57.1%

### Interventions

**Intervention group**  
- IPV screening by HCP using the PVS, and if positive, HCP support  
**Control group**  
The study authors combined the 2 A-CASI arms  
- A-CASI IPV screening (PVS), and if positive, a computer printout of locally available resources for her referral, A-CASI encouragement to show HCP her results and HCP encouragement to contact IPV services if the woman shared her results  
- A-CASI IPV screening (PVS), if positive for IPV, a short video clip provided support and encouraged help seeking, and the computer printed a list of available IPV resources for self referral

### Outcomes

**Primary outcomes**  
3 screening outcomes:  
- Rates of IPV disclosure based on PVS  
- Screening mode preference  
- Impact of IPV screening (positive and negative reactions)  
**Referral outcomes:**  
- At 1-week follow-up telephone call, women were asked to report:  
  - Recall of receiving list of services that provide help to women  
  - If women recalled receiving the list, did they share it with anyone  
  - Contact with services  
- At 3 months, the local IPV advocacy staff were asked to report records of any telephone or face-to-face contact from study participants who screened positive
**Risk of bias**

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk</td>
<td>Simple randomisation was written into the code of the computer program used to screen women and individually assigned participants to 1 of the 3 trial arms</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Low risk</td>
<td>Research assistants obtained informed consent from participants prior to any knowledge of the allocation. The allocation was revealed to the participant directly via the computer program used to conduct the health interview</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias)</td>
<td>High risk</td>
<td>Participants were not blinded. While any impact of non-blinding on performance was likely to have been low in the pure A-CASI condition, the potential for involvement of HCPs in the other 2 arms may have influenced the performance of participants especially in the face-to-face arm</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias)</td>
<td>High risk</td>
<td>Except for data on women’s contact with local advocacy services, which was provided by blinded advocacy staff, assessment of outcomes was not blinded. The research assistant collecting the data was aware of the assignment of individuals and therefore there was potential for introducing a bias into the assessment of outcomes. Also “HCPs were asked to respond to a checklist for compliance with the screening and referral protocol, HCPs were not actually observed to establish the validity of this checklist and the accuracy of their reporting”</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias)</td>
<td>Low risk</td>
<td>“Participants lost to follow-up were similar in level of education and insurance status, but were significantly younger. However, there were no differences between assigned study groups for demographic characteristics among the 24 women lost to follow-up”</td>
</tr>
</tbody>
</table>
### Selective reporting (reporting bias)

<table>
<thead>
<tr>
<th>Klevens 2012a (Continued)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Selective reporting (reporting bias)</td>
</tr>
</tbody>
</table>

### Other bias

<table>
<thead>
<tr>
<th>Klevens 2012a (Continued)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Other bias</td>
</tr>
</tbody>
</table>

### Koziol-McLain 2010

#### Methods

<table>
<thead>
<tr>
<th>Koziol-McLain 2010</th>
</tr>
</thead>
<tbody>
<tr>
<td>Study design: randomised controlled trial</td>
</tr>
<tr>
<td>Randomisation method: randomly assigned individually 1:1 to intervention or control group</td>
</tr>
<tr>
<td>Power calculation: sample size was calculated to detect a 50% treatment effect for 1 or more physically abusive events occurring in the follow-up period</td>
</tr>
<tr>
<td>Study dates: from 16 April 2007 to not reported</td>
</tr>
</tbody>
</table>

#### Participants

<table>
<thead>
<tr>
<th>Koziol-McLain 2010</th>
</tr>
</thead>
<tbody>
<tr>
<td>Setting: North Island New Zealand hospital ED</td>
</tr>
<tr>
<td>Inclusion criteria: women aged 16 years and over, presenting to the ED for care during selected shifts were eligible</td>
</tr>
<tr>
<td>Exclusion criteria: acute presentations precluding informed consent, functional or organic impairment based on clinician assessment, emergency health needs, non-English speaking or entered study during previous visit</td>
</tr>
<tr>
<td>Number (% of eligible recruited): 399/983 (40.6%)</td>
</tr>
<tr>
<td>Numbers randomly assigned: 399; intervention group 199, control group 200</td>
</tr>
<tr>
<td>Number of dropouts at exit interview: intervention group 32, control group 23</td>
</tr>
<tr>
<td>Numbers analysed (% of randomised): 344; intervention group 167 (84%), control group 177 (88.5%)</td>
</tr>
<tr>
<td>Age: median 40 years, range 16 to 94 years, interquartile range 27 to 59 years</td>
</tr>
<tr>
<td>Relationship status: current relationship 67.4%, relationship within past year 8.3%, no relationship in past year 22.3%, never had a partner 2%</td>
</tr>
<tr>
<td>Ethnicity: Maori 37.6%, New Zealand European 60.4%, other 2%</td>
</tr>
<tr>
<td>Socioeconomic status (annual individual income): NZD 0 to 10,000 15.2%, NZD 10,001 to 20,000 32.1%, NZD 20,001 to 35,001 26.1%, &gt; NZD 35,000 20.3%, do not know 5.8%</td>
</tr>
<tr>
<td>Employed: yes 49.1%, no 31.6%, retired 19.3%</td>
</tr>
<tr>
<td>Education: &lt; high school 23.3%, high school 22.8%, other completed qualification 45.6%, college degree 8.3%</td>
</tr>
<tr>
<td>Depression (CES-D): mean 14.0</td>
</tr>
</tbody>
</table>
## Mental health (SF-12): mean 64.8 (SD 24.6)
General health (SF-12): mean 61.9 (SD 30.9)
Acute injury: 79 (19.9%); intervention group 34 (17.3%), control group 45 (22.9%)
One or more children in household: 73.4%
Level of violence (treatment group only): 18% screen result positive, 51% lifetime result positive

### Interventions

**Intervention group**
- Standardised 3-item IPV screen incorporating the Partner Violence Screen and the Abuse Assessment Screen, statements about the unacceptability of violence, risk assessment, and referral by a health professional (e.g. nurse, midwife, social worker)
- Research assistants

**Control group**
- Usual emergency care

### Outcomes

**Primary outcome**
- Violence exposure by a current or past partner in the last 3 months on the Composite Abuse Scale (CAS)

**Secondary outcomes**
- Safety behaviours (9-item Safety Behaviors Checklist)
- Resource use - informal (9-item) and formal (7-item) resource use (Community Resources Checklist)

**Other outcomes**
- Medical ED charts of all presumed eligible participants were abstracted to collect data including documentation of IPV; however, these data were not reported as a comparison

**Timing of measurement/follow-up:** 3 months after index ED visit women had a face-to-face structured follow-up interview

### Notes

- Analysis: by ITT
- Funding: Health Research Council of New Zealand

## Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk</td>
<td>The biostatistician i) computer-generated a series of randomly selected shifts across 7 days of the week and times of the day during which recruitment was to be undertaken and ii) provided a computer-generated randomised sequence for group assignment within those periods</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Low risk</td>
<td>The concealment of allocation followed strict protocols. The randomisation schedule was not available to anyone other than the biostatistician. The biostatistician oversaw the preparation of sealed, opaque,</td>
</tr>
</tbody>
</table>
tamper-proof, sequentially numbered envelopes containing the randomised treatment allocation. Research log sheets were used for the real-time documentation of recruitment and the use of envelopes to provide a clear audit trail that was closely monitored by the site project leader.

<table>
<thead>
<tr>
<th>Bias Type</th>
<th>Risk Level</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blinding of participants and personnel (performance bias)</td>
<td>High risk</td>
<td>It was not feasible to blind participants in the intervention group from the purpose of the intervention. Also, personnel may have become aware of the participant’s allocation (e.g. through medical record), which may have influenced their treatment of that participant. The study did employ strict protocols in order to attempt to reduce the risk of differential behaviour by participants and personnel</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias)</td>
<td>Low risk</td>
<td>“All follow-up staff were blinded to group assignment” at 3 months in collecting the primary and secondary outcome data. Medical records were abstracted by a nurse blinded to group assignment to determine if it was documented that there was an IPV screen or diagnosis</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias)</td>
<td>Unclear risk</td>
<td>32/199 (16.1%) LTFU in the intervention group; 23/200 (11.5%) LTFU in the control group. There is a lack of information about whether or not reasons for withdrawal/loss to follow-up differed between the groups. However, the researchers indicate “logistic regression of missing data because of attrition demonstrated no significant associations with variables associated with the primary outcome measure, supporting their being missing completely at random”</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>High risk</td>
<td>There is no reference to a trial protocol. However, the trial was registered (AC-TRN12607000210471) and some pre-selected outcomes (e.g. SF-12) were not reported here</td>
</tr>
</tbody>
</table>
| Other bias                                                               | Low risk   | No evidence of contamination, measures are valid and reliable but some baseline differences reported. “There were some po-
Potentially important group differences: compared with women in the usual care group, women in the treatment group were somewhat older (42 versus 38.5); more likely to be New Zealand European (63% versus 58%) and more likely to have been admitted to hospital (43% versus 36%). They were also less likely to be poorly educated (with less than secondary school) (17.1% versus 29.5%) but study analysis tested and adjusted for baseline differences. “Age and ethnicity were individually associated with violence in the follow-up period and included in the final model as design effects caused by differences at baseline... the final best subset model included measures of socioeconomic status... Hosmer and Lemeshow test statistic was NS”

### MacMillan 2006

<table>
<thead>
<tr>
<th>Study design: quasi-randomised controlled trial</th>
</tr>
</thead>
<tbody>
<tr>
<td>Study dates: from May 2004 to January 2005</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Setting: 2 EDs, family practices, and women’s health clinics</th>
</tr>
</thead>
<tbody>
<tr>
<td>Country: Canada</td>
</tr>
<tr>
<td>Inclusion criteria: women were eligible for participation if they were: (1) 18 to 64 years old, (2) at the site for their own healthcare visit, (3) able to separate themselves from individuals who accompanied them, (4) able to speak and read English, (5) able to provide informed consent</td>
</tr>
<tr>
<td>Exclusion criteria: too ill to participate</td>
</tr>
<tr>
<td>Number (% of eligible recruited): 2461/2602 (94.4%)</td>
</tr>
<tr>
<td>Numbers assigned: 2461 intervention group 853, control group one 769, control group two 839</td>
</tr>
<tr>
<td>Number of dropouts (varied by screening tool): intervention group 3.7% to 5.2%, control group one 3.5% to 5.7%, control group two 1.5% to 3.0%</td>
</tr>
<tr>
<td>Numbers analysed (varied by screening tool): intervention group 788, control group one 741, control group two 810 (CAS); intervention group 404, control group one 725, control group two 814 (PVS); intervention group 411, control group one 742, control group two 826 (WAST)</td>
</tr>
<tr>
<td>Marital status: single/never married 41%</td>
</tr>
<tr>
<td>Ethnicity: born outside Canada 11%</td>
</tr>
<tr>
<td>Employment: working full- or part-time 52%</td>
</tr>
<tr>
<td>Income: annual income &lt; CAD 25,000 47%</td>
</tr>
<tr>
<td>Education: achieved education &gt; 14 years 52%</td>
</tr>
<tr>
<td>Children: ≥ 1 child at home 52%</td>
</tr>
</tbody>
</table>
### Interventions

**Intervention group**
- Face-to-face screening by the HCP using 1 of the 2 screening instruments randomly determined. Any disclosure became part of the clinical encounter and women were offered usual care

**Control groups**
- Control group one: computer-based self-completed screening using the PVS and the WAST randomly ordered
- Control group two: written self-completed screening using the PVS and the WAST randomly ordered

### Outcomes

**Primary outcomes**
- Identification (12-month prevalence based on instrument compared to CAS)
- Extent of missing data
- Women's preference for screening approach

### Notes

Funding: the Ontario Women's Health Council (Ontario Ministry of Health and Long-term Care). Authors MacMillan and Wathen held Canadian Institutes of Health Research grants/fellowships; Dr Boyle held a Canada Research Chair in the Social Determinants of Child Health

### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk</td>
<td>A random number table was used to assign clinic shifts</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>High risk</td>
<td>“The research coordinator created calendars that informed site coordinators of the assignments.” There is, therefore, a risk that advance awareness of shift/day allocations may have introduced selection bias in intervention assignment by not protecting the allocation sequence before and until assignment, for example, recruiters appear to have had knowledge of the allocation prior to inviting individuals into the study, which could have influenced their behaviours differentially</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias) All outcomes</td>
<td>High risk</td>
<td>The study did not specify a control condition and it was not feasible to blind participants from the method of screening they would receive. While any impact of non-blinding on performance was likely to have been distributed similarly across the written and computerised groups (who were told their HCPs would be unaware of their re-</td>
</tr>
</tbody>
</table>
sponses), it may have influenced the performance of participants in the face-to-face arm since their providers conducted the screening and therefore "would necessarily be aware of women's responses." In this arm, it was also not feasible to blind personnel to the allocation following assignment as they would have been informed by the recruiter of the woman's participation.

**Blinding of outcome assessment (detection bias)**

- **All outcomes**
  - **High risk**
  - Outcome assessment was unable to be blinded and based on women's responses to the screening instruments, self-completion of the CAS, and their evaluation of the method. It was therefore subjective, although the extent of any systematic differences in responses is likely to be randomly distributed.

**Incomplete outcome data (attrition bias)**

- **All outcomes**
  - **Low risk**
  - Data collection was conducted immediately following the treatment. Although there was slightly higher attrition (4%) in the face-to-face arm of the trial, overall attrition was low at 5%. Reasons for missing data were not supplied.

**Selective reporting (reporting bias)**

- **Low risk**
  - All specified outcomes reported. Trial was registered (NCT00336297)

**Other bias**

- **High risk**
  - A higher proportion of women in the computer group were from the lowest income quintile and may have been more likely to both be abused and to disclose by computer.

---

**MacMillan 2009**

**Methods**

- Study design: randomised controlled trial
- Randomisation method: a table for each day/shift of the week was created for an 8-week period and a random number table was used to determine the order of weeks 1 through 8 in the cells
- Power calculation: yes
- Study dates: from July 2005 to December 2006. Individual women were each followed up for 18 months, starting in July 2005 and ending in July 2008

**Participants**

- Setting: 12 primary care sites (family practices and community health centres), 11 acute care sites (EDs) and 3 specialty care sites (obstetrics/gynaecology)
- Country: Canada
- Inclusion criteria: women aged 18 to 64 years, had a male partner at some time in the
last 12 months, presented for their own healthcare visit, able to separate themselves from individuals who accompanied them, were living with 120 km of the site, were able to speak and read English, and able to provide informed consent
Exclusion criteria: too ill to participate
Number (%) of eligible recruited: 6743/8293 (81.3%)
Numbers assigned: 6743; intervention group 3271, control group 3472
Number (%) of assigned that completed all healthcare visit questionnaires: 5681/6743 (84.3%); intervention group 2733, control group 2948
Number (%) with positive results and followed up: 707 (12.4%); intervention group 347, control group 360
Number of dropouts: intervention group 48, control group 148
Numbers analysed (and % with positive result) 411; intervention group 199 (57%), control group 212 (59%)
*Age: intervention group mean 33.8 years (SD 10.8), control group mean 33.9 years (SD 10.7)
Marital status: single/never married 41%
Ethnicity: born outside Canada 11%
Employment: working full- or part-time 52%
Income: annual income < CAD 25,000 47%
Education: intervention group mean 13.7 years (SD 2.8), control group mean 13.5 years (SD 2.8)
Children: ≥ 1 child at home 52%

### Interventions

<table>
<thead>
<tr>
<th>Group</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intervention group</td>
<td>Women in the screened group self completed the WAST; if a woman screened positive this information was provided to her clinician before the healthcare visit. Subsequent discussions or referrals, or both, were at the discretion of the HCP.</td>
</tr>
<tr>
<td>Control group</td>
<td>Women in the non-screened group self completed the WAST after their visit.</td>
</tr>
</tbody>
</table>

### Outcomes

Primary outcomes
- Recurrence of IPV (CAS)
- Quality of life (WHO Quality of Life-Bref)

Timing of measurement: followed up baseline (< 14 days), 6, 12, 18 months post-intervention (collected through self report by women)

We obtained clarification about the number of participants who discussed abuse with their provider (MacMillan 2015 [pers comm]).

### Notes

*Characteristics of participants are provided for the 707 women who had positive results for IPV in last 12 months. Age and education details for the group were obtained through personal communication (MacMillan 2011 [pers comm]).

Funding: the Ontario Women’s Health Council (Ontario Ministry of Health and Long-Term Care) with investigator grants from Canadian Institutes of Health Research. Author Boyle held a Canada Research Chair in the Social Determinants of Child Health.

### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
</table>

*Screening women for intimate partner violence in healthcare settings (Review)*

Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
<table>
<thead>
<tr>
<th>Bias Type</th>
<th>Risk Level</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk</td>
<td>Randomisation was by day or shift. &quot;A table for each day of the week was created for an 8-week period, and a random number table was used to determine the order of weeks 1 through 8 in the cells.&quot; This suggests there was balance across shifts and days of the week, and that systematic differences in presentation by day or shift were avoided.</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>High risk</td>
<td>“The research coordinator created monthly calendars showing shift allocations for site coordinators.” There is, therefore, a risk that advance awareness of shift/day allocations may have introduced selection bias in intervention assignment by not protecting the allocation sequence before and until assignment. For example, recruiters would likely have had knowledge of the allocation prior to inviting individuals into the study, which could have influenced their behaviours differentially.</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias)</td>
<td>High risk</td>
<td>It was not possible to protect the allocation sequence after assignment given that participants “were told that they might be asked questions about their relationships by completing a form that may be passed on during this visit to the clinician, who might discuss their situation in more detail.” Thus, participants may have had awareness that they were receiving an intervention (or not), which could have affected their performance. It was also not feasible to blind personnel to the allocation following assignment as they would have been prompted by the questionnaire placed in the patient record.</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias)</td>
<td>Low risk</td>
<td>“Interviewers blinded to group assignment met with women within 14 days of the index visit to conduct a baseline interview and again at 6, 12, and 18 months”</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias)</td>
<td>Low risk</td>
<td>“Participant loss to follow-up was high but evenly balanced: 43% (148/347) in screened women and 41% (148/360) in non-screened women” over 18 months making a true ITT analysis difficult. It</td>
</tr>
</tbody>
</table>
was noted by authors that women in the screened group who were LTFU reported higher scores on the WAST and CAS. Such differences between retained and lost were not observed in the non-screened group. Thus, there is a possibility that the observed effect estimate is biased. In contrast, there were no group differences in proportions lost, or reasons for dropout, although those LTFU in the intervention group were more likely to be more severely abused. To deal with missing data, average growth measures were estimated from 5 complete files generated through multiple imputation to test the robustness of the observed findings for all enrolled women.

**Selective reporting (reporting bias)**

| Selective reporting (reporting bias) | Low risk | All outcomes for all time points reported. Trial was registered (NCT00182468) |

**Other bias**

| Other bias | High risk | Protection against contamination: sites involved both screening (intervention group) and non-screening (control group) shifts/days and therefore there is a risk that those who were in the control group could have received care that was influenced by physicians’ prior experience of delivering the intervention |

**Rhodes 2002**

**Methods**

| Study design: quasi-randomised controlled trial |
| Randomisation method: alternate allocation of individual patients |
| Power calculation: none reported |
| Study dates: none reported |

**Participants**

| Setting: 1 urban university hospital emergency department |
| Country: USA |
| Inclusion criteria: English-speaking women and men, aged 18 to 65 years, who presented for emergency care with a non-urgent complaint, and triaged into lowest 2 categories of 5-level system |
| Exclusion criteria: those in pain, blind, overtly psychotic, or unable to read |
| Number (%) of eligible recruited: 470/542 (86.7%) of which 322 (68.5%) were female |
| Numbers (of women) assigned: intervention group 170, control group 152 |
| Number of dropouts: 20% of charts were missing, differences by arm unspecified |
| Numbers analysed (by groups into which they were allocated): intervention group 170, control group 152 |
| Age: mean (women) 33 years (intervention group), 41 years (control group) |
| Marital status (men and women): married 19% (intervention group), 27% (control group) |
group); single 60% (intervention group), 58% (control group); widowed/separated or divorced 21% (intervention group), 15% (control group)
Ethnicity (all patients): Black; intervention group 91%, control group 90%
Insurance status (all patients): Medicaid, intervention group 37%, control group 40%; Medicare, intervention group 17%, control group 19%; private, intervention group 34%, control group 27%; none, intervention group 12%, control group 14%
Reason for visit (all patients): medical, intervention group 50%, control group 58%; injury, intervention group 27%, control group 23%; gynaecologic or urinary, intervention group 20%, control group 18%; other, intervention group 3%, control group 1%}

<table>
<thead>
<tr>
<th>Interventions</th>
<th>Intervention group</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Women completed a computer-based screen, which included other health lifestyle and behavioural risks. Patients were then offered a computer printout to take with them. Results on a one-page computer printout were attached to the patient's ED chart. This included a prompt to assess for DV if one or more DV questions were answered positively. Resources for IPV support in hospital and in the community were listed on the prompt</td>
</tr>
<tr>
<td></td>
<td>Control group</td>
</tr>
<tr>
<td></td>
<td>Usual care</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>Documentation by physicians was assessed by blinded chart review</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Screen positive data were assessed from computer responses (in the intervention group only)</td>
</tr>
<tr>
<td></td>
<td>This study also examined other psychosocial risks for both victimisation and perpetration</td>
</tr>
</tbody>
</table>

| Notes | Funding: the Chicago Community Trust (#6-35467), the Robert Wood Johnson Clinical Scholars Program, and the Section of Emergency Medicine, University of Chicago |

<table>
<thead>
<tr>
<th>Risk of bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>High risk</td>
<td>Randomisation method: “Patients were alternately assigned to a computer-based intervention or usual care.” This method is open to selection bias and there is inadequate description of protection from such bias</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>Not all eligible patients were enrolled due to limited computer availability. Furthermore, “to avoid selection bias, when the computer was available, the patient to be recruited was the one most recently arrived and assigned as non-urgent at triage.” This method remains fallible to bias, but it is unclear whether it would have biased selection</td>
</tr>
</tbody>
</table>
### Results of screening were attached to the patient file in order to alert the treating physician to psychosocial issues as part of the intervention. This meant that the treating physician was also made aware that the patient was in the intervention group. There was therefore a high risk of performance bias.

### “Chart reviewers were blinded to whether a patient had participated in the computer screening and whether these results were shared with the treating physician and were blinded to the assessment of the other chart reviewer”

### “Findings are based on a review of 80% of charts. The percentage did not vary by whether the patient had received computer screening” - but detailed figures of and reasons for the missing 20% are not given

### The trial was not registered so we were unable to check the selected outcomes, but as it is a screening trial, identification, documentation and information-giving are expected outcome measures.

### Characteristics of participants both male and female were evenly distributed across intervention and control groups, but it is unclear how this applied to females. There is a high risk of contamination as the participants were screened or not screened alternately and then saw their physician at the clinic visit, with physicians seeing both intervention and control participants.
**Methods**

- Study design: randomised controlled trial
- Randomisation method: consenting women were randomly assigned in a 1:1 ratio. Treatment assignment was ascertained by the research assistant by opening sealed randomisation envelopes in sequential order. The envelopes were prepared from a randomisation list generated by computer in blocks of size 10 to ensure balance between groups over short time spans such as shifts and days of the week as well as over the entire course of the study.
- Power calculation: no
- Study dates: from June 2001 to December 2002

**Participants**

- Setting: 2 socio-economically diverse EDs - an urban academic medical centre serving mainly publicly insured inner city African-American population and a suburban community hospital serving a privately insured suburban white population.
- Country: USA.
- Inclusion criteria: consenting women, aged 18 to 65 years, triaged as medically non-emergent.
- Exclusion criteria: none stated.
- Number (% of eligible recruited): 1281/2165 (59.2%).
- Numbers recruited: 1281; intervention group 637, control group 644.
- Number of dropouts: intervention group 216, control group 194.
- Numbers analysed (% recruited): 871; intervention group 421 (66.1%), control group 450 (70%) (based on audio-recording data).
- Age: mean 33.3 years (SD 12 years).
- Marital status: married 21%, single 45%, divorced/separated/widowed 13%, unknown 21%.
- Ethnicity: African-American 60%, white 29%, other 7%, unknown 4%.
- Socioeconomic status: < USD 20,000 40%, USD 20,000 to 39,999 24%, USD 40,000 to 79,999 16%, ≥ USD 80,000 8%.
- Education: 1 < high school diploma 10%, high school or equivalent 18%, > high school 48%, unknown 24%.
- Positive IPV screen result on exit questionnaire: 218/903 (24%); urban 151/578 (26%), suburban 67/325 (20.6%).

**Interventions**

- Intervention group:
  - Self administered computer-based health risk assessment (Promote Health Survey), which generated health recommendations for participants and alerted physicians to various potential health risks, including domestic violence. If the woman answered ‘yes’ to any of the 8 IPV assessment items, then the report generated for the physician had a prompt ‘Possible partner violence: assess for current abuse’ and suggested referral options.
- Control group:
  - Usual ED care.

**Outcomes**

- Primary outcomes:
  - Discussion of IPV
  - Disclosure of IPV to HCP
  - Provision of domestic violence services.
- Data were collected through audio-recording of consultations (primary method). Data were also abstracted from medical records and collected directly from participants.
### Notes

Funding: Grant RO1 HS 11096-03 from the Agency for Healthcare Research and Quality. Dr Rhodes was also supported by grant K23/ MH64572 from the National Institute of Mental Health.

### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk</td>
<td>The randomisation for participating patients was generated by “computer in blocks of size 10 to ensure balance between groups over short time spans, such as shifts and days of the week, as well as over the entire course of the study.”</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Low risk</td>
<td>Women were recruited and consented prior to the “research assistant opening sealed randomization envelopes in sequential order.” ”Consenting patients were then randomly assigned”</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias) All outcomes</td>
<td>High risk</td>
<td>Providers were not blinded to the purpose of the study or the intervention: “health care providers were informed that the study objective was to study the effect of a computer prompt on IPV communication and were encouraged to screen all women for abuse.” However, this was unlikely to have led to benefits extraneous to the intended effect of the intervention for women in the intervention group: the outcome of interest is unlikely to have been influenced by lack of blinding. Women were blinded to the purpose of the study being told it was a “study of physician-patient communication.” Women in the intervention group may have realised that the computer-based health risk assessment was part of the intervention thus influencing how they behaved. However, we would not expect that the outcome would have been influenced by this incomplete blinding. For example, changes in women’s behaviour such as being more encouraged to discuss IPV with the HCP would not differ from what would be expected to arise from the intervention. Lack of blinding in the situation where participants in the control group inadvert-</td>
</tr>
</tbody>
</table>
tently became aware of the intervention through interactions with other women or staff could conceivably have influenced the outcome. We are not given sufficient information about the degree of awareness of other staff regarding women's allocations, which could have influenced their interactions with women and, therefore, the outcomes.

Blinding of outcome assessment (detection bias)

<table>
<thead>
<tr>
<th>All outcomes</th>
<th>Unclear risk</th>
</tr>
</thead>
</table>

We are not told about who edited the audio-recordings of the ED visits “a 7-hour ED visit might be edited to 20 minutes of actual health care provider-patient interaction”; it would have been important for them to be blinded as knowing the allocation could have affected the editing process. Although research assistants who were to undertake the primary data collection via coding of audio-recordings of both intervention and control group consultations were said to be blinded, the allocation of participants could have been revealed during the remaining audio data and thereby influenced coders' interpretation of what they heard. It is also not known if the person who edited differed from the coders. If the coder was also the editor then it would have increased the likelihood that the allocation of the participant would have become known. “Charts of all enrolled patients were coded using a structured chart abstraction form to assess evidence of DV documentation;” however, there is no indication of blinding of assessors. It is likely that the allocations of women in the intervention group were quite evident by virtue of presence of the IPV risk report and it is unclear if presence of a report was considered different to other documentation of IPV. Finally, both groups of women self completed an exit survey and were not blinded; however, any effect was likely equal in both groups.

Incomplete outcome data (attrition bias)

<table>
<thead>
<tr>
<th>All outcomes</th>
<th>Unclear risk</th>
</tr>
</thead>
</table>

21/101 (21%) providers did not consent to having their consultations recorded and thus there was incomplete outcome data for their participants. However, this lack
of recording should have been equal in both groups since providers were seeing participants in both the intervention and the control groups. The overall attrition of participants was 32% and we are not given clear information about the extent to which the providers’ refusal to audio-record sessions accounted for this rate (i.e. what proportion of patients declined the audio-recording post-randomisation). While the attrition levels in audio-recording appear balanced across the two groups: 216/637 (intervention group 34%), 194/644 (control group 30.1%), there was no sensitivity analysis included in the report to ascertain the impact of those missing data on the robustness of the effect. Attrition rates on chart review were similarly spread and low at 8%, and moderately high but spread on the exit survey. There is a lack of information on reasons for these (albeit low) attrition rates in the chart review. There were four cases in the control group that appear in the participant flowchart but are absent from the observed rates in Table 3.

### Selective reporting (reporting bias)

<table>
<thead>
<tr>
<th>Unclear risk</th>
</tr>
</thead>
<tbody>
<tr>
<td>Data on medical records were not furnished except that it is indicated in the text that there was no difference between groups on the documentation of IPV. No reference to a trial protocol and thus no confirmation that the original trial aims and primary outcomes were as reported here</td>
</tr>
</tbody>
</table>

### Other bias

<table>
<thead>
<tr>
<th>High risk</th>
</tr>
</thead>
<tbody>
<tr>
<td>Protection against contamination: the same providers delivered the intervention or usual care to participants. While they should have remained unaware of who the participants were in the control group, their experience of consulting with participants in the intervention group could have influenced their performance with the participants in the control group</td>
</tr>
</tbody>
</table>
### Trautman 2007

| Methods | Study design: quasi-experimental control study  
|         | Randomisation method: there were 3 distinct consecutive 2-week enrolment periods. In the second enrolment period all eligible women who presented to the ED were assigned to the intervention group. During the first and third enrolment periods all eligible presenting women were allocated to a TCG  
|         | Power calculation: yes  
|         | Study dates: enrollment occurred between April and May 2003 |

| Participants | Setting: adult urban ED of a large university hospital serving a primarily socio-economically disadvantaged, minority population  
|             | Country: USA  
|             | Inclusion criteria: women aged ≥ 18 years who presented to the ED for medical treatment  
|             | Exclusion criteria: acute or critically ill presentation, illiteracy, impaired mental status, disorientation or apparent intoxication, would not separate from their partner; or already enrolled  
|             | Numbers (%) of eligible recruited: 1005/1395 (72%)  
|             | Numbers recruited: 1005; intervention group 411, control group 594  
|             | Number of dropouts: intervention group 0, control group 0  
|             | Numbers analysed (% recruited): 1005; intervention group 411 (100%), control group 594 (100%)  
|             | Age range (years): 18 to 24 years 22.9%, 25 to 34 years 23.3%, 35 to 54 years 41.4%, ≥ 55 years 12.4%  
|             | Marital status: married/living with partner 20%, never married 53.8%, divorced/separated 21%, widowed 5.2%  
|             | Ethnicity: White 16.1%, Non-white 83.9%  
|             | Socioeconomic status (annual household income): < USD 10,000 42.4%, USD 10,000 to 15,999 20.6%, USD 16,000 to 20,999 12.2%, USD 21,000 to 35,999 14.8%, ≥ USD 36,000 10%  
|             | Education: < high school 30.5%, high school or equivalent 42.3%, > high school 27.2%  
|             | Children in household: yes 50.9% |

| Interventions | Intervention group  
|               | • Self administered computer-based health survey, including 4 items about IPV. If the woman answered yes to any of the 4 IPV assessment items, then 2 reports were generated. One copy was attached to the woman’s medical record to alert treating staff and the second copy was placed in a box for social work referral  
|               | Control group  
|               | • Self administered computer-based health survey containing no items about IPV and usual ED care (consisting of current ED policy that recommended but did not enforce routine IPV screening) |

| Outcomes | Primary outcomes  
|          | • Screening  
|          | • Detection  
|          | • Referral  
|          | • Service rates  
|          | Timing of measurement: immediate abstraction of data from medical records |
### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>High risk</td>
<td>During 3 distinct, consecutive, 2-week enrolment periods, all eligible women were asked to complete a computer-based health survey. During the first and third enrolment periods, the computer-based health survey did not include any IPV items. During the second enrolment period, it did include IPV screening items. It is likely that this type of allocation process introduced a high risk of bias due to systematic differences between the intervention group and the control group</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>High risk</td>
<td>Patient service co-ordinators recruited and obtained consent from participants. There was no blinding of recruiters to the potential allocation of women as the allocation for the period during which women presented to the ED was defined in advance and not concealed in any way explained in the report. Therefore, awareness of the allocation could have influenced how women were recruited. Furthermore, the experimental allocation for that period may have become inadvertently known to some women through interactions with other participants and staff influencing their decision to participate or not</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias)</td>
<td>High risk</td>
<td>Women approached were told that this was a study about women’s health whereby they would be “asked to answer questions about themselves on a computer and to allow their medical record to be reviewed by study personnel.” Thus, there was some blinding of women to the purpose of the study. However, healthcare personnel were unblinded as “the medical records of all subjects were attached by coordinators to participants medical records to alert treating staff”</td>
</tr>
</tbody>
</table>
**Blinding of outcome assessment (detection bias)**

<table>
<thead>
<tr>
<th>All outcomes</th>
<th>Unclear risk</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Not stated that research assistant was un-blinded as &quot;the medical records of all subjects were reviewed by a research assistant to determine whether there was any documentation in the record&quot;</td>
</tr>
</tbody>
</table>

| Incomplete outcome data (attrition bias) | Low risk |
| All outcomes | |
| | There were no dropouts although we acknowledge that it was unclear how trialists dealt with missing data within variables |

**Selective reporting (reporting bias)**

<table>
<thead>
<tr>
<th>Unclear risk</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
<tr>
<td>There was no reference to a study protocol and therefore insufficient information to permit a judgement of 'low' or 'high' risk of bias</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Other bias</th>
<th>High risk</th>
</tr>
</thead>
<tbody>
<tr>
<td>Protection against contamination: the process of the providers consulting with women in the control group in the third, 2-week block following the 2-week intervention group block could have contaminated their interactions with participants in the control group. In fact, the authors state, &quot;Three study periods were used to determine whether usual care related to intimate partner violence would return to baseline (i.e. first enrolment period) in the third enrolment period when the intimate partner violence questions were removed or whether it would be higher as a result of the computerized intimate partner violence screening during the second study period&quot;. There is some risk that an insensitive instrument was used to measure referrals with referrals applying to social workers only (which could have led to an underestimate of physician referring)</td>
<td></td>
</tr>
</tbody>
</table>

---

A-CASI: audio computer-assisted self interviews; ALPHA: Antenatal Psychosocial Health Assessment; CAS: Composite Abuse Scale; CASI: computer-assisted screening interview; CES-D: Centre for Epidemiological Studies - Depression; ED: emergency department; FTFI: face-to-face interview screening; HCP: healthcare professional; IPV: intimate partner violence; ITT: intention-to-treat; LTFU: loss to follow-up; NS: non-significant; PVS: Partner Violence Screen; CTS2S: Revised Conflict Tactics Scale-Short Form; RCT: randomised controlled trial; RR: risk ratio; SD: standard deviation; SF: Short Form; TCG: treatment control group; VAWS: Violence Against Women Scale; WAST: Woman Abuse Screening Tool; WIC: Women, Infants, Children's (clinic)
### Characteristics of excluded studies [ordered by study ID]

<table>
<thead>
<tr>
<th>Study</th>
<th>Reason for exclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bair-Merritt 2006</td>
<td>Screening results not passed on to healthcare professional</td>
</tr>
<tr>
<td>Beatty 2014</td>
<td>Screening results not passed on to healthcare professional</td>
</tr>
<tr>
<td>Bonds 2006</td>
<td>Not a randomised or quasi-random method</td>
</tr>
<tr>
<td>Brienza 2005</td>
<td>Educational intervention targeted to clinicians with no data on women</td>
</tr>
<tr>
<td>Campbell 2001</td>
<td>Case-finding not screening</td>
</tr>
<tr>
<td>Chen 2007</td>
<td>No usual care group comparison</td>
</tr>
<tr>
<td>Coonrod 2000</td>
<td>Educational intervention targeted to clinicians with no data on women</td>
</tr>
<tr>
<td>Cripe 2010</td>
<td>Intervention exceeded 'brief' intervention</td>
</tr>
<tr>
<td>Curry 2006</td>
<td>Intervention exceeded 'brief' intervention</td>
</tr>
<tr>
<td>Dubowitz 2011</td>
<td>Intervention targeted to children and clinicians</td>
</tr>
<tr>
<td>Dubowitz 2012</td>
<td>Intervention targeted to children and clinicians</td>
</tr>
<tr>
<td>Duggan 2004</td>
<td>Intervention exceeded 'brief' intervention</td>
</tr>
<tr>
<td>Ernst 2007</td>
<td>No usual care group comparison</td>
</tr>
<tr>
<td>Feder 2011</td>
<td>Case-finding not screening trial</td>
</tr>
<tr>
<td>Feigelman 2011</td>
<td>Intervention targeted to children and clinicians</td>
</tr>
<tr>
<td>Fernández Alonso 2006</td>
<td>Educational intervention targeted to clinicians with no data on women</td>
</tr>
<tr>
<td>Florsheim 2011</td>
<td>Intervention exceeded 'brief' intervention</td>
</tr>
<tr>
<td>Furbee 1998</td>
<td>Not a randomised or quasi-random method</td>
</tr>
<tr>
<td>Garg 2007</td>
<td>Participant data included both sexes and could not be disaggregated</td>
</tr>
<tr>
<td>Gillum 2009</td>
<td>Intervention exceeded 'brief' intervention</td>
</tr>
<tr>
<td>Green 2005</td>
<td>Intervention exceeded 'brief' intervention</td>
</tr>
<tr>
<td>Halpern 2009</td>
<td>Not a randomised or quasi-randomised method</td>
</tr>
<tr>
<td>Reference</td>
<td>Study Details</td>
</tr>
<tr>
<td>---------------</td>
<td>---------------</td>
</tr>
<tr>
<td>Hegarty 2013</td>
<td>Intervention exceeded 'brief' intervention</td>
</tr>
<tr>
<td>Hewitt 2011</td>
<td>Not a randomised or quasi-randomised method</td>
</tr>
<tr>
<td>Hoelle 2014</td>
<td>Screening results not passed on to healthcare professional</td>
</tr>
<tr>
<td>Hollander 2001</td>
<td>Usual care included screening results given to healthcare professional</td>
</tr>
<tr>
<td>Houry 2011</td>
<td>Screening results not passed on to healthcare professional</td>
</tr>
<tr>
<td>Jewkes 2008</td>
<td>Intervention exceeded 'brief' intervention</td>
</tr>
<tr>
<td>Kapur 2011</td>
<td>Not a randomised or quasi-randomised method</td>
</tr>
<tr>
<td>Kiely 2010</td>
<td>Intervention exceeded 'brief' intervention</td>
</tr>
<tr>
<td>Kiely 2013</td>
<td>Not a comparison of screening with usual care</td>
</tr>
<tr>
<td>Klevens 2012b</td>
<td>Screening results not passed on to healthcare professional</td>
</tr>
<tr>
<td>Knight 2000</td>
<td>Not a randomised or quasi-randomised method</td>
</tr>
<tr>
<td>Larkin 1999</td>
<td>Not a randomised or quasi-randomised method</td>
</tr>
<tr>
<td>Rickert 2009</td>
<td>No usual care group comparison</td>
</tr>
<tr>
<td>Robinson-Whelen 2010</td>
<td>Not in a healthcare setting</td>
</tr>
<tr>
<td>Saftlas 2014</td>
<td>Intervention exceeded 'brief' intervention</td>
</tr>
<tr>
<td>Subramanian 2012</td>
<td>Intervention exceeded 'brief' intervention</td>
</tr>
<tr>
<td>Taft 2011</td>
<td>Intervention exceeded 'brief' intervention</td>
</tr>
<tr>
<td>Taft 2012</td>
<td>Screening result passed on to healthcare professional in both arms</td>
</tr>
<tr>
<td>Thompson 2000</td>
<td>Case-finding not screening</td>
</tr>
<tr>
<td>Tiwari 2010</td>
<td>Intervention exceeded 'brief' intervention</td>
</tr>
<tr>
<td>Wagman 2015</td>
<td>Intervention exceeded 'brief' intervention</td>
</tr>
</tbody>
</table>
### Characteristics of ongoing studies  
*(ordered by study ID)*

**NCT01207258**

<table>
<thead>
<tr>
<th>Trial name or title</th>
<th>Social Health Intervention Project (SHIP)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Methods</strong></td>
<td>Randomised controlled trial</td>
</tr>
<tr>
<td><strong>Participants</strong></td>
<td>Inclusion criteria</td>
</tr>
<tr>
<td></td>
<td>- Female patients</td>
</tr>
<tr>
<td></td>
<td>- Aged 18 to 64 years</td>
</tr>
<tr>
<td></td>
<td>- Presenting to 1 of 2 urban emergency departments</td>
</tr>
<tr>
<td></td>
<td>- Self disclose both problem drinking and intimate partner violence</td>
</tr>
<tr>
<td></td>
<td>Exclusion criteria</td>
</tr>
<tr>
<td></td>
<td>- Intoxication at the time of screening</td>
</tr>
<tr>
<td></td>
<td>- Cognitive impairment or psychosis identified on physical examination or chart review</td>
</tr>
<tr>
<td></td>
<td>- Serious current medical illness or injury, defined as respiratory distress, haemodynamic instability, active vomiting, bleeding, labour, severe pain, or acute need for hospital admission</td>
</tr>
<tr>
<td></td>
<td>- Suicidal or homicidal ideation by chart review</td>
</tr>
<tr>
<td></td>
<td>- No identifiable residence or contact phone number</td>
</tr>
<tr>
<td></td>
<td>- Under arrest at the time of ED visit</td>
</tr>
<tr>
<td></td>
<td>- Non-English speaking</td>
</tr>
<tr>
<td></td>
<td>- Previously enrolled in the study</td>
</tr>
<tr>
<td><strong>Interventions</strong></td>
<td>Intervention</td>
</tr>
<tr>
<td></td>
<td>- Brief manual-guided motivational intervention and a phone booster at 10 days</td>
</tr>
<tr>
<td></td>
<td>Control</td>
</tr>
<tr>
<td></td>
<td>- Usual care including an 'assessed' control group and a no contact control group</td>
</tr>
<tr>
<td><strong>Outcomes</strong></td>
<td>Primary outcomes</td>
</tr>
<tr>
<td></td>
<td>- Episodes of heavy drinking</td>
</tr>
<tr>
<td></td>
<td>- Incidents of intimate partner violence</td>
</tr>
<tr>
<td></td>
<td>Timing of measurement: assessed weekly by Interactive Voice Response System for 12 weeks, and at 3, 6, and 12 months by interviewers blinded to group assignment</td>
</tr>
<tr>
<td><strong>Starting date</strong></td>
<td>Trial is complete and under review</td>
</tr>
<tr>
<td><strong>Contact information</strong></td>
<td><a href="mailto:Karin.rhodes@uphs.upenn.edu">Karin.rhodes@uphs.upenn.edu</a></td>
</tr>
<tr>
<td><strong>Notes</strong></td>
<td>Funding: National Institute on Alcohol Abuse and Alcoholism (NIAAA) Award R01-AA018705</td>
</tr>
</tbody>
</table>

**NCT01661504**

<table>
<thead>
<tr>
<th>Trial name or title</th>
<th>Evaluating a health care provider delivered intervention to reduce intimate partner violence and mitigate associated health risks: study protocol for a randomized controlled trial in Mexico City</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Methods</strong></td>
<td>Cluster-randomised controlled trial</td>
</tr>
<tr>
<td><strong>Participants</strong></td>
<td>Inclusion criteria</td>
</tr>
<tr>
<td></td>
<td>- Healthcare professionals (nurses)</td>
</tr>
</tbody>
</table>
- Women currently experiencing abuse in a heterosexual relationship  
  - 18 to 44 years of age  
  - Non-pregnant or in first trimester  

Exclusion criteria: cognitive impairment (e.g. slurred speech), seeking treatment for life-threatening emergency care, and intending to relocate within 2 years

### Interventions

<table>
<thead>
<tr>
<th>Intervention</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>- Nurses meeting eligibility criteria in treatment groups received an intensive training on screening for IPV, providing supportive referrals, and assessing for health and safety risks</td>
<td></td>
</tr>
<tr>
<td>- Women in the control clinics were given a referral card containing general information on IPV and a list of resources, which was consistent with the current goal for standard of care in the Mexico City MoH</td>
<td></td>
</tr>
</tbody>
</table>

### Control

<p>| |</p>
<table>
<thead>
<tr>
<th></th>
</tr>
</thead>
</table>
| - Women currently experiencing abuse in a heterosexual relationship  
  - 18 to 44 years of age  
  - Non-pregnant or in first trimester  

Exclusion criteria: cognitive impairment (e.g. slurred speech), seeking treatment for life-threatening emergency care, and intending to relocate within 2 years

### Outcomes

- Past-year IPV (physical or sexual, or both)
- Reproductive coercion
- Safety planning
- Use of community resources
- Quality of life.

Timing of measurement: surveys conducted at baseline, 3 months, and 15 months from baseline

### Starting date

- Trial was conducted between 2012 and 2015

### Contact information

- Jhumka Gupta
- Yale University
- jhumka.gupta@yale.edu

### Notes

The study is funded by an anonymous donor. This work was supported, in part, by Yale University's Center for Interdisciplinary Research on AIDS (CIRA), through grants from the National Institute of Mental Health (P30MH062294)

ED: emergency department; IPV: intimate partner violence.
### DATA AND ANALYSES

#### Comparison 1. Universal screening for intimate partner violence (IPV) versus control

<table>
<thead>
<tr>
<th>Outcome or subgroup title</th>
<th>No. of studies</th>
<th>No. of participants</th>
<th>Statistical method</th>
<th>Effect size</th>
</tr>
</thead>
<tbody>
<tr>
<td>Identification of IPV by health professionals</td>
<td>8</td>
<td>10074</td>
<td>Odds Ratio (M-H, Random, 95% CI)</td>
<td>2.95 [1.79, 4.87]</td>
</tr>
<tr>
<td>Identification of IPV by type of healthcare setting</td>
<td>7</td>
<td>4393</td>
<td>Odds Ratio (M-H, Random, 95% CI)</td>
<td>2.35 [1.53, 3.59]</td>
</tr>
<tr>
<td>2.1 Antenatal clinics</td>
<td>2</td>
<td>663</td>
<td>Odds Ratio (M-H, Random, 95% CI)</td>
<td>4.53 [1.82, 11.27]</td>
</tr>
<tr>
<td>2.2 Maternal health services</td>
<td>1</td>
<td>829</td>
<td>Odds Ratio (M-H, Random, 95% CI)</td>
<td>2.36 [1.14, 4.87]</td>
</tr>
<tr>
<td>2.3 Emergency departments (EDs)</td>
<td>3</td>
<td>2608</td>
<td>Odds Ratio (M-H, Random, 95% CI)</td>
<td>2.72 [1.03, 7.19]</td>
</tr>
<tr>
<td>2.4 Hospital-based primary care</td>
<td>1</td>
<td>293</td>
<td>Odds Ratio (M-H, Random, 95% CI)</td>
<td>1.53 [0.79, 2.94]</td>
</tr>
<tr>
<td>Referrals</td>
<td>2</td>
<td>1298</td>
<td>Odds Ratio (M-H, Random, 95% CI)</td>
<td>2.24 [0.64, 7.86]</td>
</tr>
</tbody>
</table>

#### Comparison 2. Face-to-face screening for intimate partner violence (IPV) versus written/computer-based screening

<table>
<thead>
<tr>
<th>Outcome or subgroup title</th>
<th>No. of studies</th>
<th>No. of participants</th>
<th>Statistical method</th>
<th>Effect size</th>
</tr>
</thead>
<tbody>
<tr>
<td>Identification of IPV</td>
<td>4</td>
<td>2765</td>
<td>Odds Ratio (M-H, Random, 95% CI)</td>
<td>1.12 [0.53, 2.36]</td>
</tr>
</tbody>
</table>
Analysis 1.1. Comparison 1 Universal screening for intimate partner violence (IPV) versus control, Outcome 1 Identification of IPV by health professionals.

Review: Screening women for intimate partner violence in healthcare settings

Comparison: Universal screening for intimate partner violence (IPV) versus control

Outcome: Identification of IPV by health professionals

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Screened group</th>
<th>Control group</th>
<th>Odds Ratio M. H.Random,95% CI</th>
<th>Weight</th>
<th>Odds Ratio M. H.Random,95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ahmad 2009</td>
<td>25/144</td>
<td>18/149</td>
<td>15.7 %</td>
<td>1.53 [ 0.79, 2.94 ]</td>
<td></td>
</tr>
<tr>
<td>Carroll 2005</td>
<td>6/112</td>
<td>2/141</td>
<td>6.6 %</td>
<td>3.93 [ 0.78, 19.88 ]</td>
<td></td>
</tr>
<tr>
<td>Fraga 2014</td>
<td>51/594</td>
<td>9/235</td>
<td>14.8 %</td>
<td>2.36 [ 1.14, 4.87 ]</td>
<td></td>
</tr>
<tr>
<td>Humphreys 2011</td>
<td>18/205</td>
<td>4/205</td>
<td>10.6 %</td>
<td>4.84 [ 1.61, 14.55 ]</td>
<td></td>
</tr>
<tr>
<td>MacMillan 2009</td>
<td>88/2733</td>
<td>17/2948</td>
<td>17.4 %</td>
<td>5.74 [ 3.40, 9.67 ]</td>
<td></td>
</tr>
<tr>
<td>Rhodes 2002</td>
<td>17/170</td>
<td>1/152</td>
<td>4.8 %</td>
<td>16.78 [ 2.21, 127.66 ]</td>
<td></td>
</tr>
<tr>
<td>Rhodes 2006</td>
<td>42/637</td>
<td>28/644</td>
<td>17.8 %</td>
<td>1.55 [ 0.95, 2.54 ]</td>
<td></td>
</tr>
<tr>
<td>Trautman 2007</td>
<td>12/411</td>
<td>7/594</td>
<td>12.2 %</td>
<td>2.52 [ 0.98, 6.46 ]</td>
<td></td>
</tr>
<tr>
<td><strong>Total (95% CI)</strong></td>
<td><strong>5006</strong></td>
<td><strong>5068</strong></td>
<td><em>100.0 %</em></td>
<td><em>2.95 [ 1.79, 4.87 ]</em></td>
<td></td>
</tr>
</tbody>
</table>

Total events: 259 (Screened group), 86 (Control group)

Heterogeneity: Tau² = 0.31; Chi² = 20.82, df = 7 (P = 0.004); I² = 66%

Test for overall effect: Z = 4.22 (P = 0.000024)

Test for subgroup differences: Not applicable
### Analysis 1.2. Comparison 1 Universal screening for intimate partner violence (IPV) versus control,
Outcome 2 Identification of IPV by type of healthcare setting.

Review: Screening women for intimate partner violence in healthcare settings
Comparison: Universal screening for intimate partner violence (IPV) versus control
Outcome: Identification of IPV by type of healthcare setting

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Screened group</th>
<th>Control group</th>
<th>Odds Ratio M-H,Random,95% CI</th>
<th>Weight</th>
<th>Odds Ratio M-H,Random,95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n/N</td>
<td>n/N</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 Antenatal clinics</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Carroll 2005</td>
<td>6/112</td>
<td>2/141</td>
<td></td>
<td>5.9 %</td>
<td>3.93 [ 0.78, 19.88 ]</td>
</tr>
<tr>
<td>Humphreys 2011</td>
<td>18/205</td>
<td>4/205</td>
<td></td>
<td>10.9 %</td>
<td>4.84 [ 1.61, 14.55 ]</td>
</tr>
<tr>
<td><strong>Subtotal (95% CI)</strong></td>
<td><strong>317</strong></td>
<td><strong>346</strong></td>
<td></td>
<td>16.8 %</td>
<td>4.53 [ 1.82, 11.27 ]</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Total events: 24 (Screened group), 6 (Control group)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Heterogeneity: Tau² = 0.0; Chi² = 0.04, df = 1 (P = 0.84); I² =0.0%</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Test for overall effect: Z = 3.25 (P = 0.0012)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2 Maternal health services</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fraga 2014</td>
<td>51/594</td>
<td>9/235</td>
<td></td>
<td>18.6 %</td>
<td>2.36 [ 1.14, 4.87 ]</td>
</tr>
<tr>
<td><strong>Subtotal (95% CI)</strong></td>
<td><strong>594</strong></td>
<td><strong>235</strong></td>
<td></td>
<td>18.6 %</td>
<td>2.36 [ 1.14, 4.87 ]</td>
</tr>
<tr>
<td></td>
<td>Total events: 51 (Screened group), 9 (Control group)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Heterogeneity: not applicable</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Test for overall effect: Z = 2.32 (P = 0.020)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3 Emergency departments (EDs)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rhodes 2002</td>
<td>17/170</td>
<td>1/152</td>
<td></td>
<td>3.9 %</td>
<td>16.78 [ 2.21, 127.66 ]</td>
</tr>
<tr>
<td>Rhodes 2006</td>
<td>42/637</td>
<td>28/644</td>
<td></td>
<td>26.4 %</td>
<td>1.55 [ 0.95, 2.54 ]</td>
</tr>
<tr>
<td>Trautman 2007</td>
<td>12/411</td>
<td>7/594</td>
<td></td>
<td>13.6 %</td>
<td>2.52 [ 0.98, 6.46 ]</td>
</tr>
<tr>
<td><strong>Subtotal (95% CI)</strong></td>
<td><strong>1218</strong></td>
<td><strong>1390</strong></td>
<td></td>
<td>43.9 %</td>
<td>2.72 [ 1.03, 7.19 ]</td>
</tr>
<tr>
<td></td>
<td>Total events: 71 (Screened group), 36 (Control group)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Heterogeneity: Tau² = 0.45; Chi² = 5.77, df = 2 (P = 0.06); I² =65%</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Test for overall effect: Z = 2.01 (P = 0.044)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4 Hospital-based primary care</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ahmad 2009</td>
<td>25/144</td>
<td>18/149</td>
<td></td>
<td>20.7 %</td>
<td>1.53 [ 0.79, 2.94 ]</td>
</tr>
<tr>
<td><strong>Subtotal (95% CI)</strong></td>
<td><strong>144</strong></td>
<td><strong>149</strong></td>
<td></td>
<td>20.7 %</td>
<td>1.53 [ 0.79, 2.94 ]</td>
</tr>
<tr>
<td></td>
<td>Total events: 25 (Screened group), 18 (Control group)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Heterogeneity: not applicable</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Test for overall effect: Z = 1.27 (P = 0.20)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Total (95% CI)</strong></td>
<td><strong>2273</strong></td>
<td><strong>2120</strong></td>
<td></td>
<td>100.0 %</td>
<td>2.35 [ 1.53, 3.59 ]</td>
</tr>
<tr>
<td></td>
<td>Total events: 171 (Screened group), 69 (Control group)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Heterogeneity: Tau² = 0.11; Chi² = 9.68, df = 6 (P = 0.14); I² =38%</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Test for overall effect: Z = 3.94 (P = 0.000082)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Test for subgroup differences: Chi² = 3.74, df = 3 (P = 0.29); I² =20%</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

---

*Screening women for intimate partner violence in healthcare settings (Review)*

Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
**Analysis 1.3. Comparison 1 Universal screening for intimate partner violence (IPV) versus control, Outcome 3 Referrals.**

Review: Screening women for intimate partner violence in healthcare settings

Comparison: 1 Universal screening for intimate partner violence (IPV) versus control

Outcome: 3 Referrals

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Screened group</th>
<th>Control group</th>
<th>Odds Ratio M-H Random 95% CI</th>
<th>Weight</th>
<th>Odds Ratio M-H Random 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ahmad 2009</td>
<td>3/144</td>
<td>1/149</td>
<td></td>
<td>30.4 %</td>
<td>3.15 [0.32, 30.63]</td>
</tr>
<tr>
<td>Trautman 2007</td>
<td>4/411</td>
<td>3/594</td>
<td></td>
<td>69.6 %</td>
<td>1.94 [0.43, 8.70]</td>
</tr>
<tr>
<td><strong>Total (95% CI)</strong></td>
<td><strong>555</strong></td>
<td><strong>743</strong></td>
<td></td>
<td>100.0 %</td>
<td><strong>2.24 [0.64, 7.86]</strong></td>
</tr>
</tbody>
</table>

Total events: 7 (Screened group), 4 (Control group)

Heterogeneity: $\tau^2 = 0.0$, $\text{Chi}^2 = 0.12$, df = 1 ($P = 0.73$); $I^2 = 0.0$

Test for overall effect: $Z = 1.26$ ($P = 0.21$)

Test for subgroup differences: Not applicable
### Analysis 2.1. Comparison 2 Face-to-face screening for intimate partner violence (IPV) versus written/computer-based screening, Outcome 1 Identification of IPV

Review: Screening women for intimate partner violence in healthcare settings

Comparison: 2 Face-to-face screening for intimate partner violence (IPV) versus written/computer-based screening

Outcome: 1 Identification of IPV

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Face-to-face group</th>
<th>Written/computer group</th>
<th>Odds Ratio M-H Random 95% CI</th>
<th>Weight</th>
<th>Odds Ratio M-H Random 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n/N</td>
<td>n/N</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fincher 2015</td>
<td>84/191</td>
<td>50/177</td>
<td>29.5 %</td>
<td>1.99 [1.29, 3.08]</td>
<td></td>
</tr>
<tr>
<td>Kataoka 2010</td>
<td>16/165</td>
<td>7/163</td>
<td>21.9 %</td>
<td>2.39 [0.96, 5.98]</td>
<td></td>
</tr>
<tr>
<td>Klevens 2012a</td>
<td>4/46</td>
<td>17/80</td>
<td>18.3 %</td>
<td>0.35 [0.11, 1.12]</td>
<td></td>
</tr>
<tr>
<td>MacMillan 2006</td>
<td>35/404</td>
<td>173/1539</td>
<td>30.2 %</td>
<td>0.75 [0.51, 1.10]</td>
<td></td>
</tr>
<tr>
<td><strong>Total (95% CI)</strong></td>
<td><strong>806</strong></td>
<td><strong>1959</strong></td>
<td><strong>100.0 %</strong></td>
<td><strong>1.12 [0.53, 2.36]</strong></td>
<td></td>
</tr>
</tbody>
</table>

Total events: 139 (Face-to-face group), 247 (Written/computer group)

Heterogeneity: $\tau^2 = 0.44$; $\chi^2 = 17.52$, df = 3 ($P = 0.00055$); $I^2 = 83\%$

Test for overall effect: $Z = 0.31$ ($P = 0.76$)

Test for subgroup differences: Not applicable

### APPENDICES

Appendix 1. Search strategies used for 2015 update

Cochrane Central Register of Controlled Trials (CENTRAL)

CENTRAL 2015, Issue 1, searched 17 February 2015. Limited to publication year = 2012 to 2015 [41 records]

#1 MeSH descriptor: [Battered Women] explode all trees
#2 MeSH descriptor: [Domestic Violence] this term only
#3 MeSH descriptor: [Spouse Abuse] this term only
#4 "domestic violence"
#5 abuse* near/3 spous*
#6 abuse* near/3 partner*
#7 wife near/3 abuse*
#8 wives near/3 abuse*
#9 wife near/3 batter*
#10 wives near/3 batter*
#11 batter* near/3 wom*n
Screening women for intimate partner violence in healthcare settings (Review)
Ovid MEDLINE In-process and other non-indexed citations

Ovid MEDLINE In-process February 13 2015, last searched 17 February 2015 [253 records]
1 (abuse$ adj3 wom#n).tw.
2 (abuse$ adj3 spous$).tw.
3 (abuse$ adj3 partner$).tw.
4 (abuse$ adj3 (wife or wives)).tw.
5 (batter$ adj3 (wife or wives)).tw.
6 (batter$ adj3 wom#n).tw.
7 (partner$ adj3 violen$).tw.
8 (spous$ adj3 violen$).tw.
9 domestic violence.tw.
10 (gender adj3 violen$).tw.
11 or/1-10
12 screen$.tw.
13 identif$.tw.
14 (routine$ adj3 (ask$ or question$)).tw.
15 ((history adj3 tak$) or medical history).tw.
16 detect$.tw.
17 disclos$.tw.
18 or/12-17
19 (wom#n or female$).tw.
20 adolescen$.tw.
21 teen$.tw.
22 or/19-21
23 11 and 18 and 22

Embase (Ovid)

Embase 1980 to 2015 Week 07, searched 17 February 2015. Limited to publication year=2012 to current [1187 records]
1 partner violence/
2 Domestic Violence/
3 marital rape/
4 (abuse$ adj3 wom#n).tw.
5 (abuse$ adj3 spous$).tw.
6 (abuse$ adj3 partner$).tw.
7 (abuse$ adj3 (wife or wives)).tw.
8 (batter$ adj3 (wife or wives)).tw.
9 (batter$ adj3 wom#n).tw.
10 domestic violence.tw.
11 (partner$ adj3 violen$).tw.
12 (spous$ adj3 violen$).tw.
13 (gender adj3 violen$).tw.
14 or/1-13
15 Mass Screening/
16 Screening/
17 anamnesis/
18 screen$.tw.
19 identif$.tw.
20 (routine$ adj3 (ask$ or question$)).tw.
21 ((medical history or history) adj1 tak$).tw.
22 detect$.tw.
23 disclos$.tw.
24 or/15-23
25 exp Women/
26 Adolescent/
27 (wom#n or female$).tw.
28 adolescence$.tw.
29 teen$.tw.
30 or/25-29
31 14 and 24 and 30
32 limit 31 to yr="2012 -Current" (1187)

CINAHL Plus (EBSCOhost)
CINAHL Plus 1937 to current searched 17 February 2015. Limited to EM = 20120601 onwards [532 records]
S26 S24 AND S25
S25 EM 20120601-
S24 S8 AND S17 AND S23
S23 S18 OR S19 OR S20 OR S21 OR S22
S22 TI (adolescen* or teen*) OR AB (adolescen* or teen*)
S21 (MH "Adolescence")
S20 TI(wom?n or female*) OR AB(wom?n or female*)
S19 (MH "Women")
S18 (MH "Female")
S17 S9 OR S10 OR S11 OR S12 OR S13 OR S14 OR S15 OR S16
S16 TI(routine* N3 (ask* or question*)) OR AB(routine* N3 (ask* or question*))
S15 TI(detect* or identif* or disclos*) OR AB(detect* or identif* or disclos*)
S14 TI(medical history) or AB(medical history)
S13 TI(history N1 tak*) or AB(history N1 tak*)
S12 TI(screen*) or AB(screen*)
S11 (MH "Patient History Taking")
S10 (MH "Patient Assessment")
S9 (MH "Health Screening")
S8 S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7
S7 TI(domestic violence) or AB (domestic violence)
S6 TI(partner* or spouse* or gender) N3 (violien*) or AB(partner* or spouse* or gender) N3 (violien*)
S5 TI(batter* N3 (wom?n or wife or wives)) OR AB(batter* N3 (wom?n or wife or wives))
S4 TI(abuse* N3 (wom?n or spouse* or partner* or wife or wives )) or AB(abuse* N3 (wom?n or spouse* or partner* or wife or wives ))
S3 (MH "Battered Women")
S2 (MH "Domestic Violence")
S1 (MH "Intimate Partner Violence")

PsycINFO (Ovid)
PsycINFO 1806 to February Week 2 2015, searched 17 February 2015. Limited to up=20120604 to 20150209 [726 records]
1 Battered Females/
2 Domestic Violence/
3 Partner Abuse/

Screening women for intimate partner violence in healthcare settings (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Screening women for intimate partner violence in healthcare settings (Review)

Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Cochrane Database of Systematic Reviews (CDSR), part of the Cochrane Library

CDSR 2015 Issue 2, searched 17 February 2015. No date limits [4 records]
#1 MeSH descriptor: [Battered Women] explode all trees
#2 MeSH descriptor: [Domestic Violence] this term only
#3 MeSH descriptor: [Spouse Abuse] this term only
#4 (abuse* near/3 wom*n):ti,ab
#5 (abuse* near/3 spous*):ti,ab
#6 (abuse* near/3 partner*):ti,ab
#7 (wife near/3 abuse*):ti,ab
#8 (wives near/3 abuse*):ti,ab
#9 (wife near/3 batter*):ti,ab
#10 (wives near/3 batter*):ti,ab
#11 (batter* near/3 wom*n):ti,ab
#12 (partner* near/3 violen*):ti,ab
#13 (spous* near/3 violen*):ti,ab
#14 (domestic next violence):ti,ab
#15 gender near/3 violenc*:ti,ab
#16 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15
#17 MeSH descriptor: [Mass Screening] this term only
#18 MeSH descriptor: [Medical History Taking] this term only
#19 screen*:ti,ab
#20 identif*:ti,ab
#21 ((medical history) or (history near/1 tak*)):ti,ab
#22 routine* near/3 ask*:ti,ab
#23 routine* near/3 question*:ti,ab
#24 disclos*:ti,ab
#25 detect*:ti,ab
#26 #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25
#27 MeSH descriptor: [Women] explode all trees
#28 MeSH descriptor: [Female] explode all trees
#29 MeSH descriptor: [Adolescent] explode all trees
#30 (wom*n or female*):ti,ab
#31 adolescen*:ti,ab
#32 teen*:ti,ab
#33 #27 or #28 or #29 or #30 or #31 or #32
#34 #16 and #26 and #33 in Cochrane Reviews (Reviews and Protocols)

Database of Abstracts of Reviews of Effects (DARE), part of the Cochrane Library

DARE 2015 Issue 1, searched 17 February 2015. Limited to year=2012 to 2015 [3 records]
#1 MeSH descriptor: [Battered Women] explode all trees
#2 MeSH descriptor: [Domestic Violence] this term only
#3 MeSH descriptor: [Spouse Abuse] this term only
#4 (abuse* near/3 wom*n):ti,ab
#5 (abuse* near/3 spous*):ti,ab
#6 (abuse* near/3 partner*):ti,ab
#7 (wife near/3 abuse*):ti,ab
#8 (wives near/3 abuse*):ti,ab
#9 (wife near/3 batter*):ti,ab
#10 (wives near/3 batter*):ti,ab
#11 (batter* near/3 wom*n):ti,ab
#12 (partner* near/3 violen*):ti,ab
#13 (spous* near/3 violen*):ti,ab

Screening women for intimate partner violence in healthcare settings (Review)

Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
#14 (domestic next violence):ti,ab
#15 gender near/3 violenc*:ti,ab
#16 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15
#17 MeSH descriptor: [Mass Screening] this term only
#18 MeSH descriptor: [Medical History Taking] this term only
#19 screen*:ti,ab
#20 identif*:ti,ab
#21 ((medical history) or (history near/1 tak*)):ti,ab
#22 routine* near/3 ask*:ti,ab
#23 routine* near/3 question*:ti,ab
#24 disclos*:ti,ab
#25 detect*:ti,ab
#26 #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25
#27 MeSH descriptor: [Women] explode all trees
#28 MeSH descriptor: [Female] explode all trees
#29 MeSH descriptor: [Adolescent] explode all trees
#30 (wom*n or female*):ti,ab
#31 adolescen*:ti,ab
#32 teen*:ti,ab
#33 #27 or #28 or #29 or #30 or #31 or #32
#34 #16 and #26 and #33
Publication Year from 2012 to 2015, in Other Reviews

International Clinical Trials Registry Platform (who.int/ictrp/en/)
ICTRP searched 18 February 2015 No date limits applied [34 records]
CONDITION: intimate partner violence OR domestic violence OR battered women AND Intervention: screen OR screening OR identify OR identification OR detect OR detection OR disclose OR disclosure AND Recruitment status is ALL

ClinicalTrials.gov (clinicaltrials.gov)
ClinicalTrials.gov, searched 18 February 2015. No date limits applied [17 records]
Interventional Studies | intimate partner violence OR domestic violence OR battered women | screen OR screening OR identify OR identification OR disclose OR disclosure OR detect OR detection | Studies with Female Participants

Appendix 2. Search strategies used for previous version of review

Cochrane Central Register of Controlled Trials (CENTRAL)
Last searched 5 July 2012
#1 MeSH descriptor Battered Women explode all trees
#2 MeSH descriptor Domestic Violence, this term only
#3 MeSH descriptor Spouse Abuse, this term only
#4 abuse* near/3 wom*n
#5 abuse* near/3 spous*
#6 abuse* near/3 partner*
#7 wife near/3 abuse*
#8 wives near/3 abuse*
#9 wife near/3 batter*
#10 wives near/3 batter*
#11 partner* near/3 violen*
#12 spous* near/3 violen*
#13 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12)
#14 MeSH descriptor Mass Screening, this term only
#15 screen*
#16 identif*
#17 routine* near/3 ask*
#18 routine* near/3 question*
#19 detect*
#20 (#14 OR #15 OR #16 OR #17 OR #18 OR #19)
#21 MeSH descriptor Women explode all trees
#22 MeSH descriptor Adolescent explode all trees
#23 wom*n or female*
#24 adolescen*
#25 teen*
#26 (#21 OR #22 OR #23 OR #24 OR #25)
#27 (#13 AND #20 AND #26)

Ovid MEDLINE(R)
Last searched 5 July 2012
1 Battered Women/
2 Domestic Violence/
3 Spouse Abuse/
4 (abuse$ adj3 wom#n).tw.
5 (abuse$ adj3 spous$).tw.
6 (abuse$ adj3 partner$).tw.
7 ((wife or wives) adj3 abuse$).tw.
8 ((wife or wives) adj3 batter$).tw.
9 (partner$ adj3 violen$).tw.
10 (spous$ adj3 violen$).tw.
11 or/1-10
12 Mass Screening/
13 screen$.tw.
14 identif$.tw.
15 detect$.tw.
16 (routine$ adj3 (ask$ or question$)).tw.
17 or/12-16
18 exp Women/
19 Adolescent/
20 (wom#n or female$).tw.
21 adolescen$.tw.
22 teen$.tw.
23 or/18-22
24 11 and 17 and 23

Ovid MEDLINE(R) In-Process and Other Non-Indexed Citations
Last searched 5 July 2012
1 (abuse$ adj3 wom#n).tw.
2 (abuse$ adj3 spous$).tw.
3 (abuse$ adj3 partner$).tw.
4 ((wife or wives) adj3 abuse$).tw.
5 ((wife or wives) adj3 batter$).tw.
6 (partner$ adj3 violen$).tw.

Screening women for intimate partner violence in healthcare settings (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(spous$ adj3 violen$).tw.
or/1-7
(screen$).tw.
(identif$).tw.
(routine$ adj3 (ask$ or question$)).tw.
detect$.tw.
(or/9-12
(wom#n or female$).tw.
adolescen$.tw.
(teen$).tw.
or/14-16
8 and 13 and 17

**Embase (Ovid)**
Last searched 5 July 2012
1 Battered Women/
2 Domestic Violence/
3 Spouse Abuse/
4 (abuse$ adj3 wom#n).tw.
5 (abuse$ adj3 spous$).tw.
6 (abuse$ adj3 partner$).tw.
7 ((wife or wives) adj3 abuse$).tw.
8 ((wife or wives) adj3 batter$).tw.
9 (partner$ adj3 violen$).tw.
10 (spous$ adj3 violen$).tw.
or/1-10
12 Mass Screening/
13 screen$.tw.
14 identif$.tw.
15 (routine$ adj3 (ask$ or question$)).tw.
detect$.tw.
or/12-16
18 exp Women/
19 Adolescent/
20 (wom#n or female$).tw.
adolescen$.tw.
(teen$).tw.
or/18-22
11 and 17 and 23

**CINAHL Plus (EBSCOhost)**
Last searched 5 July 2012
S24 S17 and S23
S23 S18 or S19 or S20 or S21 or S22
S22 adolescent* or teen*
S21 AG adolescent
S20 women or woman or female*
S19 (MH “Women”)
S18 (MH “Female”)
S17 S9 and S16
S16 S10 or S11 or S12 or S13 or S14 or S15

Screening women for intimate partner violence in healthcare settings (Review)
S15 (MH "Health Screening")
S14 identif*
S13 MH "Experimental Studies"
S12 detect*
S11 (routin* N3 ask*) or (routin* N3 question*)
S10 screen*
S9 S1 or S2 or S3 or S4 or S5 or S6 or S7 or S8
S8 (partner* N3 violen*) or (spouse* N3 violen*)
S7 (wife N3 batter*) or (wives N3 batter*)
S6 abuse* N3 spouse*
S5 abuse* N3 partner*
S4 abuse* N3 wom?n
S3 MH "Intimate Partner Violence"
S2 MH "Domestic Violence"
S1 MH "Battered Women"

PsycINFO (Ovid)
Last searched 5 July 2012
1 Battered Women/ (2689)
2 Domestic Violence/ (7821)
3 Spouse Abuse/ (4154)
4 (abuse$ adj3 wom#n).tw. (2995)
5 (abuse$ adj3 spouse$).tw. (908)
6 (abuse$ adj3 partner$).tw. (1266)
7 ((wife or wives) adj3 abuse$).tw. (570)
8 ((wife or wives) adj3 batter$).tw. (316)
9 (partner$ adj3 violen$).tw. (3626)
10 (spous$ adj3 violen$).tw. (351)
11 or/1-10 (15402)
12 Screening/ (5344)
13 screen$.tw. (48857)
14 identif$.tw. (287698)
15 (routine$ adj3 (ask$ or question$)).tw. (244)
16 detect$.tw. (73953)
17 or/12-16 (383820)
18 exp Women/ (97549)
19 (wom#n or female$).tw. (380933)
20 adolescen$tw. (157334)
21 teen$.tw. (13531)
22 or/18-21 (535027)
23 11 and 17 and 22 (2087)

Sociological Abstracts (ProQuest)
 Last searched 5 July 2012
((SU.EXACT("Females") or SU.EXACT("adolescents") or (wom*n or female*) or (adolescent*or teen*)) AND ((screen*)or (identif*)) or ((routine* NEAR/3 question*) or (routine* NEAR/3 ask*)) or (detect*))) AND (SU.EXACT("Familyviolence")) or SU.EXACT("Partner Abuse") or ("Battered Women") or (abuse NEAR/3 wom*n) or (abuse NEAR/3spouse*) or (abuse NEAR/3 partner*) or (wife NEAR/3 abuse*) or (wives NEAR/3 abuse*) or (wife NEAR/3 batter*) or (wives NEAR/3 batter*) or (partner* NEAR/3 violent*) or (spouse* NEAR/3 violent*))

Screening women for intimate partner violence in healthcare settings (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Database of Abstracts of Reviews of Effects (DARE), part of the Cochrane Library

Last searched 5 July 2012
#1 MeSH descriptor Battered Women explode all trees
#2 MeSH descriptor Domestic Violence, this term only
#3 MeSH descriptor Spouse Abuse, this term only
#4 abuse* near/3 wom*n
#5 abuse* near/3 spous*
#6 abuse* near/3 partner*
#7 wife near/3 abuse*
#8 wives near/3 abuse*
#9 wife near/3 batter*
#10 wives near/3 batter*
#11 partner* near/3 violen*
#12 spous* near/3 violen*
#13 (#1 OR #2 OR #3 OR #4 OR #5 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12)
#14 MeSH descriptor Mass Screening, this term only
#15 screen*
#16 identif*
#17 routine* near/3 ask*
#18 routine* near/3 question*
#19 detect*
#20 (#14 OR #15 OR #16 OR #17 OR #18 OR #19)
#21 MeSH descriptor Women explode all trees
#22 MeSH descriptor Adolescent explode all trees
#23 wom*n or female*
#24 adolescen*
#25 teen*
#26 (#21 OR #22 OR #23 OR #24 OR #25)
#27 (#13 AND #20 AND #26)

metaRegister of Controlled Trials (mRCT)

Last searched July 2012
Search string: intimate partner violence OR domestic violence

Sociological Abstracts (CSA)

Search up to 2009
Query: ((DE="domestic violence") or(DE="battered women") or(abuse* within 3 wom*n) or(abuse* within 3 spous*) or(abuse* within 3 partner*) or((wife within 3 abuse*) or (wives within3 abuse*)) or((wife within 3 batter*) or (wives within 3 batter*)) or(partner* within 3 violen*) or(spous* within 3 violen*)) and((screen*) or(identif*) or((routine* within 3 question*) or (routine* within 3 ask*)) or(detect*)) and((DE="women") or(DE="adolescents") or(wom*n or female*) or(adolescen*) or(teen*))

ASSIA (CSA)

Search up to 2009 only
Query: ((DE="domestic violence") or(DE="battered women") or(abuse* within 3 wom*n) or(abuse* within 3 spous*) or(abuse* within 3 partner*) or((wife within 3 abuse*) or (wives within3 abuse*)) or((wife within 3 batter*) or (wives within 3 batter*)) or(partner* within 3 violen*) or(spous* within 3 violen*)) and((screen*) or(identif*) or((routine* within 3 question*) or (routine* within 3 ask*)) or(detect*)) and((DE="women") or(DE="adolescents") or(wom*n or female*) or(adolescen*) or(teen*)))
### Appendix 3. Additional methods

<table>
<thead>
<tr>
<th>Analysis</th>
<th>Method</th>
</tr>
</thead>
<tbody>
<tr>
<td>Measures of treatment effect</td>
<td>Where measurements were comparable and on the same scale, we intended to combine them to obtain mean differences. Where scales measured the same clinical outcomes in different ways (e.g. depression, quality of life), mean differences were to be standardised in order to combine results across scales. There have been insufficient data in studies in the review and update to undertake these analyses. These methods will be retained for subsequent updates.</td>
</tr>
<tr>
<td>Unit of analysis issues</td>
<td>There was one included cluster-RCT to date, which did account for clustering. For future updates, where studies have not appropriately accounted for clustering, we will re-analyse data using methods recommended by Donner 1980.</td>
</tr>
<tr>
<td>Dealing with missing data</td>
<td>Rates of missing data on the primary outcome have not required thus far that we undertake best-case and worst-case scenario analyses to estimate the effect of the missing data on the results of pooled studies. Such analyses would enable us to ascertain if observed effect sizes increased or decreased as a function of the extent of attrition in the two arms of the trial. These methods will be retained for subsequent updates.</td>
</tr>
<tr>
<td>Assessment of reporting biases</td>
<td>We planned to draw funnel plots to investigate any relationship between effect size and study precision (closely related to sample size) (Egger 1997) to investigate a relationship that could be due to publication or related biases or due to systematic differences between small and large studies. Funnel plots (estimated differences in treatment effects against their standard error) were not drawn because there was an insufficient number of included studies (more than 10 are recommended), to identify asymmetry due to publication bias.</td>
</tr>
<tr>
<td>Subgroup analyses</td>
<td>We planned to conduct subgroup analysis for type of healthcare setting (which was done) and the type of screening intervention (based on types of tools, questions), which could be done in a future update with more studies. We also stated in the protocol that we would undertake subgroup analysis based on screening intervention only or where it was embedded as part of a larger multi-component intervention. However, the implications of our altered criterion for assessing inclusion of interventions/comparisons, which explicitly excludes interventions that extended beyond an immediate response and referral phase following screening, meant that this subgroup analysis has not been relevant to date.</td>
</tr>
<tr>
<td>Sensitivity analysis</td>
<td>Our original protocol stated our intention to use sensitivity analysis to deal with study quality and differential dropout, which has been undertaken in this review. However, we have not used sensitivity analysis for intention-to-treat issues and duration of follow-up as neither have applied to date. These methods will be retained for subsequent updates.</td>
</tr>
</tbody>
</table>

RCT: randomised controlled trial.
WHAT'S NEW

Last assessed as up-to-date: 17 February 2015.

<table>
<thead>
<tr>
<th>Date</th>
<th>Event</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>7 May 2015</td>
<td>New citation required but conclusions have not</td>
<td>Two new studies included in the review.</td>
</tr>
<tr>
<td></td>
<td>changed</td>
<td></td>
</tr>
<tr>
<td>17 February 2015</td>
<td>New search has been performed</td>
<td>The review was updated following a new search in February 2015</td>
</tr>
</tbody>
</table>

HISTORY

Protocol first published: Issue 1, 2008
Review first published: Issue 4, 2013

<table>
<thead>
<tr>
<th>Date</th>
<th>Event</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>16 September 2008</td>
<td>Amended</td>
<td>Converted to new review format.</td>
</tr>
</tbody>
</table>

CONTRIBUTIONS OF AUTHORS

AT originally developed the search strategy. AT and LOD selected the studies prior to 2009; AT, LOD and KH selected studies for the 2009 to 2012 period and AT and LOD extracted the data; AT undertook the analysis with the help of LOD and KH and drafted the original review. All authors provided topic expertise and contributed to writing and editing the original review.

LOD led the 2015 update with guidance from all co-authors. AT, LOD, and KH independently selected studies from the point at which full-text articles had been retrieved. Extraction and ‘Risk of bias’ assessment was done by LOD with Tess Lawrie (not author). All authors provided topic expertise and contributed to writing and editing the update of the review.

DECLARATIONS OF INTEREST

Lorna O’Doherty - the La Trobe funding went towards contracting Lorna from the University of Melbourne to work on the original Cochrane Review. She is responsible for the 2015 update to the review and conducted the 2015 work within the remit of her current position at Coventry University. The National Health and Medical Research Council (NHMRC) funded her former position as research fellow at the University of Melbourne. She does not have any competing interest to declare. She was first author of an abridged version of the original review published in the BMJ in 2014.

Kelsey Hegarty* - has been funded through a NHMRC Grant to undertake a randomised controlled trial in the field of intimate partner violence (IPV) - women's evaluation of abuse and violence care in general practice (WEAVE) trial (Hegarty 2013), which was completed by the time of the 2015 update. Angela Taft, Lorna O'Doherty, and Gene Feder were also involved in the trial. The author team examined the WEAVE trial against inclusion criteria and it was judged as ineligible on the basis that the intervention was too intensive to be considered a screening-only trial. Kelsey participated in the World Health Organization (WHO) Guideline Group on health practitioners’ responses to IPV and received payment from the General Practice Victoria for training provided to general practitioners in how to manage partner violence.
Jean Ramsay - none known.

Leslie Davidson - National Institutes of Health (NIH) Fogarty International Center paid travel, accommodation, and meeting expenses for Leslie to attend the Society of Neuro Scientists of Africa (SONA) and a NIH workshop in March 2015 in South Africa unrelated to IPV.

Gene Feder - Gene chaired the WHO IPV and sexual violence guideline development group. Gene's institution received funds from the National Institute for Health and Care Excellence (NICE) for him to chair the Domestic Violence and Abuse guidelines development group. Gene's institution also receives funds from Safer Lives for his consultancy work and from a National Institute of Health Research applied research programme grant on domestic violence and abuse.

Angela Taft* - received an Australian Research Council Grant to undertake a screening trial (Taft 2015). Kelsey Hegarty was also involved in the trial. Its eligibility was considered for the 2015 update. The author team examined the Improving maternal and child health care for vulnerable mothers (MOVE) trial against inclusion criteria and it was judged as ineligible on the basis that screening was conducted by healthcare professionals in both arms of the trial.

Kelsey Hegarty* and Angela Taft* were involved in (Taft 2012), which was previously examined by the author team and was judged ineligible for inclusion in the review as it was case-finding and not a screening trial.

* Kelsey Hegarty and Angela Taft were excluded from making decisions about the trials they led.

**Sources of Support**

**Internal sources**
- No sources of support supplied

**External sources**
- La Trobe University, Australia.
  Financial (salary) and technical support

**Differences between protocol and review**

1. Altered objective

   We made it explicit in the objective for the review that we would also examine the impact of screening in health settings on women's re-exposure to violence and to determine if screening causes any harms.

2. Altered criterion for assessing inclusion of interventions/comparisons

   The treating healthcare professional must have been informed of the result of the screening assessment undertaken at the time of the relevant consultation if they did not conduct the screening themselves face-to-face. Essentially, there must be some involvement of a healthcare professional in the intervention arm.

   The comparison condition was also considered to determine if the overall comparison was valid for inclusion. Originally we defined the comparison as usual care. We acknowledge, however, that 'treatment-as-usual' (TAU) arms may involve some kind of screening technique such as computer or paper-based screening. Providing that there was no healthcare professional involvement, we considered it to be a comparison consistent with other included studies.

   Some studies compared face-to-face screening with other techniques of identification, but the way in which identification was operationalised differed from the main body of studies, reflecting prevalence rather than clinical identification.

   We excluded interventions where the timing of these consultations went beyond an immediate response and referral phase, and included further counselling or therapeutic sessions as we wanted to isolate the effect of screening only.

3. Amendments to outcomes
We added the outcome below as it has bearing on the potential for beneficial support to women at a later date.

G. Services and resource use:
   i. family/domestic violence services;
   ii. police/legal services;
   iii. counselling or therapeutic services;
   iv. other services.

In this update, we conducted a meta-analysis on an outcome that was not pre-specified but represents an alternative definition of 'identification', which was more research-based than clinical. The methods used to gather data on this outcome were more consistent with prevalence studies. It was necessary to treat this outcome separately to clinical identification given that women may be more inclined to disclose abuse when the enquiry occurs outside the clinical encounter and context. Thus, it would be expected that non-clinical identification rates would exceed rates of clinical identification, and more closely reflect best estimates of IPV in clinical populations.

4. Search strategy amendment

We were unable to complete the planned handsearching of several journals and we were unable to search 'Domestic Violence Data source' as the webpage was no longer available. However, given the extent of the alternative searching, we believe the likelihood of overlooking an eligible trial was low.

5. Incorporation of a separate review

Although the 2015 update incorporates another review (Coulthard 2010), we have only included studies of screening interventions for women. Screening interventions for men might be addressed in a future review.

**INDEX TERMS**

**Medical Subject Headings (MeSH)**

*Efficiency, Organizational; *Mass Screening; Randomized Controlled Trials as Topic; Spouse Abuse [*diagnosis; statistics & numerical data]*

**MeSH check words**

Female; Humans